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Preface
Cell biology is a multidisciplinary scientific field that its modern expansion in new knowl‐
edge and applications owes to important support of new technologies with the rapid devel‐
opment, such as ICTs. By integrating knowledge from nano-, molecular, micro-, and
macroareas, it represents a strong foundation for almost all biological sciences and disci‐
plines, as well as for biomedical research and application. This book is a compilation of in‐
spiring reviews/original studies, which are divided into sections: New Methods in Cell
Biology, Molecular and Cellular Regulatory Mechanisms, and Cellular Basis of Disease and
Therapy. The book will be very useful for students and beginners to gain insight into new
area, as well as for experts and scientists to find new facts and expand their scientific hori‐
zons through biological sciences and biomedicine.
Stevo Najman, PhD
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Section 1
New Methods in Cell Biology

Chapter 1
A Proposal for a Machine Learning
Classifier for Viral Infection
in Living Cells Based
on Mitochondrial Distribution
Juan Carlos Cardona-Gomez, Leandro Fabio Ariza-Jimenez and
Juan Carlos Gallego-Gomez
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/61293
Abstract
The study of viral infections using live cell imaging (LCI) is an important area with
multiple opportunities for new developments in computational cell biology. Here,
this point is illustrated by the analysis of the sub-cellular distribution of mitochon‐
drium in cell cultures infected by Dengue virus (DENV) and in uninfected cell cul‐
tures (Mock-infections). Several videos were recorded from the overnight
experiments performed in a confocal microscopy of spinning disk. The density dis‐
tribution of mitochondrium around the nuclei as a function of time and space
ρ(r ,  θ,  t) was numerically modeled as a smooth interpolation function from the
image data and used in further analysis. A graphical study shows that the behavior
of the mitochondrial density is substantially different when the infection is present.
The DENV-infected cells show a more diffuse distribution and a stronger angular
variation on it. This behavior can be quantified by using some usual image process‐
ing descriptors called entropy and uniformity. Interestingly, the marked difference
found in the mitochondria density distribution for mock and for infected cell is
present in every frame and not an evidence of time dependence was found, which
indicate that from the start of the infections the cells are showing an altered subcel‐
lular pattern in mitochondrium distribution. Ulteriorly, it would be important to
study by analysis of time series for clearing if there is some tendency or approxi‐
mate cycles. Those findings are suggesting that using the image descriptors entropy
and uniformity it is possible to create a machine learning classifier that could recog‐
nize if a single selected cell in a culture has been infected or not.
Keywords: Computational Cell Biology, Dengue Virus, Mitochondria, Machine Learning
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
1. Introduction
At the latter years of the past century, cell biology experienced a fast growth, thanks to the
convergence of several techniques, which have substantially improved the confocal micro‐
scopy field. Now, the observation in real time of the structural and functional unit of life is
possible. The ultrarefrigerated CCD-cameras with electromultipliers; the implementation of
confocality based on disk spinning without the necessity of high-energy lasers (which could
damage the living cells in a few seconds); the increasing capacity of computational processors;
and the ability of the genetic engineering for coding fluorescent proteins mutants [1, 2], offering
the possibility of a color palette that was previously unthinkable for the cell molecular
biologists [3, 4]. All together with the ability to generate cells with fluorescent compartments,
opened the doors to maybe the most remarkable and important scientific and technological
development for a new era in cell biology named Live Cell Imaging. Before the 1990’-s this
kind of research was known by the unpopular name “time-lapse video microscopy”, as it is
detailed in a protocol book widely known at that time written by A.J. Lacey [5].
At the beginning of the new millennium, the necessity of introducing new and improved
mathematical and computational tools was made evident. This was because the amount of
data produced in a single experiment could overload the capacity of personal computers and
the conventional software was not loaded with the required algorithms to process such data.
Then a strategic alliance with researchers on the areas of artificial intelligence, applied
mathematics, and physics was apparent. These new cooperations make perfect sense due that
even from the beginning of life science studies, it was clear that the dynamical rules involved
were complex, non-linear, and possibly not even deterministic but probabilistic. The virolo‐
gists, for example, have discovered that the infection rate is governed by a non-linear pattern
and the cellular physiology of several processes turn out to be more complicated than it was
expected. In consequence, the mathematical modeling became the main strategy in the journey
for knowing and understanding the cell biology. The amount of the data available nowadays
could not be analyzed by conventional human heuristics. Fortunately, the computational
biology field and its tools offer the required resolution and robustness in diverse problems. It
goes even further, because the computational algorithms work evenly in any case. When
dealing with complex biological problems, to have a working computational model will get
us closer to the reality and help us avoiding the human bias present in heuristic approaches.
It is in complex problems where the convenience of using powerful statistical tools to build
models became apparent. The main strategy here is to try to “learn” the model directly from
the experimental or observational data.
The term “machine learning” (ML) refers to a branch of the artificial intelligence field, that
concerns to the study and construction of algorithms with the ability to learn from the existing
data. In such algorithms, a set of parameters is fitted to provide the best input-output rela‐
tionship between the information available. When talking about a computational code that
implements the techniques, algorithms, or principles found in machine learning theory, it is
usually called a machine learning program. The literature on this topic is quite large; however,
some very popular books are those by Duda et al. [6], Webb [7], and Bishop [8].
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A commonly accepted definition of the process of “learning” is due to Tom M. Mitchell [9]: a
machine learns to perform a task T if its performance as measured by P  increases with the experience
E. The experience E is the feedback the machine received to validate its output. The ML set of
techniques have a broad range of applications in several fields of knowledge, including the
building of autonomous robots [10], the astrophysical data mining [11], the study of dynamical
systems and complex networks without the explicit knowledge of the dynamical equations
[12], the patterns and shape recognition [6, 8] in images as used by the face recognition
programs in social networks web pages, the hand writing OCR (optical character recognition),
and of course, in medicine (automatic diagnosis based on symptoms) and biology (gene
sequencer, classification of cellular morphology, etc.).
Particularly, the shape recognition capabilities have important applications to live cell image
processing. For example, in 2006, Neumann and collaborators use live cell imaging to study
the RNAi screening [13]. They developed a ML that recognize the morphologies present in the
cells images and associate them (classify) with the corresponding phenomenology: interphase,
mitosis, apoptosis and binucleated cells morphologies were studied through a multi-class
classifier using support vector machine (SVM). They reported to obtain up to 97% accuracy
from the SVM in comparison with “manual” classification through the observation by some
very well-trained biologists.
Due to the huge amount of data provided by a live cell image (LCI) measure, it becomes
unpractical to relay only on the lecture and interpretation by a well-trained researcher. It is
also possible to have different interpretations coming from different scientists when analyzing
the same image. Then, the ML ability to recognize and characterize particular morphologies
present in an image is very useful to avoid the slow and tedious process of visual discrimina‐
tion. Also, it can avoid some human bias by following well-defined rules. However, to fully
train the machine, it can be necessary to have a large number of image samples from the
phenotype under study. It means, to have enough sample cells expressing the phenotype and
some other cells to use as a control group. Sometimes, that condition is not fulfilled. In order
to asset this kind of problem, Thouis R. Jones and collaborators implement a ML with inter‐
active feedback to characterize diverse and complex morphological phenotypes [14]. They use
the criteria of well-trained researchers as a feedback in the learning stage of the machine, and
provide the code [15] for the world to use under a free license.
Several generic implementations of ML techniques have been developed and presented as
toolbox in scientific software. However, it is pretty common to find the particular phenomenon
under study to be better fitted by some unique implementation developed explicitly to deal
with it. This can be a consequence of the particularities of the problem or sometimes this is just
due to the lack of proper documentation on the available tools.
This chapter is organized as follows: first, a brief description of some common methods used
to build a ML are provided, followed by a description of the performed experiment and
computational analysis to obtain the information from the graphical data. Finally, the results
and a proposal to create a ML to characterize viral infection are presented.
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2. Machine learning concepts overview
From the mathematical point of view, a ML can have one of two primary objectives: regression
and classification. When the machine is used to compute the best response to a given situation
among a continuous range of possible answers, it is called a regression problem. And when
the machine is due to choose among a discrete set of possibilities, it is called a classification
problem.
The shape recognition and feature extraction from images is a classification problem, where
the duty of the machine is to find the class which has the highest probability to contain the
current input value. In this context, a class is defined based on a set of measurable attributes
found in an image; it can be geometrical attributes (length, shape, eccentricity, size), pixel
intensity, etc. In general, the input for a ML program is a set of measurable variables or
attributes, which are set in vectors. It is common in ML literature to call these attributes features
and the vectors feature vectors, so these names will be used in such framework in the rest of this
chapter. Each input in a feature vector represents an attribute and each vector represents a
state of the system.
Before the machine is ready to be used as a classifier or predictor, it needs to be trained among
some data. Here, “training” refers to the process of parameters optimization, where the
machine is optimized to get the best result against the training set. This process is not perfect,
and some human criteria need to be implemented. If the model has not enough freedom to fit
to the training set, it gets under fitted and do not reproduce the characteristics of the system
under study. On the other hand, having too much freedom in the ML leads to a model that fits
pretty well in the training set, but is unable to predict accurately the outcome for a feature
vector outside of the training set. This is called bias. To avoid bias, it is customary to split the
available data in two sets, the training set and the testing set. A trained machine is challenged
with the testing set, and the accepted ML model is the one that has the best results against it.
There are two main paradigms for the training of a classifier, the supervised and the unsu‐
pervised learning. In supervised learning, each sample in the training set is consisting on a
features vector and a class flag, i.e., the classes to which each sample in training set belongs
are known a priori. After the learning process, a computational model that can predict the right
class flag for most of the training set is obtained, and hopefully, it would predict the correct
class for a new sample with high accuracy. Also, the classifier must return information about
how confident its prediction is, i.e., a value of dude must be reported.
When no predefined classification is available, a ML algorithm can be used to search for
common patterns or similarities into the training set, which do not contain class information
yet. The machine would cluster samples with similar feature vectors to define a class, and then,
it will use the found class to characterize new input data. To do that, it is necessary to define
some measure of similarity (Euclidean distance in features space, for example) that can be used
to group the input vectors into clusters. The objectives of this kind of ML are first to cluster
the data from the training set into classes, and then, set a classifier to characterize new inputs.
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ML are suitable to treat complex problems in which the explicit mathematical form describing
the interactions occurring in the process are not known, i.e., the dynamical equation ruling the
systems are unknown. Being so, the computations involved in a model built with ML are not
deterministic but probabilistic, based on the information gathered by direct measures. The
more data are available to train the machine, the more accurate the prediction will become.
2.1. Supervised learning
The objective of the classifier is to draw a frontier that splits the feature space into k disjoint
subsets [16] called the border line or border hyperplane. Hopefully, each subset will contain
the feature subspace associated with one single class.
2.1.1. Hypothesis function
Let the features space be called X , where a feature vector is x, and let the whole set of classes
be Y , with an individual class denoted y. Develop a ML model consists in building a function
h  : X →Y  that is a good predictor of the corresponding y to a given input x. In supervised
learning, a computational model function with adaptable parameters θ, hθ(x)must be build;
this function is usually called “hypothesis”. Also, a cost function J (θ) must be defined to
provide an idea of how accurate the hypothesis is when predicting the output values or classes
for the whole training set. A common choice is the least square cost function:







J h x yqq
=
= -å (1)
where m is the number of samples or elements in the training set, and the notation x (i) and y (i)
denotes the feature vector of the i-th sample and the class value for it. The optimization of the
model (learning process) is then achieved by minimizing the cost function. Once the ML model
is set up, the predictions are made with the optimized hypothesis as y  =  h (x). Depending on
if h (x) is a continuous function or a discrete one, the machine will be doing regression or
classification respectively.
Another approach comes from a probabilistic interpretation of the hypothesis function.
Suppose that y (i) =h (x (i)) +∈(i) , where ∈(i)  is a random error which takes care of unmodeled
effects and possibly random noise. And assume that ∈(i)  are IID (independent and identically
distributed), and follows a Normal distribution (Gaussian distribution), of mean zero and some
variance σ 2, P(∈(i) ) = 1
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As any set (x (i), y (i)) is independent from the others, the probability of the whole set P(Y | X ;θ)
is the product of all the individual probabilities. When P(Y | X ;θ) is taken as a function of the
parameters θ, it is called the likelihood function:






P y xq q
=
=Õl (3)
The principle of maximum likelihood establishes that the best model representation of the data
is given by the set of parameters θ that provides the maximum probability. Then, maximizing
the likelihood function for the whole training set (or any monotonically increasing function of
it) is equivalent to minimize the cost function Eq. (1).
2.1.2. Logistic regression
Suppose the problem at hand is to determine if the measure of some experiment belong to one
out of two possible outputs (like, for example, to determine if a tumor is benign or malign). A
class flag 0 or 1 must be associated for each output. In this case, a common approach is to
propose a logistic function (also known as sigmoid function) as a classifier, it is called a logistic
regression:











( ) ( )  Th x g xq q= (5)
The sigmoid function sig(z) has asymptotic values of 1 when z→∞ and 0 when z→ −∞. So the
conditional probability for the feature vector x to belong to each one of the two available classes
is written as:
( ) ( )
( ) ( )
1| ; ,
 
0| ; 1 .
P y x h x








Which can be summarized in a single probability density function (PDF)
( ) ( )( ) ( )( )11 .| ; y yP y x h x h xq qq
-
= - (7)
Once the PDF is set, the process of learning consist in maximizing the likelihood of such PDF
to the training data set. By computational simplicity, it is convenient to maximize instead some
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monotonically increasing function of the likelihood. It is common to work with the logarithm
of the likelihood (log-likelihood function). When using the logistic regression, this hypothesis
function would not return the prediction of an output class, but the probability for the sample
feature vector belongs to a given class.
If it is needed to get a class value as an output, it can be done by setting z =sig(θ T x) instead of
Eq. (4) and defining
( ) 1 0.5,  0 ,






then minimizing the cost function Eq. (1). This last strategy is known as the perceptron learning
algorithm. The classifier in this example can be extended to k classes by a simple one vs all
algorithm. It is, defining a logistic regression to compute the probability for any of the k classes,
hθ1,1(x), hθ2,2(x), hθk −1,k−1(x),..., hθk ,k (x), and returning the class which has the highest probability.
Note that for each class, a parameters vector θi must be optimized.
2.1.3. Non-linear classifiers
One limitation of the techniques summarized so far is that they provide a linear model for the
classifier, i.e., the decision border is represented by a straight line or hyperplane. This can work
perfectly fine if the data are linear separable, or if a linear border line provides enough accuracy
in the final prediction. What happens if the feature space requires a more complex non-linear
decision border? i.e., if the decision border is given considerably better by an hyper surface?
One possible way to create non-linear models is to use neural networks (NN). A neuron is a
computational unit, i.e., a piece of code that performs a single task or function, usually called
the activation function. This method was developed as a gross mimic of a biological neuron,
where each computational neuron has a set of wires connecting it with its input and a set of
wires that are used to communicate its output to the next set of neurons. Each wire between
two neurons has associated a parameter, sometimes called “weight”, which is adjusted in the
leaning process. So the computational model is created as an array of neurons, configured in
layers that can be fully or partially connected. This kind of computational structure allows the
creation of pretty complex nonlinear functions just by the selection of the network wires. After
optimization, the NN computes a continuous function ready to be used for regression. For
classification, a helper selection function can be implemented. A simple and yet powerful
arrangement is the feedforward structure (see Figure 1), in which the neurons are arranged in
a network where each layer receives its inputs directly from the layer before, and provides its
outputs only to the layer after it, i.e., where the i-th layer receives the information from the (i
- 1)-th layer, and sends its output to be the inputs to the (i + 1)-th layer. A common neural
network used for classifiers is a three layer fully connected network, i.e., each neuron receives
information for any neuron in the layer before. The first layer, called input layer, has a
computational unit for each attribute in the feature vector. This unit sends its associated value
to any neuron in the second or hidden layer, where each neuron computes a sigmoid function
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hθi(x)= g(θiT x) as in Eq. (4). θi is the parameters vector, containing the weights for each input
wire to neuron i. Each neuron in the hidden layer sends its output to any neuron in the third
or output layer. And finally, the neurons in the output layer computes another logistic function
h (θj'T z), where z is the vector of outputs from the second layer and θj' is the vector of weights
for each input wire to the output neuron j. h (θj'T z) corresponds to the probability for the input
feature vector to belong to the class j. Then, a selector function chooses the class with the
highest probability to be assigned as the final output of the classifier.
Figure 1. A schematic figure of a feed-forward three layers neural network. Here, an input vector of three features is
classified in one out of two known classes. The hidden and output layers compute logistic functions in each neuron,
represented by the s-like curve. θi , j is the weight of the i-th wire to the neuron j.
Any neuron in the second and third layer has an associated vector of parameters that need to
be trained. The training of a NN is a difficult task, where the weights connecting each pair of
neuron must be learned for all neuron in any layer. For the output layer, the cost function can
be computed taking into account the expected values in the training set. But for the inner layers,
no expected value is known. As a consequence of this, the cost function associated to a NN is
in general a non-convex function. This has strong repercussions in the optimization problem.
Due to the existence of several local minimum, the convergence to a global minimum is not
guaranteed.
The variational parameters have several ways to be changed that will provide approximately
the same level of correction from one iteration to the next. One strategy to find the “right
direction” to move the network is to take minimal changes, i.e., from all the possible variation
of parameters providing the same level of correction, the network is changed in the way that
the set of parameters defers the less from its previous state. This is done by applying a
generalization of the gradient descent method to deal with multilayer networks, called the
back propagation algorithm, the complete description of which will be found elsewhere [17].
2.1.4. Support vector machine
Another method to create a nonlinear classifier is the support vector machine SVM. To illustrate
the idea behind SVM, consider a two class problem. The main objective is to draw the decision
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border between two classes that provides the best separation of sub sets among all the possible
border lines (see Figure 2).
 
Figure 2. Among all the possible border lines, SVM chooses the one that provides the maximum margin between the
classes. Here, two classes, marked with a circle and an x in a two-dimensional feature space are shown. a) Some possi‐
ble non-optimal border lines. b) The right, the maximum margin border. Margins are shown in dots.
SVM finds the border line that has the largest margin or distance from the closest sample of
each class. The equation of the decision border is then the equation of the hyperplane:
0 TW x b+ = (9)
W  is a vector perpendicular to the hyperplane. x is a vector in feature space and b is a bias
term. In this part, it is convenient to split the optimization parameters θ in W  and b, to explicitly
take the interception term apart from others. Now propose the hypothesis function:
( ) ( ) ;Th g W bxx = + (10)




ì ³ï= í- £ïî
(11)
and the optimization problem is to find the optimal values for W  and b that maximize the
margin size. Starting from the Lagrangian
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which includes the Lagrange multipliers αi  to hold the restrictions imposed by g(z) in Eq.
(11). The optimality conditions for the objective function are found by differentiating Eq.
(12) against W  and b and setting it equal to zero. It can be found that W =∑ αi y (i)x (i) and







(i) =0. Also, the multipliers vanish for all the feature vectors outside the margin lines,
the remaining vectors are called support vectors and give rise to the method’s name. After
some algebra,  the minimization problems turn out  to be the maximization of  the objec‐
tive function [17]
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(i) =0. Here, the kernel function is just the inner product
K (x (i), x (i)) = (x (i))T x (i) that corresponds to a linear classifier, i.e., when the two classes can be
separated by a straight line. In the case that the data are not linear separable, SVM can become
non-linear by simply replacing the kernel by a non-linear one. If the kernel represents the inner
product of two vectors in the feature space, what does it mean a non-linear kernel function?
When changing the kernel, a representation of the feature space in a higher dimensional space
is obtained, related to the original feature space by some nonlinear transformation than is not
necessary to know. The only thing required is the form of the inner product in the new
coordinates expressed in terms of the original ones. This “kernel trick” allows the computation
of pretty complex decision borders. However, not any function of two features constitutes a
valid kernel. To solve this situation, a special case of Mercer’s theorem [18] guarantees the
validity of a kernel function, as far as the kernel matrix ki , j = K (x (i), x ( j)) is a symmetric positive
semi-definitive matrix.
In real application, it is common to find that the training set at hand is not separable, i.e., it is
not possible to find a border hyper surface that splits the feature space without misclassifica‐
tion of some training samples. And forcing the model to fit any training vector will produce
high bias. Then it is a good practice to implement regularization. This is done by introducing
the regularization term C∑
i
n
ξ( θ i) in the cost to minimize. Here θ i is the i-th component of
the parameter vector, ξ is a penalty function which accomplish ξ(θ)≥0 and C  is the regulari‐
zation parameter set by the user. C  allows to control how much bias is acceptable for the final
model.
2.1.5. Confusion matrix
To assess the accuracy of the ML model a confusion matrix for our classifier can be build. The
confusion matrix is an evaluation of how many feature vectors in the training and/or testing
set are misclassified. The matrix is built by contrasting the predicted class flag with the real
one for each feature vector. For example, consider a two class problem (like the benign or
malign tumor problem) that when trained against a set of 100 feature vectors report the
classification presented in table 1:
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Predicted / Real Benign Malign
Benign 45 12
Malign 15 25
Table 1. Example of a confusion matrix for a two classes clasiffier based on imaginary benign or malign tumor data.
In the example, 45 benign tumors have been classified as benign by the ML, and 15 have been
misclassified as malign tumors. The error estimate for a ML code is computed as the average
of miscalculated classes over the total of samples. It is the sum over all the off diagonal elements
over the total number of cases. In the example, the error range of 30%. And the accuracy,
defined as 1 − err is 70%.
2.2. Unsupervised learning
In this case, the first objective of the ML is to find some similarities among the data, which can
be used to divide it into clusters. Each cluster will then define a class, and new inputs to the
machine (outside the training set) will be classified following the clustering of the training
space.
2.2.1. Clustering
So far, the feature vector is represented as a set of numerical values in real space. From the
mathematical point of view, each input “box” inside a vector is called a dimension and the
value in the box is a coordinate. The length of the vector is the number of dimensions of the
containing space. A space is a collection of vectors that follow a set of rules (an algebra). If a
distance measure for any two points in the space (features vectors) can be build, then the data
can be clustered [19]. A common choice is the Euclidean distance, defined as the square root
of the sums of the squares of the differences between the coordinates of the two vectors in each
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2.2.2. K-means
A common clustering algorithm known as K-means is as follows: chooses a number of clusters
k to be found, and initialize the clusters centroids µ1 , µ2 ,...,µk  randomly. Then assign each
one of the training feature vectors to a cluster by relating it to the closest centroid (the one
which has the minimum distance to the sample). When all vectors in the training set are labeled,
recompute the position of the centroids as the average of the feature vectors inside the cluster,
for each cluster. If there are centroids without any feature vector assigned, it can be dismissed
or repositioned randomly. Now iterate again relabeling the training set and recomputing the
centroids positions until convergence is achieved.




It is a quite expensive algorithm to obtain clusters which is based on finding a partition
hierarchy among the data. It can be started by making each feature vector a cluster with one
single member. Then, the distance between any pair of vectors is computed. If the distance is
lesser than some selection parameter, the clusters are mixed to form one. In the new distribu‐
tion of clusters, each cluster is represented by its centroid, and iterates the process until some
convergence criteria is achieved. For example, a predefined number of clusters is reached. Due
to the computational cost involved in hierarchical clustering, it is not recommended for
problems with large training set.
2.2.4. The CURE algorithm
This is a large-scale-clustering algorithm. When centroids are used to define clusters, it is
expected that any cluster would have a regular shape in features space, and the space is
expected to be Euclidean. The clustering using representatives (CURE) algorithm is a little
more general, due that it can handle irregular shaped clusters. This method defines a cluster
in terms of a set of representative members of the cluster. These representatives must be chosen
in a way that they are as far as possible from each other. Then, the representatives are points
on the “surface” of the cluster. This kind of construction allows any shape for the cluster,
including rings. To apply the CURE algorithm, first an initial clustering must be done, then
the representatives are chosen for each cluster, and finally, two clusters are united if they have
a pair of representatives that are close enough following some user-definedcriteria.
3. LCI experiments and data extraction
3.1. Experiment description
3.1.1. Materials and methods
3.1.1.1. Cell lines expressing fluorescent mithondria (Vero-Mito)
The Vero epithelial cells (ATCC) were maintained under standard culture conditions as
described in other works from this lab [20-21], and in another chapter of this book [22]. The
temperature was set at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide.
The monoclonal cell line over-expressing the plasmid pmKate2-Mito (Evrogen®) were
obtained with a cell sorter (Moflo XDP, Beckman Coulter®), with ulterior antibiotic selection
(Kanamycin) of transfectants during 21 days in accordance to the experimental procedures
described in detail in [23].
3.1.1.2. Virus preparation, titration and infection protocols
The strain New Guinea of Dengue Virus Serotype 2 (DENV-2) was grown and maintained in
insect cells C6/36 HT under the standard practices as described in [20, 21], and this book [22].
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Briefly the DENV were amplified at a very low MOI (multiplicity of infection) to avoid genetic
drift and apparition of DIs (defective interfering particles), which could be altering the whole
data concerning the real synchronized infections [24]. Viral titers were detected by plaque
assay, using a Vero cell monolayer culture under 1% methylcellulose overlay medium as it
was reported by [20, 21]. The viral infections were done by the same way of our previously
reported works [20, 21], with the difference that for live cell imaging the cells were seed and
registered in 35-mm glass bottom dishes (MatTek Corporation) with 0.7 mm in thickness of
the glass coverslides, which is adequate in refraction index for this kind of inverted confocal
microscope for registering living cells. The negative controls of infections were named mock
infections, as it had been standardized traditionally for the virology community [24].
3.1.1.3. Live cell imaging
The Vero-Mito (3x105 cells) cell line was seed in Petri dishes adequate for living cells with
bottom with coverslide of 0.17 mm, and previous to the register the normal culture medium
used was changed by a DMEM without red phenol for avoiding the autofluorescence of this
pH-indicator chemical. The videos of living cells over expressing fluorescent mitochondria (+/-
infections) were obtained with a confocal microscopy based on disk spinning Unit (Olym‐
pus®IX-81 DSU), coupled to incubator and mixing gases Tokai-Hit Co® systems, which
regulate the micro environment of cell culture with temperature and carbon dioxide in all
system. The mock infections and infections of the overnight micrographs were captured in an
OrcaR2CCD (Hamamatsu®) ultra-refrigerated camera with electro multiplier, coupled to the
illumination systems with Arc burners of 150 W constituted by mercury-xenon or xenon lamps
(Olympus®-MT10 Illumination System). The photonic signals emitted by the biological
specimen were transduced to electromagnetic waves for the CCD (charge coupled device),
transmitted by a light fiber 2 m of single quartz to the Workstation Xcellence-Pro (Olympus®)
for image processing, which also include the application of deconvolution tools for improving
the signal/noise ratio of images.
3.2. Image segmentation and extraction of information
A total of nine videos generated by LCI where studied. Four of them correspond to mock cells
(uninfected) and five to infected cells. Each video has 36 frames taken each 20 min for a period
of 12 h. The videos are recorded in color at 1024x1344ppi resolution. As the color has no relevant
information, they have been converted into gray scale. The last 34 vertical lines of each frame
were dismissed in order to get rid of the microscope watermark. Then the resolution has been
decreased to 495 x 672. The cells in this study have been selected under the following criteria:
• The whole cell is present in any frame of the video and the nucleus was clearly distinguish‐
able on any frame.
• There were not other cells too close, so the mitochondrial distribution does not seem to be
overlapped with those from neighbor cells.
Under this procedure, 11 cells were selected, 4 mock and 7 infected. Any selected cells were
modeled as having an elliptical nuclei, by manually choosing four points on the nuclei
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borderline and applying the Hough transform [25] (see Figure 3 and 4). The nucleus and the
cell are proven to be approximately aligned [26] so the nuclear envelope is approximated by
another ellipsis centered in the nuclei, with the same inclination and the axis twice as long.
This rudimentary model provides us with the necessary segmentation to perform the cell
tracking by simply creating a mask over the region where the ellipsis is located for any frame
in the video. The images are stored as intensity matrices where each entry is a pixel. Masks are
stored as matrices of the same dimension, whose entries take values of zero or one. If the pixel
belongs to the segmented region the associated mask value is one. Those matrices are stored
in binary format to be processed in a Python script that takes advantage of numpy and Scipy
libraries for further analysis.
Figure 3. An infected cell appearing in the original image present on video.
Figure 4. The segmented region used to track and study the cell. Nucleus is modeled as having an elliptic shape. The
exterior membrane is modeled as a concentric ellipsis with the major semi axis twice as long as the nucleus.
Cell Biology - New Insights16
borderline and applying the Hough transform [25] (see Figure 3 and 4). The nucleus and the
cell are proven to be approximately aligned [26] so the nuclear envelope is approximated by
another ellipsis centered in the nuclei, with the same inclination and the axis twice as long.
This rudimentary model provides us with the necessary segmentation to perform the cell
tracking by simply creating a mask over the region where the ellipsis is located for any frame
in the video. The images are stored as intensity matrices where each entry is a pixel. Masks are
stored as matrices of the same dimension, whose entries take values of zero or one. If the pixel
belongs to the segmented region the associated mask value is one. Those matrices are stored
in binary format to be processed in a Python script that takes advantage of numpy and Scipy
libraries for further analysis.
Figure 3. An infected cell appearing in the original image present on video.
Figure 4. The segmented region used to track and study the cell. Nucleus is modeled as having an elliptic shape. The
exterior membrane is modeled as a concentric ellipsis with the major semi axis twice as long as the nucleus.
Cell Biology - New Insights16
3.3. Information processing
In the gray-scale video, the mitochondrial distribution is shown as bright points, been more
brilliant those places where the density of mitochondrium is higher. Then, the density
distribution of mitochondrium can be estimated as proportional to the intensity distribution
ρ(x,  y,  t)  =  αI (x,  y,  t). In each frame of each video, a discrete set of pixel intensity values
is recorded. This means that the intensity distribution in a discrete grid of point (X ,  Y ) has
been measured, where x  ∈  X  and y  ∈  Y  are the sets of pixels coordinates.
The shape of the density distribution of mitochondrium is the same shape of the intensity
distribution. Those functions differ only by a constant of proportionality that became irrelevant
when the density function is normalized. So further in this reading both functions would be
referred indistinguishable as ρ(x,  y,  t).
The continuous density function can be approximated from the set of pixel intensity meas‐
urements by some interpolation method. In this work, a two-dimensional interpolation in
terms of bivariate splines has been used on each segmented frame. This procedure allows us
to extract important information about the mitochondrial behavior. Each frame is taken after
a fixed period of time of 20 mins, so they form a time series of the density distribution function
ρ(x,  y,  t) through the whole experiment.
4. Results and discussion
In cell biology studies live cell imaging is a newcomer; however, the innovation in computa‐
tional biology tools is been forced by the convergence of distinct research programs. Being so,
LCI is no longer only a “technique” but a new exploratory science [27], that brings the
possibility of encompassing cross-disciplines. In this sense, the subcellular patterns of distinct
cellular organelles and macromolecular structures within the cell are important for dynamical
studies, which will be useful in predictive medicine [28].
The mitochondrial morphology is a remarkable area for biomedical research since more than
a decade [29], because these cellular organelles change under physiological and pathological
conditions, like metabolism, thermogenesis, homeostasis of calcium and several kinds of cell
death [30, 31]. But there is lacking information about the subcellular distribution of mitochon‐
drium after a cell injury like the viral infections, and this quantitative information is key for
tracking some cellular events of virus cycle that have been covered to the computational cell
biology exploration.
New developments have been focused in the high-resolution microscopy images of the fine
morphology of mitochondria [32]. Having in mind the improved time resolution, this infor‐
mation is decisive for understanding of the dynamics and functioning of these cellular
organelles at high-throughput screenings [33].
But here, the work was mainly directed to study and characterize the subcellular distribution
of mitochondria with and without Dengue virus infections on epithelial cells that are consti‐
tutively expressing these organelles in red fluorescence.
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Recently, it had demonstrated that not only shape, number and size of the organelles are
important  for  the  cellular  function,  but  also  their  subcellular  distribution,  which  is  the
consequence of the intracellular transport [34]. Since Dengue virus like many other members
of the most diverse viral  families are using the cytoskeleton [22],  here we have tried to
follow indirectly the infection process using the alterations of subcellular distributions of
mitochondria.
Both mock and DENGV infected cells have been prepared by a standardized procedure that
provides approximately the same initial state among all cells of each type even when different
experiments are considered. So at frame 0 each of the studied cells provides a possible initial
state. Each of these states must adjust to the density distribution of mitochondrium. Assuming
that any possible initial state is equally probable, then our approximation to the density
function at time zero ρ(r ,  θ,  t  =  0) must come from the average over all the known (meas‐
ured) possible states. Each frame has the same time spacing for all the videos (20 minutes), so
the same analysis is valid for the i−th frame and the mitochondria density distribution at time
t  would be the average over all the known states for all cells of the same kind.
The distribution as a function of two variables given by the pixel position related to the center
of the cell is ρ(x,  y). However, before taking the average, it has to be taken into account that
a single cell can have any random orientation. The elliptical shape of the nucleus makes the
distribution not symmetrical. This means that all function must be rotated to have the same
orientation before been able to average over them.
A Python script was written to automatically determine the major semi axis of each cell in each
frame by measuring the maximum distance between two points into the segmented region.
The center of the ellipsis is found as the average of all the coordinates in the image. To get ρ(r,
θ, t) for any cell referred to the same polar axis, and so be able to compute the density average,
the polar axis is set equal to the major semi axis in each of the cells analyzed. In polar coordi‐
nates ρ(r ,  θ) will give us the density of mitochondrium at a distance r  from the nuclei center
and at an angle θ from the major semi axis.
The average density of mitochondrium distribution ρ(r, θ, t) is shown for three frames (t = 0,
320, 720 minutes) in Figures 5, 6, and 7. Those are the initial state, one intermediate state and
the final state of the study. The vertical axis is the level of intensity (proportional to the
mitochondrium density) and the horizontal axis is the distance to the nuclei center in pixels.
In each subplot the projection of ρ(r, θ, t) for a given angle in radians is presented.
It can be seen that mock cells present prominent peaks for some radial positions, i.e., the
distance between the peak and the closest local minimum is large compared with the back‐
ground density. Also, the background density is low. This suggests that mock cells have the
mitochondrium distributed in clusters around the nuclei. At variance, the infected cells
average mitochondrium density distribution presents a higher background intensity com‐
pared with the maximum of the distribution. The peaks are less defined than those for mock
cells, which means that the mitochondrium clusters are less defined or inexistent. And the
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Recently, it had demonstrated that not only shape, number and size of the organelles are
important  for  the  cellular  function,  but  also  their  subcellular  distribution,  which  is  the
consequence of the intracellular transport [34]. Since Dengue virus like many other members
of the most diverse viral  families are using the cytoskeleton [22],  here we have tried to
follow indirectly the infection process using the alterations of subcellular distributions of
mitochondria.
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provides approximately the same initial state among all cells of each type even when different
experiments are considered. So at frame 0 each of the studied cells provides a possible initial
state. Each of these states must adjust to the density distribution of mitochondrium. Assuming
that any possible initial state is equally probable, then our approximation to the density
function at time zero ρ(r ,  θ,  t  =  0) must come from the average over all the known (meas‐
ured) possible states. Each frame has the same time spacing for all the videos (20 minutes), so
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distribution not symmetrical. This means that all function must be rotated to have the same
orientation before been able to average over them.
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frame by measuring the maximum distance between two points into the segmented region.
The center of the ellipsis is found as the average of all the coordinates in the image. To get ρ(r,
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and at an angle θ from the major semi axis.
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the final state of the study. The vertical axis is the level of intensity (proportional to the
mitochondrium density) and the horizontal axis is the distance to the nuclei center in pixels.
In each subplot the projection of ρ(r, θ, t) for a given angle in radians is presented.
It can be seen that mock cells present prominent peaks for some radial positions, i.e., the
distance between the peak and the closest local minimum is large compared with the back‐
ground density. Also, the background density is low. This suggests that mock cells have the
mitochondrium distributed in clusters around the nuclei. At variance, the infected cells
average mitochondrium density distribution presents a higher background intensity com‐
pared with the maximum of the distribution. The peaks are less defined than those for mock
cells, which means that the mitochondrium clusters are less defined or inexistent. And the
mitochondrium tends to fill all the space available. Is also noticeable that the infected cells
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show more local maximum, which suggest that the distribution is somehow disorganized
(more random).
These  findings  imply  that  a  general  structural  change  in  mitochondrium distribution  is
caused by viral infection and it can be evidenced directly by examination of a cell’s picture.
The clustered behavior presented by mitochondrium on mock cells implies that they are
grouped when normal function of the cell is in process. This is an organized distribution.
On  the  other  hand,  the  lack  of  clusters  in  infected  cells  shows  that  when  infected  the
mitochondrium distribution became erratic, maybe random, which will be associated with
a lack of organization.
A possible way to detect the presence of a viral infection will be to measure the level of
randomness present in mitochondrium distribution. Remembering that ρ(r, θ, t) is experi‐
mentally measured through the pixel intensity in each video frame, it is found that the
randomness in mitochondrium distribution will be the same than the randomness in pixel
intensity distribution of the segmented image.
An image on gray scale is described digitally in terms of intensity values ranging from 0 (black)
to 255 (white), a total of 256 possible shades of gray, each one of those possibilities is known
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Figure 5. Average density of mitochondria ρ(r, θ, t), for t = 0 min. Mock cell mitochondrial density average is in blue
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P(i)is the probability of finding the i−th level of intensity inside the image. As mock cells shows
more order than infected cells in ρ(r, θ, t), it can be expected that for the entropy in mock cell’s
image to be lesser than the entropy in the image of an infected one.
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Figure 6. Average density of mitochondria ρ(r, θ, t), for t = 320 min. Mock cell mitochondrial density average is in blue
(color online) dashed line and infected mitochondrial density is in red continuous line.
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means that the intensity is changing more frequently, so the tone in the pictures is less uniform.
Then it can be expected from the uniformity descriptor on the picture of an infected cell to be
low.
In Figure 8, a plot on the uniformity vs entropy parameters space shows the computed values
for those image descriptors for all studied cell in all frames. It can be seen that the mock and
infected cells occupy mainly different regions on parameter space. So, these descriptors
constitute a promising candidate to be a feature vector (or a part of it) in a machine learning
code designed to classify infected cells.
5. Conclusion
A detailed analysis of the mitochondrium distribution around the nuclei for seven infected
cells and four mock cells in nine videos has been performed. The study shows that mock cells
clusters its mitochondrium and present an organized distribution in space. The organized
character of the mitochondrium density distribution is maintained through time. At variance,
infected cells loose these organized characteristics and the distribution of mitochondrium
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Figure 7. Average density of mitochondria ρ(r, θ, t), for t = 720 min. Mock cell mitochondrial density average is in blue
(color online) dashed line and infected mitochondrial density is in red continuous line.
A Proposal for a Machine Learning Classifier for Viral Infection in Living Cells Based on Mitochondrial Distribution
http://dx.doi.org/10.5772/61293
21
performing its natural process. But when a DENV infection is affecting the cell, those natural
process are interrupted and it is reflected in the way how mitochondrium behaves. From this
analysis, two image attributes are found to be suitable to be used as features in a ML classifier
between infected and mock cells. These features are simple common image processing
descriptors: entropy and uniformity, whose computation is easy and fast. Entropy is related with
the randomness presented in the gray tones of the image and uniformity is related with the
prevalence of a single gray tone. Both image attributes in a LCI photograph taken over a cell
culture prepared with coloured cells are directly related with the mitochondrium density
distribution behavior ρ(r, θ, t). The presence of clusters in mock cells and the softer ρ(r, θ, t)
behavior are translated to higher values of uniformity and lower values of entropy image
descriptors than those present in infected cells images.
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Abstract
Na+,K+-ATPase is an ATP-powered ion pump that establishes concentration gradients for
Na+ and K+ ions across the plasma membrane in all animal cells by pumping Na+ from the
cytoplasm and K+ from the extracellular medium. This heterodimeric enzyme, a member
of P-type ATPases, is composed of a catalytic α-subunit with ten transmembrane do‐
mains and a heavily glycosylated auxiliary β-subunit. The Na+,K+-ATPase is specifically
inhibited by cardiotonic steroids like ouabain, which bind to the enzyme’s α-subunit
from the extracellular side and thereby block the ion pumping cycle. Na+,K+-ATPAse gen‐
erates ion gradients that establishes the driving force for the transepithelial transport of
several solutes and nutrients. The effectiveness of this vectorial transport motivated by
Na+,K+-ATPase depends on the integrity of epithelial junctions that are essential for the
maintenance of the polarized localization of membrane transporters, including the lateral
sodium pump. This chapter reviews the facts showing that, in addition to pumping ions,
the Na+,K+-ATPase located at the cell borders functions as a cell adhesion molecule and
discusses the role of the Na+,K+-ATPase β-subunit in establishing and maintaining cell–
cell interactions. Furthermore, Na+,K+-ATPase is a multifunctional protein that, in addi‐
tion to pumping ions asymmetrically and participating in cell–cell contacts, acts as specif‐
ic receptor for the hormone ouabain and transduces extracellular signals. Thus, when
bearing in mind with transporting epithelia phenotype, the importance of modulation of
cell contacts by Na+,K+-ATPase can hardly be underestimated.
Keywords: Epithelial cells, Na+, K+-ATPase, Polarity, cell adhesion
1. Introduction
Epithelium is the name given to the cells that line a surface. Epithelia separate biological
compartments with different composition, a fundamental role that depends on the establish‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
ment of occluding junctions. Thus, epithelial cells are always contiguous with one another and
are usually joined by special junctions—the tight junctions. The functions of epithelia differ
markedly. Although all form a barrier, some are much more impermeable than others. The
trans-epithelial movement of ions and molecules is reached by the action of a multitude of
specialized transporting proteins that are asymmetrically distributed on the apical or basolat‐
eral plasma membrane domains of epithelial cells. This remarkable polarity of epithelial cells
depends on the selective insertion and the recycling of newly synthesized proteins and lipids
into distinct plasma membrane domains and on the maintenance and modulation of these
specialized domains once they are established during epithelial development. The two basic
characters of epithelial transporting phenotype are polarity and tight junctions (TJs). Polarity
offers the necessary direction for substances transported across epithelia to be absorbed or
secreted. TJs guarantee that the transported substances do not leak back through the intercel‐
lular space [1, 2]. The Na+,K+-ATPase, known as the sodium pump, has been shown to play a
central role in the transporting phenotype of epithelia. Today, we already know its crystal
structure, the chemical composition as well as the spatial arrangement of its three subunits (α,
β, and γ) (Fig. 1A), the relationship between ATP hydrolysis and ion movement, and several
diseases related to its malfunction. Surprisingly, despite such detailed information, we keep
finding new remarkable properties and new physiological functions of the Na+,K+-ATPase.
The present chapter is focused on three recently found properties: its expression at the lateral
membrane of epithelial cells due to the self-adhesive property of the β-subunit, its role as
hormone receptor, and its ability to modulate several types of cell contacts.
2. Na+,K+-ATPase in epithelia
The history of Na+,K+-ATPase can be compared to a double-sided step ladder, one climbed by
biologists that investigated its intrinsic mechanisms and subunits the other by accomplished
physicists who first criticized but finally solved immense theoretical obstacles in the road
toward active transport. Thus, for a long while, the peculiar composition of the cytoplasm was
attributed to presumed membrane impermeability to Na+. This alternative was invalidated
right after the Second World War, when radioisotopes became available for biological research,
and it was discovered that tracer Na+ added to the bathing solution readily penetrates and
distributes into the cell. This revived the question why Na+ in the cytoplasm remains at a
concentration much lower (∼15 mM) than in the extracellular water (∼140 mM). The simplest
assumption was that there should be an enzyme in the plasma membrane that dissipates
metabolic free energy to pick up Na+ from the cell water and pump it out. This response was
not readily accepted because it appeared in violation of the Curie principle: “Processes of
different tensorial order cannot be coupled.” In simple worlds, metabolism and ATP hydrol‐
ysis are chemical reactions, which at that time were taken to be scalar processes; hence, they
could not drive a vectorial process like the extrusion of Na+ from the cytoplasm. Later on, it was
argued that, in fact, chemical reactions are vectorial at microscopic level. However, this
vectoriality is masked at macroscopic scale, in particular, when working with homogenized
tissues where pumps point in all directions. However, if they were ordered in a membrane,
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finding new remarkable properties and new physiological functions of the Na+,K+-ATPase.
The present chapter is focused on three recently found properties: its expression at the lateral
membrane of epithelial cells due to the self-adhesive property of the β-subunit, its role as
hormone receptor, and its ability to modulate several types of cell contacts.
2. Na+,K+-ATPase in epithelia
The history of Na+,K+-ATPase can be compared to a double-sided step ladder, one climbed by
biologists that investigated its intrinsic mechanisms and subunits the other by accomplished
physicists who first criticized but finally solved immense theoretical obstacles in the road
toward active transport. Thus, for a long while, the peculiar composition of the cytoplasm was
attributed to presumed membrane impermeability to Na+. This alternative was invalidated
right after the Second World War, when radioisotopes became available for biological research,
and it was discovered that tracer Na+ added to the bathing solution readily penetrates and
distributes into the cell. This revived the question why Na+ in the cytoplasm remains at a
concentration much lower (∼15 mM) than in the extracellular water (∼140 mM). The simplest
assumption was that there should be an enzyme in the plasma membrane that dissipates
metabolic free energy to pick up Na+ from the cell water and pump it out. This response was
not readily accepted because it appeared in violation of the Curie principle: “Processes of
different tensorial order cannot be coupled.” In simple worlds, metabolism and ATP hydrol‐
ysis are chemical reactions, which at that time were taken to be scalar processes; hence, they
could not drive a vectorial process like the extrusion of Na+ from the cytoplasm. Later on, it was
argued that, in fact, chemical reactions are vectorial at microscopic level. However, this
vectoriality is masked at macroscopic scale, in particular, when working with homogenized
tissues where pumps point in all directions. However, if they were ordered in a membrane,
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the asymmetry would be recovered, and a macroscopic flux would take place. A model put
forward by Koefoed-Johnson and Ussing [3] proposed a pump located asymmetrically on the
basal side of the epithelial cell that together with the specific Na-permeability of the outer cell
membrane and the specific K-permeability of the inner facing membrane is responsible for the
net movement of Na+. This made theoreticians happy, yet where was “the pump,” i.e., the
membrane molecule, that would align and be responsible for the sided, asymmetrical move‐
ment of Na+? On 1957, Jens Christian Skou prepared an extract of crab tissue that contained
an enzyme that splits molecules of ATP (hence deserving the name “ATPase”) into ADP + Pi,
provided the medium contains K+ and Na+ ions at concentrations that compare with those in
the cell and in the surrounding extracellular space. Therefore, the enzyme was aptly named
Na+,K+-ATPase. Interestingly, Skou [6] was able to inhibit the ATP splitting activity of his
extract by adding ouabain, a substance of vegetal origin that was found a few years earlier to
inhibit active potassium and sodium transport in erythrocyte membrane [5]. By performing
the Na+/K+ translocations cyclically, Na+,K+-ATPase transfers those ions in a net amount toward
the extracellular medium and toward the cytoplasm, respectively, so it was justified to call it
“pump” [6]. Another experimental/theoretical conflict occurred with sugars and amino acids
transported in a net amount across epithelia. Since this transport occurs in a net amount and
can be inhibited with ouabain, for a while, it was taken as a proof that there exists a glucose
pump as well as other pumps for diverse amino acid species. Yet eventually, it was demon‐
strated that carriers for sugars and for amino acids are not pumps as they are not directly
coupled to metabolism. Therefore, the Na+,K+-ATPase is the primum movens, responsible for
the exchange of substances between the metazoan and the environment, across transporting
epithelia, as well as for net exchange between the internal milieu and the cytoplasm.
2.1. Structure–function relationship of Na+,K+-ATPase
Na+,K+-ATPase is expressed in all animal cells and is one of the most important members of
the P-type ATPases. The Na+,K+-ATPase creates the Na+ and K+ concentration gradients across
the plasma membranes of most higher eukaryotic cells. Per cycle, it pumps three Na+ ions out
and two K+ ions into the cell, coupling the energy derived from the hydrolysis of one ATP
molecule. The Na+ and K+ gradients originated and maintained by Na+,K+-ATPase are the
energy source for secondary active transport, which are used for the maintenance of cell
osmolarity and volume, for the generation of action potentials along nerve cells, and for many
other cellular purposes. The functional Na+,K+-ATPase is a heterodimer of α- and β-subunits.
In addition to the αβ heterodimer, there are tissue-specific regulatory γ-subunits, also known
as FXYD proteins [7]. In this section, we will review the general structural and functional
characteristic of each subunit and how the pumping of Na+ and K+ is achieved. Important
findings about the function are briefly discussed in the light of several X-ray crystallography
studies of Na+,K+-ATPase published in recent years [8–10] (Fig. 1A).
2.1.1. The α-subunit
The catalytic α-subunit is composed of approximately 1000 amino acid residues with a
molecular mass of about 110 kDa. Since the first sequencing and cloning of the α-subunit of
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the Na+,K+-ATPase [11], many biochemical studies pointed out to a model of ten transmem‐
brane domains (M1–M10) and three cytoplasmic domains: A (actuator), N (nucleotide
binding), and P (phosphorylation domain) (Fig. 1A). Another myriad of studies identified
motifs crucial for cation binding and conformational transitions [12]. Four distinct isoforms of
the α-subunit have been identified (α1–α4) in which sequence differences are minor. Each
isoform has different kinetic properties which may be essential in adapting cell Na+,K+-ATPase
activity to specific physiological requirements [3]. The major form α1 is found in most tissues
and is the main or only form in kidney and most other epithelia.
The Na+,K+-ATPase A domain consists of the N-terminal segment plus the loop between M2
and M3 (Lys212-Glu319), which form a distorted jelly roll structure plus two short helices in
the 40 residues of the N-terminal segment. The movements of this domain, especially of the
loop M2–M3, are determinants for the TM conformational rearrangements, needed for the
occlusion and release of cations (see Fig. 1B) [14]. N domain contains the ATP-binding site and
extends from the phosphorylation site Asp376, with the 377-KTGTL sequence, to the C-
terminal 593-DPPR hinge motif. Finally the P domain can be described as a six-stranded parallel
β-sheet and contains three important motifs: 376-DKTGTL, which contains the aspartic acid
residue that phosphorylates during catalysis; 617-TGD on strand 3, which associates with the
phosphorylation motif during the conformational transition E1 to E2; and 715-TGDGVND,
which terminates the sixth β-strand of the P-domain where Asp717 is required for binding of
Mg2+ and phosphorylation (Fig. 1B).
The first crystal structure of Na+,K+-ATPase α-subunit published was that of Rb+-bound pig
renal Na+,K+-ATPase. Each of the three cytoplasmic domains and transmembrane helices of
α-subunit are superimposable with Ca2+-ATPase (SERCA). The two sites for K+ binding are
found between helices M4, M5, and M6, and many of the residues involved had already been
identified in various studies as cation-binding residues [8]. The first complete high-resolution
crystal structure of Na+,K+-ATPase was obtained in a potassium-bound state and provided
further detail into the molecular basis for K+ specificity [9] (Fig. 1A). The carboxy terminal part
of the L7/8 loop is the primary interaction site with the β-subunit, in which a consensus
sequence 901 SFGQ, proposed as a key interaction site is located [15].
2.1.2. The β-subunit
The β-subunit of the Na+,K+-ATPase was initially identified as a glycoprotein associated with
the α-subunit in purified functional enzyme preparations [16]. The association between α- and
β-subunits is relatively strong and remains stable in most non-ionic detergents. All of the
known β-subunit species and isoforms share a common domain structure: a short N-terminal
cytoplasmic tail, a single transmembrane segment, and a large extracellular C-terminal domain
containing six extracellular cysteine residues forming three disulfide bridges, whose locations
are completely conserved among the isoforms. Na+,K+-ATPase β-subunit is composed of
approximately 310 residues with an apparent molecular mass of 55 kDa due to N-glycosyla‐
tion. The β-subunit of the Na+,K+-ATPase has three isoforms designated β1, β2, and β3. Among
these isoforms, there are various degrees of difference, and although all β-subunits are
glycosylated, the number of N-glycosylation sites varies with the isoform. The β1 isoform of
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identified in various studies as cation-binding residues [8]. The first complete high-resolution
crystal structure of Na+,K+-ATPase was obtained in a potassium-bound state and provided
further detail into the molecular basis for K+ specificity [9] (Fig. 1A). The carboxy terminal part
of the L7/8 loop is the primary interaction site with the β-subunit, in which a consensus
sequence 901 SFGQ, proposed as a key interaction site is located [15].
2.1.2. The β-subunit
The β-subunit of the Na+,K+-ATPase was initially identified as a glycoprotein associated with
the α-subunit in purified functional enzyme preparations [16]. The association between α- and
β-subunits is relatively strong and remains stable in most non-ionic detergents. All of the
known β-subunit species and isoforms share a common domain structure: a short N-terminal
cytoplasmic tail, a single transmembrane segment, and a large extracellular C-terminal domain
containing six extracellular cysteine residues forming three disulfide bridges, whose locations
are completely conserved among the isoforms. Na+,K+-ATPase β-subunit is composed of
approximately 310 residues with an apparent molecular mass of 55 kDa due to N-glycosyla‐
tion. The β-subunit of the Na+,K+-ATPase has three isoforms designated β1, β2, and β3. Among
these isoforms, there are various degrees of difference, and although all β-subunits are
glycosylated, the number of N-glycosylation sites varies with the isoform. The β1 isoform of
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Na+,K+-ATPase, which is consistently predicted to have three N-linked glycosylation sites, has
been most extensively studied. All three consensus sites of β1 are glycosylated [17, 18], and the
oligosaccharides are terminally sialylated. Treuheit et al. [19] showed by mass spectrometry
that the oligosaccharides of the β1-subunit from dog and lamb kidney are of tetra-antennary
structure with extensions of 2–4 N-acetyllactosamine units, and the units of extension seemed
to differ between the dog and the lamb β1-subunits. Nevertheless, detailed information is not
available for the oligosaccharide composition of the two other isoforms, but it seems clear that
there is a high degree of species variability for the β2 isoform too. This isoform contains 7–9 N-
glycosylation sites. It holds the high mannose-type carbohydrate epitopes L3 and L4 [20] also
present on the neural recognition molecules L1, MAG, and P0 that mediate adhesion among
neural cells [21]. Indeed, the β2 subunit was originally identified as an adhesion molecule,
AMOG, in glial cells [22].
The essential function of the β-subunit is acting as the molecular chaperone of the α-subunit.
Na+,K+-ATPase α-subunit is inactive without its β-subunit. It has been demonstrated that the
association of the β-subunit facilitates the correct packing and membrane integration of the
newly synthesized α-subunit. Also, as the intimate partner of α-subunit, it modulates cation-
Figure 1. Structure of the Na+,K+-ATPase. (A) Ribbon model of the crystal structure of shark Na+,K+-ATPase [9; PDB
code: 2ZXE], indicating α-subunit transmembrane domains in gray and cytoplasmic domains A, N, and P in red,
green, and blue, respectively. The β-subunit is colored in orange and lacks most of its N-terminal cytoplasmic domain
as in the crystal. The γ-subunit is colored in magenta. Alpha subunit transmembrane helices are numbered with the
exception of TM 1 and 9, which are not visible from this projection. The two potassium ions occluded in the crystal
structure are depicted in yellow. In the N domain, the ATP binding site is also indicated in yellow. (B) Schematic de‐
piction of the catalytic cycle of Na+,K+-ATPase. A structural rearrangement, especially in domain A (pink-colored), is
suggested by the cartoons at both conformational states E1 and E2. For simplicity, the rest of the cycle stages are repre‐
sented only with the TM region in gray. (A) The outward transport of three Na+ ions is coupled to the E1 to E2 transi‐
tion. (B) Two K+ ions bind at binding sites positioned to the extra cellular space. (C) Extracellularly bound K+ ions
activate dephosphorylation that in turn results in ion occlusion. Ouabain (cardiotonic steroid silhouette in brown)
binds at this conformational state halting the cycle. (D) ATP with a low affinity triggers the acceleration of inward
transport of K+ ions through the pore as the pump enters the E1 conformational transition with low affinity for K+. (E)
Three Na+ ions bind the intracellularly oriented sites. (F) Phosphorylation from ATP occurs, and Na+ ions are occluded.
Several transitional substates exist during the cycle; nevertheless, they are not depicted for simplification.
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binding affinity [23, 24]. The complete crystal structure of Na+,K+-ATPase explains, at least
partially, previous implications of the β-subunit in modulation of cation transport. The
transmembrane helix of the β-subunit runs slightly separated from those of the α-subunit and
is rather inclined than perpendicular to the membrane. It forms several interactions with M7
and M10 helices of the α-subunit. The extracellular domain of the β-subunit contains the well-
conserved YYPYY motif that mediates several salt bridges with α-subunit L7/8 loop and also
contains at least three additional clusters of residues interacting with α-subunit [9]. In epithelia,
in addition to the classical chaperone function of the β-subunit, a cell-to-cell adhesion function
has been ascribed to the β1 subunit. This novel role of the β1-subunit will be described in a
separate part of this chapter.
2.1.3. The γ-subunit
In addition to the αβ heterodimer, there are tissue-specific regulatory γ-subunits, which are
small membrane proteins characterized by an FXYD sequence, and therefore known also as
FXYD proteins, of approximately 80–160 residues [24]. FXYD proteins mainly consist of a single
transmembrane helix and an N-terminal extracellular domain where the FXYD motif is located.
This domain anchors to the β-subunit extracellular and transmembrane domains. These
proteins modulate the function of Na+,K+-ATPase adapting kinetic properties of cation active
transport to the specific needs of different tissues [7]. The most studied FXYD proteins are
FXYD1 or phospholemman mainly expressed in heart and skeletal muscle and is involved in
heart contractility. In epithelia, kidney-specific FXYD2 decreases affinity of Na+,K+-ATPase for
sodium and FXYD4 or CHIF, expressed in colon and kidney epithelia acts as a modulating
several ion transport mechanisms that have Na+,K+-ATPase as a common denominator [26, 27].
2.2. The pumping catalytic cycle
Ion movements through the Na+,K+-ATPase have been studied by biophysical experiments for
many years [28–30]. Those studies were incorporated into the conceptual framework called
post-Albers cycle that depicts the sequence of reaction steps that couple ion transport and ATP
hydrolysis (Fig. 1B). Na+ and K+ transport follow a “ping-pong” mechanism, wherein the two
ion species are transported sequentially. Pumping of ions is achieved by alternation between
two major conformational states, E1 and E2 [31, 32]. In E1, the cation-binding sites have high
affinity for Na+ and face the cytoplasm; in E2, the cation-binding sites have low affinity for Na
+ but high affinity for K+ and face the extracellular. As it is the case for all P-type ATPases, Na
+,K+-ATPase autophosphorylates and dephosphorylates during each reaction cycle. In E1, after
three Na+ ions are bound at the cytoplasmic face, the phosphoryl group is transferred to a
conserved aspartic residue in the P-domain. At this point, the pump enters the E1P state with
occluded Na+ ions, and when ADP leaves, another conformational change occurs, and the Na+
ions are released at the extracellular face. At this stage, the enzyme is no longer sensitive to ADP
addition but to aqueous hydrolysis (E2P state) so that Pi is released at the catalytic site and so
are two K+ ions occluded at the extracellular face. To complete the cycle, ATP binds the
phosphorylation site leading to the departure of the two K+ ions in the cytoplasm. At this point,
the pump returns to the E1 state with high affinity for Na+ ready to launch a new catalytic cycle
(Fig. 1B).
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The first crystal structures of Na+,K+-ATPase have been obtained in the E2 state, which is more
stable [8, 9]. Nevertheless, they lack information about the Na+-bound state and in particular
the location of the third Na+ site. Two recently published crystals both of Na+,K+-ATPase from
pig kidney are of E1 states. These crystals are stable analogues of the transition state (E1P-ADP
+▪3Na+) preceding E1P▪3Na+. The molecular comparison of the two states, E1 and E2, show that
the α-subunit suffers important conformational changes in its cytoplasmic domains, especial‐
ly in the A domain, which is rotated around an axis nearly perpendicular to the membrane. The
transmembrane helices involved in cation binding also undergo important  conformation
changes, most of all TM 4, 5, and 6 (Fig. 1B). Based on these structural evidences, the third Na
+-binding site has been clearly localized, and a cooperative process for the sequential binding
of Na+ has now been formulated in detail [33, 34].
2.3. Mechanism of Na+,K+-ATPase polarity in epithelia
The apical and basolateral plasma membrane proteins of epithelial cells are synthesized in the
endoplasmic reticulum (ER) and then sorted in the tans-Golgi network (TGN) to be sent into
different carrier vesicles to apical or basolateral domain [35, 36]. The polarity of those routes
depends significantly on specific signals encoded inside the membrane proteins. The basolat‐
eral proteins have short peptides sequences in the cytoplasmic domain. Some signals resemble
endocytic signals (dileucine, YXXϕ, and NPXY), while others are unrelated to endocytic signals
(the tyrosine motifs in LDL receptor [37] and the G-protein of the VSV [38]). Early studies
demonstrated that the Na+,K+-ATPase, comprised of α- and β-subunits, is sorted in the TGN
and delivered directly to the basolateral membrane without significant appearance at the
apical surface in certain strains of the Madin–Darby canine kidney cells (MDCK) [39, 40].
Therefore, a basolateral signal was assumed to exist in the α-subunit of the Na+,K+-ATPase.
The Na+,K+-ATPase and the H+,K+-ATPase are highly homologous ion pumps, yet in LLC-PK1
cells they are polarized to the basolateral and the apical domains, respectively. The polarized
expression of chimeric constructs of the α-subunit of the H+,K+-ATPase and the Na+,K+-ATPase
in LLC-PK1 cells has been studied [41–43]. Uncommonly, an apical sorting information in the
α-subunit of the H+,K+-ATPase was recognized within the fourth transmembrane domain.
Swapping this domain into the Na+,K+-ATPase resulted in the redirection of that basolateral
pump to the apical surface of LLC-PK1 cells [44]. Nevertheless, these studies do not clarify
whether the α-subunit of the Na+,K+-ATPase contains a basolateral sorting signal in its fourth
transmembrane domain. Therefore, it seems that a non-canonical polarity signal is involved
in the basolateral targeting of Na+,K+-ATPase.
Clathrin plays a fundamental role in basolateral sorting. It interacts with endocytic or baso‐
lateral proteins through a variety of clathrin adaptors [45]. It has been shown that the adaptor
involved in basolateral protein sorting is the epithelial cell-specific AP-1B (adaptor protein 1B).
Nevertheless, the basolateral localization of the Na+,K+-ATPase is independent of AP-1B
expression because its localization was not significantly affected by knocking down clathrin
expression and it remained localized to the basolateral surface in both the µ1B-deficient cell
line LLC-PK1 [46] and in MDCK cells in which µ1B expression had been suppressed via RNAi
[47]. By taking advantage of the SNAP tag system to reveal the trafficking itinerary of the newly
synthesized Na+,K+-ATPase, it was shown that the basolateral delivery of the Na+,K+-ATPase
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is very fast (at 5 minutes after Golgi release, 50% of newly synthesized Na pump is colocalizing
with the PM) and does not involve passage through recycling endosomes en route to the
plasma membrane. Moreover, Na+,K+-ATPase trafficking is not regulated by the same small
GTPases as other basolateral proteins [48]. Some membrane proteins may achieve polarity by
selective retention at the apical or basolateral surface. Although less well understood, this
polarity may reflect interactions with extracellular ligands or with intracellular scaffolds, such
as cytoskeletal elements or arrays of PDZ domain-containing proteins [35, 49–51]. As described
and discussed below, this is also the case of the epithelial Na+,K+-ATPase, which is retained at
the lateral membrane domain due to trans adhesion of its β1 subunits on neighboring cells.
3. Na+,K+-ATPase β subunit as an adhesion molecule
3.1. The β1-isoform is a self-adhesion molecule in epithelia
The β-subunit is a glycoprotein of 40–60 kDa that was shown to be involved in the structural
and functional maturation of the holoenzyme [52, 53] and subsequent transport of the α-
subunit to the plasma membrane [54–56]. Ion transport requires the participation of both α-
and β-subunits [54, 57]. The β-subunit has a short cytoplasmic tail, a single transmembrane
segment, and a long extracellular domain heavily glycosylated, a typical structure of a cell-
attachment protein [25]. Fig. 1A depicts the position and arrangement of the three subunits of
Na+,K+-ATPase: α-subunit, β-subunit, and γ-subunit obtained by crystallography. Note that
the β-subunit is mostly exposed toward the intercellular space, while most of the α-subunit is
contained in the cytoplasm [9]. Observations made in MDCK cells suggested that the β-subunit
is a cell–cell attachment protein: (1) As most transporting epithelia, the monolayer of MDCK
expresses Na+,K+-ATPase polarized toward the basolateral side [58]. Nevertheless, confocal
immunofluorescence analysis of Na+,K+-ATPase localization shows that the pump is not
located on the basal domain of the plasma membrane, but only in the lateral, at cell–cell contacts
(Fig. 2A). (2) Upon previous treatment with EGTA, the confocal images show the apparent
single green line splits into two indicating that in order to express Na+,K+-ATPase at a cell–cell
contact both neighboring cells have to contribute part of the enzyme. (3) The expression of the
Na+,K+-ATPase at a given lateral borders is observed when both contributing neighboring cells
are homotypic and from the same species, for instance, MDCK/MDCK (dog/dog, Fig. 2A) but
not MDCK/NRK (dog/rat) [59] (Fig. 2B). (4) When CHO cells (fibroblasts from Chinese
Hamster Ovary) were transfected with a gene coding for the β1-subunit of the dog (CHO-dog
β1), these cells become more adhesive, as estimated by aggregation assays [60]. (5) On the other
hand, mixed monolayers of MDCK and NRK-dog β1 show that MDCK cells expose the Na+,K
+-ATPase at the heterotypic border (Fig. 2C).
All together, these observations indicated that the lateral localization of the Na+,K+-ATPase in
MDCK cells depends on the recognition and adhesion between the β1-subunits of neighboring
cells [60] (Fig. 2D). Of course, the first question that arises is whether two corresponding β-
subunits from different cells would get close enough to be able to span the intercellular space
and interact directly as proposed. To answer this question, several protein–protein interaction
Cell Biology - New Insights36
is very fast (at 5 minutes after Golgi release, 50% of newly synthesized Na pump is colocalizing
with the PM) and does not involve passage through recycling endosomes en route to the
plasma membrane. Moreover, Na+,K+-ATPase trafficking is not regulated by the same small
GTPases as other basolateral proteins [48]. Some membrane proteins may achieve polarity by
selective retention at the apical or basolateral surface. Although less well understood, this
polarity may reflect interactions with extracellular ligands or with intracellular scaffolds, such
as cytoskeletal elements or arrays of PDZ domain-containing proteins [35, 49–51]. As described
and discussed below, this is also the case of the epithelial Na+,K+-ATPase, which is retained at
the lateral membrane domain due to trans adhesion of its β1 subunits on neighboring cells.
3. Na+,K+-ATPase β subunit as an adhesion molecule
3.1. The β1-isoform is a self-adhesion molecule in epithelia
The β-subunit is a glycoprotein of 40–60 kDa that was shown to be involved in the structural
and functional maturation of the holoenzyme [52, 53] and subsequent transport of the α-
subunit to the plasma membrane [54–56]. Ion transport requires the participation of both α-
and β-subunits [54, 57]. The β-subunit has a short cytoplasmic tail, a single transmembrane
segment, and a long extracellular domain heavily glycosylated, a typical structure of a cell-
attachment protein [25]. Fig. 1A depicts the position and arrangement of the three subunits of
Na+,K+-ATPase: α-subunit, β-subunit, and γ-subunit obtained by crystallography. Note that
the β-subunit is mostly exposed toward the intercellular space, while most of the α-subunit is
contained in the cytoplasm [9]. Observations made in MDCK cells suggested that the β-subunit
is a cell–cell attachment protein: (1) As most transporting epithelia, the monolayer of MDCK
expresses Na+,K+-ATPase polarized toward the basolateral side [58]. Nevertheless, confocal
immunofluorescence analysis of Na+,K+-ATPase localization shows that the pump is not
located on the basal domain of the plasma membrane, but only in the lateral, at cell–cell contacts
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single green line splits into two indicating that in order to express Na+,K+-ATPase at a cell–cell
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Na+,K+-ATPase at a given lateral borders is observed when both contributing neighboring cells
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cells [60] (Fig. 2D). Of course, the first question that arises is whether two corresponding β-
subunits from different cells would get close enough to be able to span the intercellular space
and interact directly as proposed. To answer this question, several protein–protein interaction
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assays have been performed: (1) By pull-down assay, it was shown that dog β1-subunit
immobilized on Ni-beads could specifically bind to the soluble extracellular domain of β1-
subunits of the same animal species (dog). (2) Co-IP experiments have shown that rat β1-
subunits on NRK cells co-precipitate with rat YFP-β1 subunit transfected in MDCK cells. (3)
FRET (fluorescence resonance energy transfer) analysis of monolayers with a mixed popula‐
tion of MDCK cells transfected with a β1-subunit fused to a cyan fluorescent protein (CFP), or
with a β1-subunit fused to yellow fluorescent protein (YFP), has shown that energy can be
transferred from the first to the second cell type; in other words, two β1-subunits can interact
directly at <10 nm, thereby anchoring the whole enzyme at the cell membrane facing the
intercellular space. Taken together, these evidences [61] supported by works from other groups
[62-65] indicated that the β1 subunit is indeed an adhesion molecule in epithelia.
In Moloney sarcoma virus-transformed MDCK cells (MSV-MDCK) that have an invasive
phenotype, the level of Na+,K+-ATPase β1-subunit is reduced as well as the expression level of
E-cadherin. As expected, these transformed cells are also deficient in tight and desmosome
Figure 2. Hints to propose a model for the polarized distribution of Na+,K+-ATPase in transporting epithelia. (A) Mon‐
olayer of MDCK cells in a horizontal and a transversal section. Na+,K+-ATPase is stained in green, and nuclei in red,
showing that the pump is expressed on the lateral membrane of the cells. (B) A confocal image of a monolayer pre‐
pared with a mixture of MDCK cells and NRK (normal rat kidney) cells; notice that the MDCK cells surrounding the
NRK cell (previously stained in red with CMTMR) in the center only express their Na+,K+-ATPase on the membrane
contacting MDCK cells, but not on the side contacting the NRK epithelial cell (indicated by arrows). (C) A confocal
image showing a mixture of MDCK and NRK cells transfected with dog β1-subunit. Arrows indicate the presence of
Na+,K+-ATPase at heterotypic borders. (D) Proposed model for the polarized distribution of Na+,K+-ATPase in trans‐
porting epithelia. Scheme showing Na+,K+-ATPase α- and β-subunits expressed at the lateral border, where they are
anchored by the β-subunits interaction at the intercellular space. Scale bar: 10 µm.
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junctions. Interestingly, transfection of both E-cadherin and Na+,K+-ATPase β1-subunit induces
the formation of junction complexes, reestablishes epithelial polarity, and suppresses inva‐
siveness and motility, suggesting that β-subunit and E-cadherin are required to maintain the
polarized epithelial phenotype [66]. Furthermore, stable adherens junctions are a requisite for
proper tight junction function. In this regard, improving the Na+,K+-ATPase β1–β1 interaction
by reducing the complexity of the N-glycans of the β-subunit increases the resistance to
detergent extraction of junction proteins and decreases the paracellular permeability. In other
words, the fewer the branches are in β-subunit’s N-glycans, the tighter are the intercellular
junctions. Conversely, the impairment of the β1–β1 binding by removing the N-glycans or
altering the amino acid sequence of one of the interacting proteins decreases detergent
resistance and increases the paracellular permeability, indicating that stability of adherens,
and in turn tight junctions, does depend on β1–β1 interaction [65, 67].
Studies in Drosophila have also shown that the β-subunits (in drosophila are named Nrv1,
Nrv2, and Nrv3) are determinant of the Na+,K+-ATPase subcellular localization as well as
function. Of the three Drosophila isoforms, Nrv1 and Nrv2 are localized in epithelia, while
Nrv3 is expressed in the nervous system. Remarkably, while Nrv1 is expressed in the baso‐
lateral membrane of almost all epithelial cells, Nrv2 is localized at the septate junctions (tight
junctions in insect) and co-localizes with coracle [68]. Furthermore, it has been shown that the
extracellular domain of Nrv2 regulates the function of septate junctions and the size of the
tracheal tube in a free manner independent of the pumping task [69].
3.2. β2/AMOG is a heterophilic adhesion molecule in nervous system
The Na+,K+-ATPase β2-subunit was first described in the nervous system. Schachner’s group
identified a cell surface glycoprotein and named it as Ca2+-independent adhesion molecule on
glia (AMOG). AMOG was shown to mediate the neuron-to-astrocyte adhesion in the process
of granule cell migration [70–72]. Further analysis revealed that AMOG is an isoform of the
Na+,K+-ATPase β-subunit, named as the β2-subunit [22]. A remarkable characteristic of the β2-
subunit is the multiple N-glycosylation sites in the extracellular domain [13]. Treatment with
endoglycosidase H produces the shift of the apparent molecular weight from 50 to 35 kDa
[70,20]. In a mass spectrometry analysis of the endoglycosidase H, released oligosaccharides
from the β2-subunit three molecular ions were found corresponding to oligosaccharides
composed of one N-acetylglucosamine and 5, 6, or 7 mannoses [20]. The β2-subunit promotes
the neurite outgrowth by AMOG-to-neuron binding [73]. Schachner’s group has assayed
different partners for AMOG association in trans. They found that AMOG-containing lipo‐
somes only bind to small cerebellar neurons. When L1 and N-CAM antibodies were added to
a monolayer of cerebellar neurons, none of these antibodies inhibited binding of AMOG-
containing liposomes to neurons. Also, cells preincubation with an AMOG-antibody prior to
addition of AMOG-containing liposomes did not reduce AMOG-containing liposomes-to-
neurons adhesion [71]. These experiments suggest that neither L1 nor N-CAM is the β2-subunit
ligand; thus, AMOG/β2-subunit is a heterophilic CAM. As mentioned above, β1–β1 adhesion
in epithelial cells is homophilic. Accordingly, when assaying β1 to β2 adhesion, we found a null
binding between these two isoforms, as well as between two β2-subunits (our unpublished
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results). These findings are in agreement with previous studies [71]. As heterophilic CAM, the
β2-subunit was shown to cis-interact with an oligomannose binding lectin, basigin. Basigin or
CD147 is an ancillary protein of the monocarboxylate transporters 1, 3, and 4-isoforms [74–77]
and, as a receptor molecule for high mannose carbohydrates, basigin binds specifically with
oligomannoside carrying glycoproteins and neoglycolipids [78]. Kleene and coworkers
showed that PrP, the AMPA receptor subunit GluR2, the astroglial α2/β2 ATPase, basigin, and
the MCT1 form a functional complex at the plasma membrane of astrocytes. In this regard, the
β2-subunit and basigin interact by means of the carbohydrate structure of the β2-subunit. The
functional interplay of PrP, GluR2, the α2/β2 ATPase and basigin regulates the lactate transport
via MCT1. Moreover, they observed that disturbing the oligomannose-mediated interaction
of the β2-subunit and basigin leads to a deregulated and thus elevated glutamate-independent
lactate transport [79].
3.3. β2 isoform and apical polarity
The α1-subunit holds a basolateral sorting signal that commands the traffic of the epithelial
sodium pump to this membrane domain [43]. However, the role of other α-subunit isoforms
in the sorting of the Na+,K+-ATPase has not been studied yet. On the other hand, little is known
about sorting signals in any of the β-subunit isoforms, yet the β1 and β3 isoforms have exclusive
basolateral localization in epithelial cells [80], and instead, the apical distribution of the sodium
pump correlates with the expression of the β2 isoform [81–84]. In this regard, studies from our
laboratory provide evidence showing that the apical polarity of the Na+,K+-ATPase in the
retinal pigment epithelium (RPE) is related to the expression of the α2- and β2-subunits (Fig.
3A and B). Moreover, the time-dependent β2-subunit expression in the RPE model cells
ARPE-19 correlates with the epithelialization of these cells (our unpublished results).
As we mentioned before, the β2-subunit possess up to 9 N-glycosylation sites (upon the
species). Numerous studies have indicated the role of N-glycans in the polarity mechanism of
apical proteins. For instance, the mutagenic removal of N-glycosylation sites in the gastric H
+,K+-ATPase β-subunit [85], bile salt export pump [86], and glycine transporter 2 [87, 88],
significantly decreased their apical content and increased their intracellular accumulation.
Also, it has been shown that addition of N-glycans to various proteins changed their cellular
localization toward the apical membrane domain. For example, a truncated occludin and a
chimeric ERGIC-53 residing inside the Golgi in their nonglycosylated forms were apical
redistributed after addition of N-glycans [89]. Indeed, engineering the β1-subunit by adding
the N-glycosylation sites of the β2 isoform leads to apical localization of the pump in HGT-1
cells [90]. All these evidences are consistent with the important role of N-glycosylation in apical
polarization of Na+,K+-ATPase.
3.4. Structural insights into the self adhesion mechanism of Na+,K+-ATPase β1 subunits
The shark Na+/K+-ATPase crystal structure in the E2 state published by Shinoda and coworkers
was the first resolving the atomic structure of the extracellular domain of the β-subunit (PDB:
2ZXE) [9]. The extracellular C-terminal domain of the protein folds into an Ig-like β-sheet
sandwich as predicted in silico [91]; actually, deletion of this C-terminal domain abolishes the
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β1 adhesion capacity (unpublished observations). However, a large number of adhesion and
nonadhesion proteins contain domains with an immunoglobulin-like topology (CATH
database). Structural alignments of the β1 subunit extracellular domain against other well-
studied cell adhesion molecules reveal no structural homologue of β-subunits of any kind.
Detailed inspection of the ectodomain structure uncovers several features distinctive to β-
subunit family members. Namely, its Ig-like fold has a unique topology given that its β-sheet
sandwich is interrupted by a long α-helix secondary structure and has an atypical β-sheet
disposition in relation to classical Ig folds. Also, the β-subunit fold contains extensive loops
and therefore its length is twice as that of a typical Ig domain. Furthermore, the β1 subunit is
structurally compromised with the catalytic α-subunit in such a way that the C-terminal fold
must be more rigid than the typical flexibility of whole adhesion domains such as in cadherins.
Altogether, these observations suggest that the β-subunit of the Na+,K+-ATPase must possess
an adhesion mechanism that is particular to this family, as shown in Figure 4.
The first attempt to clarify this adhesion mechanism on a molecular base is related to the
regions of the ectodomain involved in β1–β1 recognition. Given that the interaction between
two β1 subunits of the same species (dog–dog or rat–rat) is more effective than the interaction
between rat and dog β1 subunits [61], Tokhtaeva and colleagues [92] looked for surface-
exposed species-specific amino acids in the sequence of β1 subunit and identified four residues,
which are different between both species and are contained in the 198–207 segment. Rat-like
amino acid substitutions introduced in the dog β1 subunit weakens its interaction with the
Figure 3. Na+,K+-ATPase expression at the apical domain of ARPE-19 cells (human retinal pigment epithelium).
ARPE-19 cells were cultured on laminin-coated inserts for 4 weeks and treated for IF analysis. Confocal image of a
monolayer stained with specific antibody against the α2 subunit (A) and against β2 subunit (B). Notice the preferential
distribution on apical domain of both subunits. Scale bar: 10 µm
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endogenous dog β1 subunit, whereas the insertion of the rat-specific Thr202 into the exogenous
dog β1 subunit impairs its interaction with the endogenous dog β1 subunit to the level observed
between dog and rat native subunits. The opposite effect is observed in the rat β1 subunit upon
the introduction of dog-like residues and the deletion of Thr202. These results suggest that the
amino acid residues important for β1–β1 binding are located upstream and downstream of the
Thr insertion position. The insertion or removal of the Thr residues in one of the two interacting
subunits probably misaligns these binding residues, and thus causes the characteristic
difference in affinity between the two species [92].
Figure 4. The intercellular adhesion between Na+,K+-ATPase β1 subunit. A surface model based on the crystal structure
illustrating the association of Na+,K+-ATPase dimer (α in green and β in blue) at the intercellular space. The magnified
square shows one of the representative models resulting from the docking algorithm performed for the coupling of
two Na+,K+-ATPase β1 subunits structures obtained from the crystals. In this specific model, two loops form the core of
the interaction, namely, the one containing the species-specific residues identified by [92] and the other comprised of
an unusual sequence of eight consecutive charged residues (214KRDEDKDR221). This charged loop and other regions
adjacent to the species-specific loop are suggested as the potential interface for β1–β1 interaction.
How specie-specific residues adjacent to Thr202 coordinate with residues residing at sur‐
rounding regions on the same β1-subunit and with its interacting partner have yet to be
elucidated. The segment 198–207 constitutes one of the characteristic protruding loops in the
connecting β-strands B and C of the β1-subunit extracellular fold. The majority of the ectodo‐
main surface-exposed residues located most distal from the membrane reside within loops
interconnecting β-strands, some of which must be involved in the dimer interface in conjunc‐
tion with segment 198–207. Since the crystal structure of the Na+,K+-ATPase β1 subunits now
available [33;93], we modeled and predicted interacting surfaces on β-subunit and thus
identified putative amino acids that participate in β1–β1 interaction. This approach will soon
lead us to uncover a detailed adhesion mechanism, which is of great importance for epithelial
physiology.
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4. The Na+,K+-ATPase is the receptor of hormone ouabain
4.1. Cardiotonic steroids (CTSs)
The CSTs have been used for at least 200 years to treat heart failure and tachycardia due to
their inotropic effect on the heart [94]. They are specific steroids and are extracted from plants
of genus Digitalis and Strophanthus and from vertebrates such as several species of toads [95].
The CSTs have a steroid nucleus and can sort as cardenolides (with a five-membered lactone
ring) or bufadienolides (six-membered lactone ring) and contain various combinations of
hydroxyl, sulfate, or carbohydrates groups (Fig. 5) [96]. All types of CST bind with its receptor,
the α-subunit of Na+,K+-ATPase, in a pocket formed by transmembrane segments M1–M6. The
best affinity for the CST is of the E2P conformation [97]. The sensitivity of the sodium pump
to CSTs is controlled by multiple elements mainly by the tissue specific distribution of α and
β isoforms and by the glycosylation of CSTs. Thus, in the case of digoxin and digitoxin (Fig.
5), the affinity toward the Na+,K+-ATPase improves with up to fourfold preference for α2/α3
over α1 isoforms [98].
Many studies have demonstrated the endogenous productions of CSTs in mammals. Thus,
ouabain was detected in plasma [99], digoxin in urine [100], and marinobufagenin in plasma
[101]. An interesting feature of Na+,K+-ATPase is the highly conserved nature of the CST-
binding site, suggesting that this site plays a significant physiological role [94]. The normal
ranges for circulating ouabain vary between 2500 ±500 pmol/l and 176 000 ± 68 000 pmol/l,
depending on the measuring condition and the test used [102]. Interestingly, the binding of
cardenolides and bufadienolides to the α-subunit of the Na+,K+-ATPase results not just in the
inhibition of Na+,K+-ATPase ion transport activity but also in the activation of signaling
cascades [103]. Moreover, endogenous ouabain is synthesized and secreted by the hypothal‐
amus [104, 105] and the adrenocortical gland [106–107]. A status of hormone was recommend‐
ed for the endogenous CSTs as it was demonstrated that it increases during exercise [108], salty
meals [109–111], and pathological conditions such as arterial hypertension and myocardial
infarction [112]. To confirm the hormone-like function, Arnaud-Batista and colleagues [113]
showed that ouabain and bufalin induce diuresis, natriuresis, and kaliuresis, mediated by
signal transduction in the isolated intact rat kidney. Furthermore, at the systemic level,
cardenolides and bufadienolides have been implicated in many physiological and pathophy‐
siological mechanisms, including cell growth and cancer, body or organ weight gain, mood
disorders, vascular tone homeostasis, blood pressure, hypertension, and natriuresis[114].
4.2. The physiological role of hormone ouabain in epithelia
Fifteen years ago, the evidence that ouabain is a hormone was convincing enough as to start
wondering what may its physiological role be. Our search was oriented by the observation
that (MDCK) epithelial cells exposed to high concentrations of ouabain (≥1 µM) do not show
sign of damage, but retrieve from the plasma membrane molecules involved in cell–cell and
cell-substrate attachment, and detach from each other and from the substrate. These observa‐
tions suggested that there is a mechanism that relates the occupancy of the pump (P) by
ouabain to adhesion mechanisms (A). Accordingly, this mechanism was called P →  A. We
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discovered that P →  A mechanism is associated with several signaling proteins such as cSrc
and ERK1/2 (Fig. 6), and it consists of a loss of cytosolic K+, an increase of cytosolic levels of
Na+ and Ca+2 and the activation of protein tyrosine kinases and ERK1/2. Ouabain binding also
increases p190Rho-GAP, which enhances the GTPase activity of RhoA [115]. Detachment may
not be ascribed to the ensuing decrease of K+ content because lowering the K-content by
incubating the cells in media with only 0.1 mM K+ (instead of the regular 4.0 mM) does not
cause cell detachment [116].Therefore, we put forward the working hypothesis that ouabain
at nanomolar concentrations, i.e., within the hormonal range in mammalian plasma, may act
on the same junctional structures without provoking irreversible damages. To explore the
plausibility of this idea, we experimentally tested the effect of ouabain on different cell–cell
adhesion complexes starting with TJs. While toxic concentration of ouabain open the TJ,
physiological concentrations of ouabain increase its hermeticity. Interestingly, the first effect
depends on the pumping activity of Na+,K+-ATPase, whose inhibition perturbs the ionic
balance of the cell. On the contrary, physiological concentrations of ouabain (i.e., in the
Figure 5. Structural features common for cardiotonic steroids (CTSs). All CTSs include a cis–trans–cis ring fused steroid
core, which adopts a U-shaped conformation with a convex β-surface, a hydroxyl group at C14 (OH14β; purple). CTSs
are classified as Cardenolides and Bufadienolides based on a five- or six-membered lactone ring in a β-conformation at
position C17. Some CTSs have a carbohydrate moiety of one to four residues attached to C3. Ouabain, the most hydro‐
philic CTSs, is constituted of a steroid core with four hydroxyl groups at the β-surface (in blue), a hydroxyl group at
the α-surface (purple), an unsaturated lactone ring of five members (green), and a rhamnose sugar moiety (pink). The
structures of two members of the bufadienolides (marinobufagenin and bufalin) and three members of the cardeno‐
lides (ouabain, digitoxin, and digoxin) are illustrated.
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nanomolar range) neither inhibit K+ pumping nor disturb the K+ balance of the cell [117]. At
these concentrations, the effects of ouabain depends mainly on the activation of the receptor
complex of Na+,K+-ATPase. While toxic levels of ouabain regulate the opening of TJs through
endocytic and degradation processes, physiological concentrations of ouabain modulate TJs
through changes in the molecular composition of the TJ through processes that provoke
changes in transcription rate and expression of its proteins [118] (Fig. 6A). Another prominent
cell–cell contact is the adherens junction (AJ) and one of the scaffolding proteins of this junction
is β-catenin, a key member of the Wnt signaling pathway (Fig. 6B). During the activation of
this pathway, β-catenin is translocated to the nucleus, where it modifies gene expression [119].
Interestingly, 10 nM and 1 µM ouabain provoke the translocation of β-catenin to the nucleus
of MDCK cells [116]. Liu and co-workers [120] have recently found evidence that Na+,K+-
ATPase, and E-cadherin are closely associated, indicating that E-Cadherin could be part of the
signalosome of the Na+,K+-ATPase. To further explore the hypothesis that nanomolar concen‐
trations of ouabain modulate cell–cell contacts, the effect of 10 nM ouabain have been studied
on another type of cell–cell contact, the gap junction. In MDCK cells treated with this concen‐
tration of ouabain cell–cell communication have been increases by up to 510% in one hour.
Moreover, inhibitors of transcription and of translation do not affect the induction of Gap
junction communication (GJC) by ouabain, indicating that cells express a sufficient level of
connexins to account for the rapid enhancement of GJC [121].
Ouabain effects through signaling were observed also in cardiac myocytes when nontoxic
concentrations of ouabain, that partially inhibit the Na+,K+-ATPase, activate signaling path‐
ways that regulate growth [122, 123]. Ouabain can activate signal cascades that vary between
cell types, depending on the dose and the α-subunit isoform expressed in the cell [124, 103].
The existence of two pools of Na+,K+-ATPase within the plasma membrane with two distinct
functions have been proposed: the classical ion pump whose partial inhibition by ouabain
provokes an increase in [Ca2+]i, and the second, the signal transducing pool which through
protein–protein interactions regulates cell growth, proliferation, differentiation, and apopto‐
sis. Part of the nontransporting Na+,K+-ATPase is located in the caveolae. cSrc is usually bound
to the Na+,K+-ATPase in caveolae. Ouabain binding to the pump located in caveolae, stimulates
cSrc activation, which consequently activates other downstream signaling pathways [125].
Signaling through Src is supported by the discovery that in a cell-free system, the addition of
ouabain modifies the Na+,K+-ATPase cSrc complex and activates cSrc [128]. Alongside, the
epidermal growth factor receptor (EGFR) is transactivated upon ouabain binding to Na+,K+-
ATPase and additional signaling occurs that activate downstream targets including She, Grb,
Ras, Raf, MEK, and ERK [125, 127] (Fig. 6). These signaling pathways regulate early response
genes associated with cell growth and also regulate cell motility and a number of metabolic
pathways [123,126]. Another signaling role was found by Aizman and coworkers [126]. In
epithelial cells, the Na+,K+-ATPase interacts with the inositol 1,4,5-triphosphate receptor (IP3R)
within the signaling microdomain. They show that interaction of ouabain with the signaling
Na+,K+-ATPase provokes synchronized Ca2+ oscillations rising from the modification of such
interaction. Those slow oscillations activate NF-kB.
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Figure 6. Signaling in the ouabain-induced modulation of cell contacts. Ouabain (red silhouette) induces the formation
of a signalosome, a caveolar complex (discontinued grey line) including the Na+,K+-ATPase, its associated cSrc (cSRC)
and the EGF receptor (EGFR). (A) Ouabain (300 nM) activates cSrc, which in turn transactivates the EGFR pathway,
causing a phosphorylation of ERK1/2. The inhibition of the pump alters the ionic gradient that also contributes to the
activation of ERK1/2. The activation of ERK1/2 is crucial for the clathrin- and dynamin-dependent endocytosis of TJ
components. Two possible types of endocytic vesicles are formed: one containing a core complex with essential TJ pro‐
teins, such as ZO-1 (encircled Z); occludin (encircled O) and Claudin-4 (encircled 4) and a second one entailing compo‐
nents such as Claudin-2 (encircled 2) that makes TJs permeable to water and Na+. ERK1/2 activation is required to
reduce the levels of Occludin, Claudin-4 and ZO-1 proteins, but not that of Claudin-2. ERK1/2 is also necessary to re‐
duce Claudin-2 and ZO-1 mRNA levels. Notably, the cellular content of Claudin-4 and occludin mRNAs increases,
during the opening of the TJs induced by Ouabain. (B) Epithelial cells treated with 10 nM of Ouabain (hormonal con‐
centration) show increased tight junction sealing [117]. Activation of ERK 1/2 modulates the expression of Claudins
(1,2 and 4) at the tight junction and promotes the expression of Claudin-2 in the cilium. Moreover, under this condi‐
tion, cell-communication by gap junctions (red cylinder) is also increased by a mechanism still not well understood
and β-catenin (khaki circles), a component of the Adherens junctions travels to the nucleus and modulates the expres‐
sion of genes involved in cell-junction regulation.
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Signal cascades vary between different cells types. For example, in cardiac myocytes and renal
cell lines derived from the porcine kidneys (LLC-PK1) and the opossum kidneys (OK),
ouabain-mediated activation of a signaling cascade has been demonstrated to be dependent
upon the activation of Src, MAPK, and PI-3K pathways [129,122], whereas in human breast
(BT20), prostate (DU145) cancer cells, and PY-17 cells, ouabain activate Src and MAPK
pathway, but not PI-3K pathway [130]. Downstream in the ouabain-activated signaling
cascade, the level of complexity increases due to the activation of several cell-specific secondary
messengers and the cross talk between distinct pathways [131]. For each cell type, different
pathways and branches are activated and only part of their complexity is known. In the MAPK
pathway, several secondary messengers, downstream targets of ERK1/2, have been identified.
Upon activation, ERK1/2 is able to migrate to the nucleus and activate several transcription
factors (STAT1/3, c-fos, CREB, Elk-1) or in the cytoplasm modulate ion channels, receptors, or
cytoskeleton proteins by direct phosphorylation.
5. Concluding remarks
Although without its β-subunit the Na+,K+-ATPase could not be expressed in the plasma
membrane, nor have an enzymatic activity, no convincing role was detected for this subunit
beyond of helping the α one to cage K+. We have shown that, due to its adhesiveness, the β1-
subunit may establish a linkage with an identical subunit located in a neighboring cell across
the intercellular space, and be thereby responsible for the polarized expression of Na+,K+-
ATPase in epithelial cells. Furthermore, it has been demonstrated that β–β interaction stabilizes
and maintains cell-junctions integrity in transporting epithelia. The molecular mechanism by
which this interaction occurs is still far from being elucidated. Nevertheless, it is clear that both
N-glycans and specific sequences exposed on the polypeptide surface are implicated. The
observation that P →  A mechanism is involved in the shuttling of β-catenin to the nucleus and
thus in the Wnt/Wingless cascade, in the growth factor signaling pathways, as well as the
ability of ouabain to enhance intercellular communication through gap junctions speaks of the
important physiological role played by the hormone ouabain. The importance of this mecha‐
nism is compounded by the fact that in the meanwhile ouabain was shown to be a hormone
that varies in response of several physiological and pathological conditions. Therefore, we may
postulate that ouabain may determine the retrieval of the β-subunit from the plasma mem‐
brane and down regulates the expression of Na+,K+-ATPase in the cell membrane and thus,
indirectly regulates the absorption and secretion of ions and nutrients. Therefore, ouabain
should be added to the list of hormones that affect transepithelial transport, along with
aldosterone, antidiuretic hormone, and the like.
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Abstract
Mitotic catastrophe (MC) has long been accounted as a cell death path activated by pre‐
mature or inappropriate entry of cells into mitosis following chemical or physical stress‐
es. Although various possible explanations related to MC have been formulated, no
general accepted definition of this phenomenon has been found yet. Recent evidences,
however, demonstrate that MC is not a distinguished way of cell death, rather a “pre‐
stage” anticipating cell death, taking place in mitotically disrupted cells, which later oc‐
curs via necrosis or apoptosis. Moreover, even though it is widely accepted that MC is the
main outcome after ionizing radiation treatment or treatment with drugs that influence
microtubule assembly/stability inducing mitotic failure, the final cell death pathway and
the final outcome of MC, which strongly depend on the cell type and its related molecu‐
lar profile, still need to be fully elucidated. Post-mitotic cells, like neurons in the central
nervous system, and podocytes or tubular cells in the kidney, are particularly susceptible
to MC. In the central nervous system, MC has been claimed as the cause of neuronal
death in many neurologic disorders, while MC in podocytes and tubular death is con‐
nected with the development of progressive glomerulosclerosis.
Keywords: Mitotic catastrophe, neuron, podocyte, tubular cell, cell-cycle reentry
1. Introduction
Cell cycle is as old as life itself. In most situations, it is a generative force that creates new cells
from old. It is a tightly regulated process whose misregulation can lead to unchecked prolif‐
eration and neoplastic disease. Moreover, a decade ago, it was hypothesized that cell-cycle
abnormalities may be intimately connected with the death of terminally differentiated cells,
such as neurons. In this case, the consequence of cell-cycle alterations is loss of cells, and this
phenomenon has been postulated as a mechanism of pathogenesis in several neurodegener‐
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ative disorders. Recently, the link between aberrant cell-cycle reentry, cell death, and degen‐
erative diseases has been observed also in other post-mitotic cell types, such as podocytes and
tubular cells in the kidney. In this kind of process, post-mitotic cells enter into the cell cycle in
response to stress signals in order to substitute death cells, but the absence or malfunction of
a specific array of cell-cycle proteins may not allow for its completion. The final result is that
the cells can neither reverse the course of the cell cycle or complete division, remaining locked
in a non-functional state that push them to trigger a programmed cell death response.
Interestingly, in in vitro and animal models of neurodegenerative diseases, the presence of
active apoptotic pathways has been observed and reported, while there are conflicting data
on the activation of classic apoptotic pathways in the human damaged tissues. Thus, it remains
possible that the cell-cycle-linked cell death response may occur through different still not
completely understood pathways. Mitotic catastrophe (MC) has long been accounted as a cell
death path activated by premature or inappropriate entry of cells into mitosis following
chemical or physical stresses. Although various possible explanations related to MC have been
formulated, no generally accepted definition of this phenomenon has been found yet. Recent
evidence, however, demonstrate that MC is not a distinguished way of cell death, rather a pre-
stage anticipating cell death, taking place in mitotically disrupted cells, which later occurs via
necrosis or apoptosis. Moreover, even though it is widely accepted that MC is the main
outcome after ionizing radiation treatment or treatment with drugs that influence microtubule
assembly/stability inducing mitotic failure, the final cell death pathway and the final outcome
of MC, which strongly depend on the cell type and its related molecular profile, still need to
be fully elucidated. Post-mitotic cells, like neurons in the central nervous system, and podo‐
cytes in the kidney, are particularly susceptible to MC. In the central nervous system, MC has
been claimed as the cause of neuronal death in many neurologic disorders, while MC in
podocytes is connected with the development of progressive glomerulosclerosis.
2. Regulation of the cell cycle
The cell cycle of eukaryotic cells comprises four main successive phases: G1 phase (first gap),
S phase (DNA synthesis), G2 phase (second gap), and M phase (mitosis) (Figure 1). The orderly
transition from one phase to the following and subsequent progression through the mitotic
cycle is controlled by a group of protein kinases whose activity is central to this process, the
cyclin-dependent kinases (CDKs). Their levels in the cell remain fairly stable, but each must
bind with their activating partners, cyclins, whose levels of expression fluctuate throughout
the cycle.
Mitogenic signals, such as soluble growth factors or cell-to-cell contact, stimulate the activation
of D-type cyclins and their connection with CDK4 or CDK6. Cyclin D-CDK4 and cyclin D-
CDK-6 complexes phosphorylate the retinoblastoma protein (Rb) and inhibit its affinity to bind
the transcription factor E2F-1. Thus, E2F-1 is free to induce the transcription of specific genes
involved in DNA replication. Moreover, in late G1, inhibition of Rb activates the expression
of cyclin E that binds with CDK2. The cyclin E-CDK2 complex ensures the G1/S transition to
occur by fully inactivating Rb by hyperphosphorylation. Thus, CDK2 to regulate progression
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from G1 into S phase. Cyclin A binds with CDK2 that phosphorylates various substrates
allowing DNA replication. The formation of cyclin A/CDK2 complex is required during S
phase. After completion of S phase, DNA replication ceases and cells enter the G2 phase of the
cycle. The cyclin A-CDK1 complex plays a central role in the transition from S to G2/M phase
of the cell cycle by regulating the phosphorylation of specific substrates necessary for the
completion of the G2 and M phases of the cell cycle. Mitosis is further regulated by cyclin B-
CDK1 complex, which appears in late G2 and triggers the G2/M transition. Cyclin A is
degraded and the system is reset. In this way, cells are now ready to start a new cell cycle when
the presence of mitogenic stimuli induces the upregulation of D-type cyclins.
Figure 1. Schematic representation of the eukaryotic cell cycle.
CDK activity can be counteracted through post-translational modifications and subcellular
translocations of specific CDK inhibitors (CDKIs), which bind with CDK alone or to the CDK–
cyclin complex. CDKIs are organized in two families: INK4 and Cip/Kip. The INK4 family
(inhibitors of cyclin D-dependent kinases) includes four members—p16INK4a, p15INK4b, p18INK4c,
and p19INK4d—which specifically inactivate G1 CDK (CDK4 and CDK6) and the Cip/Kip family
(inhibitors of cyclin D-, cyclin E-, and cyclin A-dependent kinases) comprises p21Cip1, p27Kip1,
and p57Kip2. CDKIs are regulated by both internal and external signals. The intracellular
localization of different cell-cycle-regulating proteins also contributes to a correct cell-cycle
progression.
Two important checkpoints (G1/S and G2/M) coordinate CDKs activity and ensure that each
stage of the cell cycle is correctly completed before allowing further progress through the cycle.
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If conditions are inadequate, the cell will not be allowed to progress through the cell cycle and
be both arrested, until conditions are favorable, or induced to die through apoptosis (reviewed
in reference [2]). The G1/S checkpoint, also known as the restriction point in mammalian cells,
is defined as a point of no return in G1, following which the cell is committed to enter the cell
cycle. It is necessary to control the progression of cell cycle in the presence of DNA damage.
At this checkpoint, p53 activity arrests cell cycle induced by DNA damage, stimulating the
transcription of different genes including p21. At the G2/M checkpoint, mitotic entry is
prevented in response to DNA damage by mechanisms similar to those in the G1/S checkpoint.
An additional checkpoint, the mitotic spindle checkpoint, occurs at the point in metaphase
where all the chromosomes should have aligned at the mitotic plate and be under bipolar
tension.
3. Molecular basis of mitotic catastrophe
“Mitotic catastrophe” has been reported, for the first time, in a temperature-sensitive lethal
phenotype of Schizosaccharomyces pombe in 1989.[3] The first hallmark that induced researchers
to distinguish this cell-death modality from others already characterized (i.e., apoptosis) was
the macroscopic alteration in chromosome segregation of some mutant strains.[3,4] Never‐
theless, alterations in sister chromatids division during mitosis can result from a vast range of
factors. Between these, alterations that perturb the structure and/or the high dynamicity of
microtubules are key factors able to impair chromosomes segregation, mainly because of the
subsequent inability to form the mitotic spindle.[5] Given the central role that microtubules
play in the MC process, it has to be pointed out that the term “catastrophe” associated with a
phenotype of cellular death reported 5 years before in 1989, when McIntosh JR. proved that
microtubule can undergo a process of disintegration that he called “microtubule catastrophe”.
[6] What is then mitotic catastrophe? According to what was demonstrated in references [3,4],
some thought this process happens to mammalian cells unable to fulfill a complete mitotic
process , which would result in tetraploidy, a double chromosome quantities (or 2N, after a
single cell cycle),[7] or endopolyploidy,[8] a situation characterized by multiple chromosome
settings in a single cell (or XN, several than a cell cycle). Actually, even if exact definitions of
MC are still missing, MC is prevalently defined as a cell death path that is activated by
premature or inappropriate entry of cells into mitosis, and that can be activated upon chemical
or physical stresses.[9] Recent evidence demonstrates that MC is not a distinguished way of
cell death, but rather represents a “pre-stage” anticipating cell death, which later occurs via
necrosis or apoptosis.[9] Moreover, even though it is widely accepted that MC is the main
outcome after ionizing radiation treatment or administration of drugs that influence microtu‐
bule assembly and stability, thus inducing mitotic failure, the final cell death pathway and the
final outcome of MC (Figure 2) strongly depend on the cell type and its related molecular
profile.[9,10] These molecular profiles still need to be fully elucidated and classified. However,
some key features of MC are already established, as failure in DNA repair mechanisms,
genomic instability, chromosome segregation impairment, and microtubules destabilization.
[6,11] But how these factors can drive through MC? It is well established that to preserve
genome integrity, DNA-damaged responses can either result in cell-cycle stalling, finalized to
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give time to activate DNA repair mechanisms, or in the removal of cells that are irreparably
injured via apoptosis, MC, or necrosis. At the same time, drugs that influence microtubule
stability, influencing mitotic spindle formation or chromosomes segregation, end up in the
elimination of cells incapable to complete a correct mitosis. The same can be said about
deficiency in cell-cycle checkpoints (especially the ones related to DNA structure analysis and
to mitotic spindle): when these checkpoints are compromised, cells might prematurely enter
into mitosis (M phase), as when DNA has still not been repaired, thus going toward MC.[9,12]
MC-related alternations are associated with morphological changes, as the acquisition of big
cellular dimensions and the formation of abnormal nuclei, mainly due to micronucleation
(chromosomes or chromosome fragments not evenly segregated into the two daughter nuclei)
and multinucleation (missegregated chromosome fragments enveloped by one or multiple
nuclear membranes of different dimension). The latter two cases generally represent the final
step of MC.[9] By this description, it appears evident that MC is a type of mitosis-related cell
death that occurs during or shortly after a defective or failed mitosis.[3,13] This concept is
further corroborated by the evidences that MC is also associated with incomplete DNA
duplication and premature chromosomes condensation (PCC).[14–16] Nevertheless, chroma‐
tin condensation is a key feature of another well-defined type of cell death, apoptosis, which,
anyway, can be distinguished from MC by the TUNEL (Terminal deoxynucleotidyl transferase
dUTP Nick End Labeling) test, which individuates nuclear fragmentation, and by cell shrink‐
age. The morphological dissimilarities let, initially, hypothesize that MC was a direct cause of
death, not connected with apoptosis, a hypothesis further corroborated by the evidence that
inhibition of caspases did not influence the formation of giant cells.[10] Nevertheless, some
papers suggest that MC could also be associated with caspase-2 and 3 activation, mitochondrial
release of pro-apoptotic factors, and DNA fragmentation, all apoptotic features.[13,17,18] This
initially created debate about MC: is it a distinct type of cell death, or is MC only a “pre-stage”
of apoptosis? Additional questions arise when it was demonstrated that heated HeLa cells
underwent PCC and premature reconstitution of nuclear envelope around asymmetric cluster,
but did not ended up in nuclear fragmentation and apoptosis, but rather in the formation of
multiple micronuclei that lead to a necrotic-like death.[14] Moreover, MC has also been
characterized as delayed form of reproductive death, described as the inability to form a viable
progeny able to undergo new mitotic divisions, since giant cells exhibiting multiple nuclei can
be temporally viable.[19–21] This underlines that a big debate is still going on about MC, which,
by some, is seen as distinct type of cell death, while others believe that it is a process that
ultimately leads to apoptosis or necrosis. Agreement has been found on the concept that MC
is a mitotic-related cell death and that, without entering the M phase, a cell cannot undergo
MC.[10] Since MC is induced by DNA damage, as well as by alterations in cell-cycle check‐
points, it might be possible that MC is a defense mechanism to avoid aneuploidization, which
might bring to neoplastic transformation. This is likely to be stimulated not only by DNA
alterations, but also by deficiencies in various proteins involved in cell-cycle regulation, as cell-
cycle-specific kinases Cdk1 (cyclin B1-dependent kinases) or Aurora kinases, cell-cycle
checkpoint proteins and mitotic spindle assembly as Chk1 (checkpoint kinase 1) and Chk2
(checkpoint kinase 2), or cell death inducers as p53, p21 and caspases.[10] When the DNA
damage is the inducer of MC, which can be induced by various chemotherapeutic agents, cells
generally die during interphase, before entering the M phase. If they survive to interphase,
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DNA-altered cells will stop in G1 or G2 to restore the damage and, eventually, reenter the
cycle. Nevertheless, DNA alterations are not always repaired, leading to the activation of the
pathways of ATM (ataxia-telangiectasia-mutated) kinases and of ATR (ataxia-telangiectasia
and Rad3-related) kinases which, through an evolutionary conserved kinases cascade, activate
the checkpoint-regulated Chk1 and Chk2.[22,23] Chk1 and Chk2 kinases are especially
essential for cell-cycle arrest in G1, S, and G2 phases. Chk1 is phosphorylated, and activated,
in response to DNA alterations, and seems to play a role at every point of the cell cycle.[24,25]
Indeed, the conditional knockout of Chk1 in transgenic mice induces a vast cell death in
proliferating somatic cells, which show clearly visible morphological alterations in the nucleus
typical of cell that are undergoing MC.[26] To further demonstrate that an intact DNA structure
checkpoint is an essential prerequisite to prevent MC, we can look at the substrate targets of
the Chk2 kinases, such as p53,[27,28] the cell-cycle-regulating phosphatases Cdc25A and
Cdc25C[29,30] and Mdm2,[28] which are not only required for MC, but appear to have an
apoptosis-sensitizing effect,[13] remarking the interconnection between MC and apoptosis.
Anyway, some authors point on the differences between MC and apoptosis and sustain that
the two pathways are distinct,[31] since some manipulations able to block the apoptotic
cascade (as overexpression of Bcl-2) increase the frequency of MC.[32] To further sustain the
hypothesis that MC is unrelated to apoptosis, Nabha et al. demonstrated that caspase inhibitors
such as Z-VAD.fmk are unable to halt the appearance of giant multinucleated cells, induced
by treatment with spindle poisons.[33] However, the latter demonstration does not account
for the possibility that apoptosis might not be mediated by caspases, which has been proved
by different authors.[34–36] Moreover, the pharmacological inhibition or genetic deletion of
genes related to the “DNA structure checkpoint” such as ATM, ATR, Chk1 and Chk2, lead to
DNA damage-induced MC.[31,37–39] Thus, inhibition of this checkpoint limits the time
available for DNA repair, constraining the cell to prematurely advance through G1, S and G2
phase and leading to MC,[40,41] a process which is markedly different from apoptosis, yet at
macroscopic level, due to large cells formation characterized by multiple micronuclei clustered
around individual or group of chromosomes.[31,42–45] Mitotic phase entry, however, relies
essentially on cyclin B/Cdk1 kinase (or cdc2) action, which must be timely activated and form
a complex that gain functional activity.[46–48] Cyclin B transcriptional levels and activity begin
during late S phase and peak in M phase, while its active form translocates to the nucleus in
early mitosis.[46,49] On the other side, Cdk1 is kept inactivated by the phosphorylation
operated by Myt1 and Wee1 until early mitosis, when the phosphate groups are removed by
a member of the Cdc25 family phosphatases and CAK kinases phosphorylate Cdk1, ensuring
its maximal activity to enter in early mitosis.[47] The interactions between these two elements
give rise to the mitosis-promoting factor (MPF), which ensures the G2 to M phase transition.
The Cdk1/cyclin B1 heterodimer induces mitosis by activating phosphorylation of enzymes
that control chromatin condensation, nuclear membrane disaggregation, and microtubule
restructuration, leading to cellular roundup.[50] The perfect coordination of spatiotemporal
patterns of Cdk1/cyclin B1 activity is crucial to ensure a regular cell cycle and is controlled at
multiple steps. Thus, the so-called DNA structure checkpoints, by activating Wee1 and Myt1,
as well as the checkpoint kinases Chk1 and Chk2, avoid Cdk1 action and entry into M phase.
While the “DNA structure checkpoint” stops cells before entering the M phase in case of DNA
alteration or not complete duplication, another checkpoint, the so-called spindle assembly
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checkpoint, prevents anaphase entry until all chromosomes are bound on both sides with the
mitotic spindle. Indeed, this will ensure a balanced chromosome segregation between
daughter cells.[47,51,52] To do this, the “spindle assembly checkpoint” promotes the formation
of the anaphase-promoting complex (APC), which ensures the rapid destruction of cyclin B1
thanks to its E3 ubiquitin ligase activity.[50,53,54] Moreover, APC-mediated ubiquitination of
securin allows the separase to bind securin itself, event that ends in the breakdown of the
cohesins that maintain the linkage between sister chromatids. By this, sister chromatid
segregation and anaphase entry are granted. When alteration in the mitotic spindle dynamics
activates this checkpoint, the cell stops M phase before anaphase onset. This may lead to
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shrinkage; on the contrary, MC is identified by the formation of clusters of nuclear envelopes
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that contains misaggregated chromosomes with various and different grade of chromatin
condensation.[9,14,41] But how do MC-related giant cells die? Notwithstanding the morpho‐
logical differences between apoptosis and MC, they do share biochemical hallmarks, as further
demonstration that MC represents a pre-stage of apoptosis. Indeed, Chk2 inhibition is able to
induce MC in HeLa cells, a process that was associated with caspase-2 and caspase-3 activation,
permeabilization of mitochondria that release apoptotic-involved factors (as cytochrome c)
and DNA fragmentation.[14,16, 65] Moreover, caspases appear to be essential in the final stages
of MC, thus supporting the hypothesis that morphological alterations associated with MC are
just the initial steps that will lead to apoptosis.[12,66] To further sustain this concept, it has
been proved that mitotic slippage and mitotic arrest address to apoptotic death.[67–69]
Nevertheless, MC-mediated death do not always require caspases activation and apoptosis,
as demonstrated by the capacity of some giant cell to undergo slow death in a necrosis-like
fashion, with loss of nuclear and plasma membrane integrities ending in cell lysis.[13] Indeed,
some evidences demonstrated that MC can happen in a caspase-independent fashion, since
MC can induce several rounds of abnormal mitosis, associated with polyploidy plus multi‐
nucleation, which direct the cells to necrotic death.[70] However, a central point when talking
about MC is p53. Several studies proved that spindle-damaged cells that are able to cross the
M phase will be halted, in a tetraploid state, during G1 phase thanks to the activation of G1
checkpoint by p53.[71,72] This, in its turns, irreversibly activates p21, thus blocking cell-cycle
progression of tetraploid cells in order to avoid altered-cell propagation. This will all end into
cell death.[7,71] Moreover, p53 is the key factor that activates apoptosis after endomitosis and
endoreplication. p53 and apoptosis, anyway, are not always required for MC-related cell death.
Several papers evidenced how MC and necrosis can be morphologically distinguished
especially when referring to loss of nuclear membrane and plasma membrane integrities.
[42,73] While more detailed characteristics of MC still remain elusive and need to be investi‐
gated to elucidate all the different involved pathways, great consensus can be found on the
determinants that will push MC-associated cell to choose between apoptosis or even necrosis:
the genetic status of the cell and the profile of proteins involved in cell-cycle regulation.[13]
Figure 2. Schematic representation of main cell death path related to MC.
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4. Cell-cycle alterations in post-mitotic neurons
Mature neurons of central nervous system are typically described as permanently post-mitotic
cells that have been recently revealed to be in a continuously activated but arrested cell-cycle
status. Thus, neurons must constantly keep their cell cycle in check, avoiding its re-initiation,
since vigilance relaxation would mean death. During the development, neurogenesis takes
place mainly in a tightly packed layer of nuclei lining the lumen of the neural tube (the
ventricular zone, VZ) and later in the closely apposed region known as the subventricular zone
(SVZ). After birth, the VZ has been depleted of all mitotic cells, but cells with stem cell
precursors properties are present throughout the adult brain particularly in the SVZ (to a
greater or lesser extent in different vertebrates) and can give rise to neurons in the adult in case
of injury. Following the last cell division, neurons mature and the still unclarified mechanisms
that will ensure a permanent mitotic arrest begin. What would happen if a neuron lost control
of its cell cycle and reentered cell division? Evidence suggests that the neuron would die. One
of the first descriptions of this phenomenon was given in 1992 analyzing the effects of
expression of SV40 T antigen in Purkinje cells or in photoreceptor. While the expression of this
viral oncogene typically promotes tumorigenesis in mammalian cells, its expression in post-
mitotic neurons induced the appearance of mitotic figures, and entry in S phase not followed
by proliferation but by cell death.[74,75] RB protein has an important role in the maintenance
of neuron cell-cycle control and mice deficient in Rb show in the nervous system, ectopic
mitoses, and massive neuronal death.[76] Freeman et al. (1994)[77] demonstrated that the death
of cultured sympathetic neurons following NGF deprivation led to the upregulation of cyclin
D1. These experimental data support the hypothesis of an association between ectopic cell
division and cell death in the nervous system. All these data converge on the idea that during
development, once a neuron leaves the VZ, its cell cycle must be actively held in check and
cell-cycle re-initiation leads to death. In the adult life, cell-cycle re-activation has been claimed
as the cause of neuronal death in many neurologic disorders such as Alzheimer’s disease (AD),
amyotrophic lateral sclerosis (ASL), ataxia telangiectasia, Parkinson’s disease (PD), and even
stroke.[78] In the early nineties of the last century, it became increasingly clear that mitogenic
pathways in neurons are aberrantly activated early during AD. In the neurons of patients who
had died with AD have been reported the presence of phosphorylated tau protein, usually
found only in dividing cells[76] and of various cell-cycle proteins, such as cyclin A, B, D and
E,[79,80] PCNA and CKIs of both the Ink and Cip/Kip families.[81] Evidence of cell-cycle
activation in post-mitotic neurons has been also observed in murine models of AD, such as
increased expression of the cell proliferation marker PCNA, and the CDK inhibitor Cdkn2a,
as detected by immunohistochemistry in cortical neurons of the APP/PS1 mice.[82] Bonda et
al. demonstrated that phosphorylated MCM2 protein, a component of the DNA replication
machinery, is localized to the cytoplasm, rather than nucleus, in neurons of AD patients, while
it was completely absent in control cases.[83] These data support the notion that neurons in
AD reenter the cell cycle and progress through the S phase, but the aberrant cellular distribu‐
tion of MCM2 may induce cell-cycle stasis and consequent neuronal degeneration. Entry into
the S phase not followed by progression through the M phase in dying neurons in AD patients
has been reported also by others.[84] Similarly, Ogawa et al., using immunohistochemistry,
Cell-cycle Alterations in Post-mitotic Cells and Cell Death by Mitotic Catastrophe
http://dx.doi.org/10.5772/61783
67
reported an increase in phosphorylated histone H3 in hippocampal neurons in AD patients.
However, phosphorylated histone H3 is localized within the nucleus in active dividing cells,
while in neurons of AD patients the proteins were aberrantly localized in the cell cytoplasm,
indicating that cells underwent MC that leads to neuronal dysfunction and neurodegeneration.
[85] In animals, AD-like neurodegeneration can be experimentally induced by the adminis‐
tration of okadaic acid (OA), a potent phosphatase inhibitor[86,87] that increases the degree
of phosphorylation of various proteins, such as the microtubule-associated protein tau. In
vitro exposure of neuroblastoma cells to OA induces the expression of G2/M phase marker
cyclin B1 and cyclin D1,[88] causing neurons to aberrantly reenter cell cycle, but the cells fail
to complete the mitotic cycle, resulting in MC. Indeed, Chen et al. demonstrated that disturb‐
ance of the protein kinase–phosphatase system caused by OA is sufficient to induce neuronal
cyclin B1 expression, force neurons into the mitotic phase of cell cycle, and cause MC.[89]
Although the presence of binucleated neurons has been reported,[90] no cytokinesis has ever
been described, consistent with the idea that susceptible neurons may be arrested at the
G2/M transition before they die. In mitotic-competent cells, G2 phase is associated with the
activation of CDK1 and phosphorylation of target proteins, that is, microtubule-associated
protein tau, that allow cell-cycle progression.[91,92] However, in neuron the presence of a
highly specialized and stabilized cytoskeleton probably hinders the possibility to disassemble
cytoskeleton structures to commit to mitotic spindle formation and cytokinesis. Interestingly,
in AD patients the presence of abnormally increased level of phosphorylated tau has been
reported and this could be explained as an unsuccessful effort to modulate G2 neuronal
architecture and prepare it for mitosis.[93] In addition, the pro-apoptotic BAD protein is
another protein phosphorylated and activated by CDK1 in G2 phase, linking the cell cycle to
the programmed cell death mechanisms.[94] However, the apoptotic nature of neuron death
in AD remains controversial. Indeed, although extensive DNA fragmentation has been
reported, only a small number of cells show signs of caspase-mediated apoptosis. Interestingly,
activation of caspases in human neurons does not lead to a rapid process of cell death but
provokes a prolonged form of apoptosis, thus explaining the long-term survival of neurons
that have progressed in late phases of the cell cycle and the protracted nature of AD. Indeed,
quantification of neuron-expressing cell-cycle proteins revealed that 5-10% of neurons are
dying at any moment. This implies that death by cell cycle in adult neurons must be a very
slow process requiring in the order of 6–12 months; otherwise, during the average course of
AD (10 years), 95% of neurons should be dead in less than a month. Thus, it is possible that in
fully mature neurons, neuronal death by cell-cycle re-initiation requires an additional stimulus
to make the transition from cycle to death.
The involvement of cell-cycle molecules was found also in ALS. Nuclear accumulation of
phosphorylated RB protein, with concurrent increase in cytoplasmic levels of cyclin D, and
redistribution of E2F-1 into the cytoplasm occur in motor neurons and glia during ALS,
suggesting overcoming of G1/S checkpoint during ALS as mechanisms regulating motor
neuron death.[95] More recently, Ranganathan et al. linked elevated levels of p53 in ALS spinal
cord motor neurons and activation of G1 to S phase cell-cycle regulators to their cell death.[96]
Using microarray analysis in single motor neuron in the SOD1 transgenic murine model of
familial ALS, researchers found a significant increase in the expression of cyclins D2, E2, and
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I.[97] In ataxia-telangiectasia (A-T), the extent of Purkinje cell loss correlates with the severity
of the clinical phenotype. Re-expression of cell-cycle proteins in the cerebellum of patients has
been reported in particular in Purkinje cells and striatal neurons in both human and mouse A-
T.[98] This linkage of the neurodegeneration with events of the cell cycle has important
implications in understanding the etiology of A-T. The involvement of cell-cycle-associated
mechanisms to neurodegeneration in PD is suggested by a series of experimental evidence. In
human, the expression of phosphorylated Rb protein, E2F1, as well as DNA synthesis, has been
reported in postmortem samples of PD patients.[99,100] Administration of 6-hydroxydopa‐
mine (6-OHDA) induced a rat model of PD in which overexpression of Cdc2 was found in
dopaminergic neurons of the substantia nigra.[101] In vitro treatment of PC12 cells with 6-
OHDA lead to oxidative stress and was associated with upregulated expression of several
markers of cell-cycle reactivation.[102] The role of cell-cycle reentry in neuronal dysfunction
and death observed in many neurodegenerative diseases has been clarified by Lee et al..[103]
These researchers developed a new transgenic mouse model in which forebrain neurons were
induced to reenter the cell cycle by overexpression of the proto-oncogene Myc under the
control of the CAMKII promoter. In this animal model, the induction of ectopic cell-cycle
reentry (determined by the expression of PCNA, Ki-67 and cyclin D1, and BrdU incorporation)
results in neuronal cell death, gliosis, and cognitive deficit, thus conclusively demonstrating
that dysregulation of cell-cycle reentry is a key determinant of neurodegeneration in vivo.
Activation of the cell cycle mediated by the loss of CDKI function is also reported as a cause
of ischemia-induced delayed neuronal death in vivo and in vitro.[104] Similarly, the phosphor‐
ylation of the RB protein is altered by transient brain ischemia.[105] However, the activation
of cell cycle and the rapid expression of cell-cycle inhibitors, such as p53 and p21cip1, may
trigger neuronal death in acute hypoxic stress,[106] while preventing cell death in the presence
of sublethal stimulus.[107] All these data suggest that cell cycle is aborted mostly at G1/S
checkpoint in ischemic death. However, in some systems, authors have shown that neurons
start to replicate DNA, thus entering the S phase before they die, as demonstrated by induction
of PCNA and incorporation of BrDU in several models of focal and global ischemia.[108–110]
However, there is no in vivo evidence of G2 entry in ischemic neurons. In spite of the accu‐
mulating in vivo experimental studies demonstrating aberrant deregulation of cell cycle in
stroke, there is little known about how/whether these processes occur in humans. Studies in
human biopsy material indicate that the neuronal death in temporal lobe epilepsy is also
associated with the expression of cell-cycle-related proteins.[111] Finally, in adult central
nervous system, some DNA-damaging agents, such as UV radiation and cytotoxic drugs, have
deleterious effects because they induce neuronal death via the activation of the cell division
cycle[112] and the cell death follows a MC that can be prevented by cyclin-dependent kinase
inhibitors.[112,113] The evidence to date is compatible with the requirement for a second "hit"
for a neuron to progress cell-cycle initiation and DNA replication to death. This finding offers
several important insights. The most important is that any intervention of blocking “second”
processes might prevent or slow the neuronal cell death in the process of disease. Finally, which
type of cell death follows the reported cell-cycle alterations in post-mitotic neurons is not
completely understood, but MC is one possibility.
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5. Cell-cycle alterations in podocytes
Podocytes are specialized renal epithelial cells that, through cytoplasmic extensions called foot
processes, interdigitate with neighboring podocytes and cover the surface of the glomerular
capillary loops, thus forming the glomerular filtration barrier (GBM). Podocytes, like neurons,
are terminally differentiated post-mitotic cells, with a sophisticated actin cytoskeleton, whose
disruption due to genetic, mechanic, immunologic, or toxic injury leads to the detachment of
cells from glomerular basement membrane, and finally to podocyte loss. Decrease in the
number of podocytes in the glomerular capillary tuft is associated with the development of
glomerular sclerosis in several human and experimental diseases. Two cellular strategies that
could act to compensate for cell stress or relative cytopenia (e.g., during organogenesis or
injury) are hypertrophy, which is an increase in cell size, and hyperplasia, which is an increase
in cell number. Both these processes require that quiescent cells reenter the G1 phase to increase
the amount of cell organelles and proteins. Podocytes can only undergo hypertrophy, pro‐
ducing additional foot processes to compensate for podocytopenia. Indeed, several protective
mechanisms prevent podocyte progression to mitosis and arrest their cell cycle at the restric‐
tion points of G1 and G2 phases. The ability of podocytes to arrest at the restriction point is
well documented. In vitro exposure of quiescent mesangial cells and podocytes to antibody
and a complement source induces sublytic injury and entry into G1 phase.[114,115] Mesangial
cells progress through the cell cycle, synthesized DNA, and divide, with resultant proliferation
and increased cell number. In contrast, podocytes undergo limited DNA synthesis, but do not
proceed beyond the G2/M phase of the cycle and do not proliferate.[116] This arrest is
associated with an increase in protein levels for p53, the CDKI p21, growth-arrest DNA
damage-45 (GADD45), and the checkpoint kinases 1 and 2.[116] Sublytic C5b-9 injury causes
DNA damage in podocytes, but not in mesangial cells,[117] and DNA damage prevents
proliferation by arresting cells at G2/M phase. Re-expression of cell-cycle proteins has been
reported during glomerular disorders, and in recent years, cell-cycle regulatory proteins have
become an area of intense research in order to understand the changes that occur in various
renal diseases. The roles of these proteins in renal diseases have been addressed in several
reviews:[118–120] cyclin A and Ki-67 staining was observed in podocytes of children collaps‐
ing glomerulopathy[121,122] and focal segmental glomerulosclerosis (FSGS);[123] cyclin D
was observed in cellular lesion of FSGS.[123] Moreover, p27 and p21 but not p57 was decreased
in CGN (crescentic glomerulonephritis), as in FSGS when compared to normal.[122] A uniform
decrease in p27 and p57 immunostaining in FSGS and collapsing glomerulopathy was reported
also by Shankland et al..[124] However, these authors reported de novo expression of p21.
Downregulation in the expression of cyclin kinase inhibitors such as p21 and p27 has been
observed in podocytes in children with idiopathic nephrotic syndrome. This downregulation
is not followed by upregulation of cyclin D and cyclin A that are needed to overcome the G1/
S transition and move the cell forward in the cell-cycle process. Thus, the podocytes remain
trapped in the G1 arrest phase. Similarly, an altered expression of 27, p21, and cyclin A was
reported by Srivastava and colleagues also in patients with minimal change disease,[122] while
Shankland et al. did not reported change in expression of p21, p27 and 57 in podocytes of
patients affected by minimal change disease and membranous glomerulopathy.[124] Using
animal models of glomerular disease such as the passive Heymann nephritis (PHN) and anti-
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glomerular antibody models, Hiromura et al. reported a marked decrease in p57 expression
that was diffuse in PHN, whereas in the murine model, loss of expression of p57 occurred
predominantly in podocytes expressing PCNA.[125] Marked podocyte expression of the CKIs,
such as p21 and p27, was reported during Heymann nephritis in diabetic ZDF-fa/fa rats,[126,
127] and in glomerular tufts affected by crescentic glomerulonephritis,[128] suggesting
upregulation of CKIs as a generalized response of podocytes to stress or injury. Interestingly,
mechanical stretch of cultured podocytes reduced cell-cycle progression and induced hyper‐
trophy in both wild-type and p27−/− podocytes.[129] Moreover, this event required the
presence of p21 and was prevented by specifically blocking extracellular signal-regulated
kinase 1/2 (Erk1/2) or Akt.[129] These data suggest that upregulation of CKIs in podocytes is
an attempt to maintain cell-cycle quiescence and preserve normal physiological function.
However, it is possible to overcome the resistance and force podocytes entering the cell cycle,
under the pressure of sufficiently strong stimuli. We recently provided evidence that the
dramatic consequences of this forced entry in mitosis are the trigger for a catastrophic mitosis.
Indeed, as already reported for neurons, podocytes are programmed to maintain their complex
cytoskeleton and cannot assemble an efficient mitotic spindle due to poor expression of Aurora
kinase B, which is essential for cytokinesis[130] (Figure 3). Thus, podocytes cannot survive
mitosis and, if forced to override these cell-cycle restriction points, detach and are lost in the
urine. This is confirmed by the presence of many binucleate podocytes in the urine in patients
affected by FSGS[131] and lupus nephritis,[132] suggesting that podocytes carrying nuclear
abnormalities generated during an abnormal cytokinesis are more susceptible to detachment
and loss. Moreover, in mitotic podocytes actin is required for the formation of the mitotic
spindle and is no more compatible with maintaining the cytoskeletal structure of secondary
foot processes. Indeed, in adherent cells the actin network is rapidly dismantled and rear‐
ranged to allow the cell to form the mitotic spindle and to enter mitosis. Therefore, mitotic cells
acquire a rather rounded shape and easily detached and are lost in urine. Thus, acquisition of
functional specialization in a cell type, such as podocytes, neurons, and cardiomyocytes, is
coupled with the permanent exit from the cell cycle[133] and the arrest in a “post-mitotic”
state. Therefore, when expression of cell-cycle markers (such as Ki-67) in podocytes is observed
in certain diseases this is probably a sign that they undergo hypertrophy, but they are unlikely
to undergo mitosis. Podocytes with mitotic figures are only occasionally observed because
they are susceptible to detachment and/or death. Nagata et al. reported one mitotic figure in a
single podocyte in a case of FSGS among 164 renal biopsy specimens with glomerular disease.
[134] Mitotic podocytes associated with proteinuria may be a desperate but aborted attempt
to regenerate epithelial injury.
Podocyte multinucleation on the other hand is a recognized feature of aberrant mitosis, also
described by Nagata et al. in 1998.[135] More recently, Mulay et al. in lieu of the fact that
aberrant  mitosis  and  podocyte  binucleation  are  synonymous  to  MC,  retrospectively
reviewed the consecutive renal biopsy specimens and found twice as many (n=12) multi‐
nucleated  podocytes.[136]  All  cases  had  significant  proteinuria,  and  diagnoses  included
minimal change, FSGS, IgA nephropathy, membranous nephropathy, collapsing glomerul‐
opathy,  and  membranoproliferative  glomerulonephritis.  Foot  process  effacement  was
invariably  present  in  association  with  binucleated  podocytes.  These  binucleated,  and
sometimes  trinucleated,  podocytes  enlarge,  with  edematous  nuclei,  with  one  or  more
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nucleoli.  The  presence  of  micronuclei  is  also  reported  and  it  is  indicative  of  genomic
instability  and  characteristic  of  MC.  Moreover,  these  podocytes  exhibit  other  alteration
typical of MC, such as increased number of organelles, mitochondria and lipid droplets or
cytoplasmic vacuoles.[137] The classic example of mature podocytes reentering the cell cycle
is  HIV-associated  nephropathy  (HIVAN).  In  HIVAN,  the  presence  of  tightly  packed
multinucleated podocyte is frequently observed.[138,139] These multinucleated podocytes
to large extent remain attached to the GBM, and there is no evidence of overt foot process
effacement  and  of  apoptotic  nuclear  condensation.  The  cytoplasm  appears  fragile  with
cytoplasmic  dense  (osmiophilic)  bodies  (lysosomes).  Eventually,  these  multinucleated
podocytes  detach  from  the  GBM,  disrupt  the  cytoplasm,  and  release  the  nucleus  and
cytoplasmic  contents  into  the  Bowman  space.[137]  Podocyte  mitoses  can  be  seen.[137]
However, the connection with MC and aberrant cell death is still vague and little studied
experimentally or clinically. Interestingly, in HIVAN p27, p57, and cyclin D are absent in
podocytes, and p21, cyclin A, and Ki-67 are induced.[121,124,140] This implies a dysregu‐
lated  podocyte  phenotype  characterized  by  bypassing  cell-cycle  restriction  points  and
podocyte loss via MC. Recently, we demonstrated that Notch activation may represent an
important  driver  of  MC  in  podocytes  during  glomerular  disorders.[130]  Indeed,  Notch
activation in  podocytes  in  vitro  induced the  downregulation of  the  p21 and p27,  which
Figure 3. Podocytes are terminally differentiated post-mitotic cells. Pathological activation such as exposure to stress
induces a compensatory response. The most important response to stress is podocyte hypertrophy, which results from
cell-cycle arrest at the G1 or G2/M checkpoint. Persistence of mitogenic stimuli forces the podocyte to complete mito‐
sis. This could lead to the formation of mitotic spindles and aberrant divisions with the formation of aneuploid cells or
to the execution of a mitotic death program.
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pushed  progression  toward  mitosis  of  a  cell  that  cannot  assemble  an  efficient  mitotic
spindle, leading to the formation of bi- or micro-nucleated cells with disrupted cytoskeleton.
[130] Accordingly, Notch protein expression was not detected in glomeruli of healthy adult
kidneys,  while  several  studies  demonstrated strong Notch upregulation in  podocytes  of
patients affected by several types of glomerular disorders characterized by podocyte death.
[130,141,142]
6. Cell-cycle alterations in renal tubular epithelial cells
6.1. G1 arrest
Acute kidney injury (AKI) is a potentially devastating, increasingly common syndrome
characterized by rapid impairment of kidney function as a result of a toxic or ischemic insult.
In the first 24 h following injury, tubular cells undergo apoptotic and necrotic cell death, and
70% of the surviving, normally quiescent proximal tubule epithelial cells enter the S phase of
the cell cycle.[143,144] This is documented by an increase in PCNA,[145–147] incorporation of
3H-thymidine and 5-bromo-2-deoxyuridine into nuclear DNA, and induction of mRNA for
“immediate-early” genes, c-fos, c-jun, and egr-1.[148,149] A rapid induction of p21, in several
models of AKI, has also been reported.[149] This cell-cycle reentry after injury has traditionally
been viewed as an appropriate repair response to the loss of adjacent cells after an initial insult.
However, this is in contrast to the observation that cell-cycle inhibition is protective against
several form of AKI. The strategic role of p21 in AKI is demonstrated by a series of experiments.
Administration of an adenovirus vector directing the expression of p21 protects mouse
proximal tubule cells in culture from cisplatin toxicity.[150] Similar results can be obtained by
treating cells with several cell-cycle inhibitors, such as roscovitine and olomoucine.[150] In
vivo, Megyesi et al.[151] demonstrated the upregulation of p21 mRNA in ARF (Acute Renal
Failure) induced by ischemia, cisplatin, or ureteral obstruction. In addition, p21 knockout mice
were shown to have increased kidney cell-cycle activity, increased cisplatin nephrotoxicity,
and higher mortality than wild-type animals.[145] In p21 (−/−) mice, 5-bromo-2-deoxyuridine
incorporation into nuclear DNA and increases in PCNA content were much higher compared
with p21(+/+) mice. Following either cisplatin administration or ischemia–reperfusion injury
(IRI), compared with their p21(+/+) littermates, p21(−/−) mice developed more severe mor‐
phological damage, displayed a more rapid onset of the physiological signs of AKI, and had
a higher mortality.[152] These findings suggested that the induction of p21 plays a protective
role in kidney cells by preventing DNA-damaged cells from progressing in the cell cycle
without repair, which eventually would result in death. Miyaji et al.[153] speculated that p21
induction may play a protective role to prevent the development of cisplatin-induced AKI,
stopping the cell cycle in the G1 phase and providing enough time for DNA repair. Similarly,
Nath and co-workers[154] reported that LLC-PK1 kidney cells overexpressing heme oxygen‐
ase-1 were resistant to several apoptotic stimuli and that this resistance was mediated by p21
upregulation. Similarly, Golzalez-Michaca et al.[155] demonstrated in a rat proximal tubule
cell culture that blocking the apoptotic effects of hemin was correlated with upregulation of
p21 levels.
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The hypothesis that cell-cycle inhibition post-insult protects against AKI is supported by
several experimental findings. As reported above, the cell-cycle-inhibitory drug roscovitine is
effective in protecting kidney cells in vitro from cisplatin-induced apoptosis.[150] Similarly,
the broad spectrum small-molecule CDKI, purvalanol, can actually protect against cisplatin-
induced cell death[156] and expression of an inactive Cdk2 mutant in mouse kidney cells
protected from cisplatin nephropathy.[157] Importantly, small-molecule inhibition of CDK2
leads to a G2/M block or an intra-S phase arrest, and G2/M arrest would likely be an undesirable
long-term effect as it has been recently reported that this induces progressive interstitial
fibrosis in the kidney and increased cell apoptosis (see following paragraph). Interestingly,
early G1 and late S phases are reported to be more resistant to genotoxic damage.[158] Thus,
delaying this cell-cycle progression after injury should also ensure more time for DNA damage
to be repaired before mitosis. DiRocco et al. recently demonstrated that a small-molecule
inhibitor of CDK4/6 effectively promotes transient G0/G1 arrest in renal epithelial cells,
protects these cells from DNA damage and apoptosis as a result of exposure to cytotoxic
chemotherapeutic agents in vitro, and ameliorates kidney damage following AKI in vivo.[159]
Their results suggest the possibility that epithelial cells may die through MC after IRI.
Thus, following injury, tubular cells enter the cell cycle, but rapidly arrest in the G1 phase. This
G1 cell-cycle arrest prevents cells from dividing when the DNA may be damaged and arrests
the process of cell division until the damage can be repaired lest resulting in the cell’s demise
or senescence. Two inducers of G1 cell-cycle arrest, insulin-like growth factor-binding protein
7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), have been recently identified
and their urinary levels serve as sensitive and specific biomarkers to early prediction of AKI
and of renal recovery.[160,161] IGFBP7 directly increases the expression of p53 and p21 and
TIMP-2 stimulates p27 expression. The upregulated p proteins in turn block cell-cycle
promotion acting on the cyclin-dependent protein kinase complexes (CyclD-CDK4 and CyclE-
CDK2), thereby inducing G1 cell cycle presumably to avoid cells with possible damage from
dividing. Markers of cell-cycle arrest such as TIMP-2 and IGFBP7 may signal that the renal
epithelium has been stressed and has shut down various function but may still be able to
recover without permanent injury to the organ.[161]
6.2. G2/M arrest
For several decades, AKI was usually assumed to be transient with usual expected recovery
of renal function if the individual survived the acute illness. Observational clinical studies and
animal models however link AKI to chronic kidney disease (CKD) progression. When kidney
injury is of mild entity with normal baseline function, the repair process can be adaptive with
few long-term consequences. On the contrary, if injury is more severe, repeated, or to a kidney
with underlying disease, the repair can be maladaptive. Maladaptive repair leads to CKD, a
process characterized by persistent parenchymal inflammation, with increased numbers of
myofibroblasts and accumulation of extracellular matrix (Figure 4). The mechanism that
triggers the fibrogenic response after injury is not well understood but a G2/M arrest of tubular
cells has been demonstrated being an important driver of maladaptive repair and progressive
CKD after AKI.[162–164] Indeed, characterization of the cell-cycle profile of tubular epithelial
cells in vivo at various times after an acute insult in multiple experimental models of murine
kidney injury, including severe bilateral IRI, unilateral IRI, aristolochic acid-induced nephr‐
Cell Biology - New Insights74
The hypothesis that cell-cycle inhibition post-insult protects against AKI is supported by
several experimental findings. As reported above, the cell-cycle-inhibitory drug roscovitine is
effective in protecting kidney cells in vitro from cisplatin-induced apoptosis.[150] Similarly,
the broad spectrum small-molecule CDKI, purvalanol, can actually protect against cisplatin-
induced cell death[156] and expression of an inactive Cdk2 mutant in mouse kidney cells
protected from cisplatin nephropathy.[157] Importantly, small-molecule inhibition of CDK2
leads to a G2/M block or an intra-S phase arrest, and G2/M arrest would likely be an undesirable
long-term effect as it has been recently reported that this induces progressive interstitial
fibrosis in the kidney and increased cell apoptosis (see following paragraph). Interestingly,
early G1 and late S phases are reported to be more resistant to genotoxic damage.[158] Thus,
delaying this cell-cycle progression after injury should also ensure more time for DNA damage
to be repaired before mitosis. DiRocco et al. recently demonstrated that a small-molecule
inhibitor of CDK4/6 effectively promotes transient G0/G1 arrest in renal epithelial cells,
protects these cells from DNA damage and apoptosis as a result of exposure to cytotoxic
chemotherapeutic agents in vitro, and ameliorates kidney damage following AKI in vivo.[159]
Their results suggest the possibility that epithelial cells may die through MC after IRI.
Thus, following injury, tubular cells enter the cell cycle, but rapidly arrest in the G1 phase. This
G1 cell-cycle arrest prevents cells from dividing when the DNA may be damaged and arrests
the process of cell division until the damage can be repaired lest resulting in the cell’s demise
or senescence. Two inducers of G1 cell-cycle arrest, insulin-like growth factor-binding protein
7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), have been recently identified
and their urinary levels serve as sensitive and specific biomarkers to early prediction of AKI
and of renal recovery.[160,161] IGFBP7 directly increases the expression of p53 and p21 and
TIMP-2 stimulates p27 expression. The upregulated p proteins in turn block cell-cycle
promotion acting on the cyclin-dependent protein kinase complexes (CyclD-CDK4 and CyclE-
CDK2), thereby inducing G1 cell cycle presumably to avoid cells with possible damage from
dividing. Markers of cell-cycle arrest such as TIMP-2 and IGFBP7 may signal that the renal
epithelium has been stressed and has shut down various function but may still be able to
recover without permanent injury to the organ.[161]
6.2. G2/M arrest
For several decades, AKI was usually assumed to be transient with usual expected recovery
of renal function if the individual survived the acute illness. Observational clinical studies and
animal models however link AKI to chronic kidney disease (CKD) progression. When kidney
injury is of mild entity with normal baseline function, the repair process can be adaptive with
few long-term consequences. On the contrary, if injury is more severe, repeated, or to a kidney
with underlying disease, the repair can be maladaptive. Maladaptive repair leads to CKD, a
process characterized by persistent parenchymal inflammation, with increased numbers of
myofibroblasts and accumulation of extracellular matrix (Figure 4). The mechanism that
triggers the fibrogenic response after injury is not well understood but a G2/M arrest of tubular
cells has been demonstrated being an important driver of maladaptive repair and progressive
CKD after AKI.[162–164] Indeed, characterization of the cell-cycle profile of tubular epithelial
cells in vivo at various times after an acute insult in multiple experimental models of murine
kidney injury, including severe bilateral IRI, unilateral IRI, aristolochic acid-induced nephr‐
Cell Biology - New Insights74
opathy, and unilateral ureteral obstruction (UUO), identified the accumulation of cells in G2/
M growth arrest as the common feature predicting progressive fibrotic kidney disease.[162]
In the UUO model, authors demonstrated that fibrotic injury induced TGF-β1 secretion by
tubular epithelial cells. TGF-β1 then induced G2/M cell-cycle arrest and profibrotic phenotype
through the upregulation of p21 and activation of the JNK pathway, respectively. TGF-β1 and
PDGF subsequently stimulated pericyte–myofibroblast transition through differentiation and
proliferation, respectively.[165] In another study, authors demonstrated how severe IRI
induces a sustained epidermal growth factor receptor (EGFR) activation, which is essential for
the tubular cell regenerative response at the early stage of reperfusion, but eventually leads to
the activation/proliferation of renal interstitial myofibroblasts and development of renal
fibrosis.[164] The correlation between G2/M-arrest and fibrosis is supported by several studies.
Pharmacological inhibition of G2/M-arrested cells reduced fibrosis, whereas increases in the
proportion of G2/M-arrested cells in the cell-cycle exacerbated fibrosis, thus confirming that
G2/M arrest in tubular cells contribute to progressive CKD after AKI.[164–166] The link
between inadequate DNA repair and renal fibrosis and CKD is underlined in study on humans
with the FAN1 mutation (a DNA damage response signaling pathway devoted to repair of
DNA interstrand crosslink damage). These patients develop karyomegalic interstitial nephri‐
tis, with evidence of increased levels of DNA damage and cell-cycle arrest in the late G2 phase.
[167] In conclusion, all these recent findings on the pathophysiology of AKI underline the
important role of tubular cell-cycle arrest in the process of maladaptive repair. Moreover, these
findings open new therapeutic perspectives to prevent, slow down, or arrest chronic fibrosis
progression and progressive CKD, as suggested by experiments in rodents performed using
agents such as histone deacetylase inhibitors[166] or p53 inhibitors[162,168], by blocking the
initiation of the G2/M checkpoint, or by stimulating transit through G2/M to complete mitosis.
Figure 4. After AKI, normally quiescent proximal tubule epithelial cells enter the cell cycle, event traditionally viewed
as an appropriate repair response to the loss of adjacent cells after an initial insult. However, rapid induction of p21
and arrest of cell-cycle progression play a protective role in kidney cells by preventing DNA-damaged cells from pro‐
gressing in the cell cycle without repair, which eventually would result in death, probably by MC. In cases where the
kidney injury is persistent or repeated, increasing numbers of epithelial cells stall between the G2 and M phases of the
cell cycle, which stimulates the production of considerable amounts of TGF-β1 and PDGF that induce a fibrotic re‐
sponse. Pharmacological inhibition of G2/M-arrested cells reduced fibrosis, whereas increases in the proportion of
G2/M-arrested cells in the cell-cycle exacerbated fibrosis, thus confirming that G2/M arrest in tubular cells contribute to
progressive CKD after AKI.
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However, application of these therapeutic strategies in humans needs careful assessment of
the safety of the drugs and pathways under investigation because the G2/M checkpoint is
extremely important in preventing the perpetuation of dangerous DNA mutations.
A great comprehension of the mechanisms involved in cell-cycle arrest could thus help not
only in the discovery of novel therapeutic strategies to prevent podocyte loss, glomeruloscle‐
rosis, proteinuria and progressive kidney disease, but also in the selection and utilization of
new specific and sensitive biomarkers for AKI.
7. Conclusions
Terminal differentiation invariably involves two closely linked phenomena: permanent
withdrawal from the cell cycle and cell type-specific differentiation characterized by the
upregulation of a panel of tissue-specific genes. Typically, post-mitotic cells do not reenter the
cell cycle when exposed to growth signals, and in some cases further increases in tissue mass
are achieved through an increase in cell size or hypertrophy. One long-standing theory to
explain the lack of cytokinesis in post-mitotic cells, such as neurons, podocytes, and adult
cardiac myocytes, is the presence of highly organized mature myofibrils which physically
prevent cell division. Because cells must disassemble their cytoskeletal filaments before
entering cell division, disassembly of the cytoarchitecture in these cell types would presumably
negatively impact their function. However, in these cells expression of a wide range of cell-
cycle proteins has been described, although no cases of cell division have ever been reported.
This, together with the finding that the expression of cell-cycle proteins is necessary to execute
cell death in response to certain stress signals, has led to the proposition that in post-mitotic
cells, cell cycle is part of a well-regulated response to stress signals. The mechanisms by which
cell-cycle reentry causes cell death are not completely known, but exploring the trigger(s) that
induce normally post-mitotic cells to re-express cell-cycle proteins late in life as well as the
molecular mechanism by which the induction of these proteins leads to cell death may produce
great advances in the treatment and prevention of several neuro- and renal degenerative
diseases.
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Abstract
Cell death plays an important role in tumorigenesis, growth, and progression and
affects the efficiency of chemotherapy to a great extent. Apoptosis is usually regarded
as the principal mechanism of chemotherapy-induced cell death. However, the
dysregulation of apoptosis occurs commonly in many cancers, which lowers the
effectiveness of therapy and allows cells to survive. The mechanisms by which cells
acquire this resistance to chemotherapy are not fully understood. Several studies
uncovered alternative cell death pathways that are mechanistically distinct from
apoptosis. These pathways, including autophagy and necrosis, represent potential
targets for novel cancer treatment. By modulating the key regulatory molecules
involved in the different types of cell death, more effective and less toxic chemother‐
apy might be developed. In this chapter, we describe the signaling pathways and the
molecular events that are involved in these three major forms of programmed cell
death. Additionally, we also discuss the emerging therapies targeting these cell death
pathways as new strategies against cancer.
Keywords: Cancer, apoptosis, autophagy, necrosis, targeted therapy
1. Introduction
According to the World Health Organization, cancers figure among the leading causes of death
worldwide, accounting for 8.2 million deaths in 2012 [1]. The annual number of cancer cases
are expected to rise from 14 million in 2012 to 22 million within the next two decades [1]. Cancer
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
can affect everyone - the young and the old, the rich and the poor, men and women - and poses
a tremendous burden on patients, families, and societies. A substantial number of cancer
patients experience a significant reduction in their quality of life due to physical pain, mental
anguish, and economic hardship. Scientists and doctors are continuously making efforts to
find better and more effective therapies against cancer. Currently, strategically targeted cancer
therapies are emerging as treatments, which use drugs or other substances, such as tyrosine
kinase inhibitors and apoptosis inducing agents, to interfere with specific molecules and
processes involved in cancer cell growth and survival [2].
In multicellular organisms, the number of cells is tightly regulated to attain a balance between
cell proliferation and death. Maintaining this balance is crucial for normal development and
tissue size homeostasis [3]. Cell death is a fundamental process that not only plays a pivotal
role in the regulation of normal physiological development and tissue balance but also acts as
a defense mechanism against diseases such as cancer [4]. Over the past two decades, our
knowledge of cell death and the mechanisms of its regulation have increased dramatically.
Programmed cell death (PCD) is a principal mechanism of tumor suppression and is triggered
in nonmalignant cells to eliminate unnecessary, aged, or damaged cells that may otherwise be
harmful to the body [5]. Of note, apoptosis, autophagy, and programmed necrosis are the three
main forms of PCD, easily distinguished by their morphological characteristics within the cell
[6, 7]. Additionally, senescence and mitotic catastrophe (MC) are two other cell death mecha‐
nisms, often triggered in cancer cells and tissues in response to anticancer drugs [8]. Cell
senescence, a state of permanent cell-cycle arrest characterized by specific changes in mor‐
phology and gene expression that differentiate it from reversible cell cycle arrest, is also
considered as a type of cell death in the context of cancer therapy [9].
Accumulated data suggest that various chemotherapeutic agents can kill tumor cells through
the induction of apoptosis [10]. Dysregulation of the apoptotic pathways can not only promote
tumorigenesis [11, 12] but also render cancer cells resistant to chemotherapy. The ability of
cancer cells to avoid apoptosis and continue to proliferate is one of the fundamental hallmarks
of cancer and is a major target of cancer therapy development [12].Development of novel
molecules that activate apoptosis by targeting both the intrinsic and extrinsic apoptotic
pathways will advance our understanding of the mechanisms behind tumor cell proliferation,
which may also lead to the development of effective cancer therapies. Autophagy is an
evolutionarily conserved process that maintains cellular homeostasis by controlling protein
and organelle turnover. It serves as critical adaptive response that recycles energy and
nutrients during periods of starvation and stress to enable cell survival. Studies have shown
that autophagy contributes to the adaptation of tumor cells to adverse microenvironments [13]
and chemotherapy [13]. Autophagy may represent a major impediment to successful cancer
therapy; therefore, targeting autophagy is considered a promising strategy in clinical cancer
treatment. However, other studies have shown that deficiency in adequate autophagy results
in various spontaneous tumors in mouse model [14], indicating a tumor suppressive role of
autophagy in the process of tumorigenesis. It seems that autophagy plays dual roles as both
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mechanisms by which autophagy influences tumorigenesis and treatment response. Analysis
of autophagic signaling may identify novel therapeutic targets. Necrosis is generally consid‐
ered a passive response to massive cellular damage. However, accumulating evidence
supports the existence of programmed necrosis, which involves cell swelling, organelle
dysfunction, and cell lysis [16, 17]. Given the fact that many cancers have defective apoptosis
machinery, it is reasonable to consider the pros and cons of activating other cell death
pathways, such as necrosis, senescence and MC, and assess their therapeutic potential.
In this chapter, we discuss three major forms of PCD at molecular, cellular, and physiological
levels. We also discuss the regulation mechanisms of these cell death pathways. Finally, the
emerging therapies and strategies targeting these cell death pathways in the treatment of
cancers are examined.
2. Apoptosis
The term “apoptosis” originates from Greek words apo, which means “since, ” and ptosis, which
means “dropping off, ” and it refers to leaves falling off trees or petals dropping off flowers.
It was first coined by Kerr et al. in 1972 and used to describe a regulated form of cell death with
specific morphological features, which is different from the necrotic cell death resulting from
acute tissue injury [18]. Since then, apoptosis has become one of the most extensively studied
forms of PCD that plays a critical role in normal biological processes, such as embryonic
development, immune response, tissue homeostasis, and cell turnover [19], as well as in a
variety of pathological conditions including cancer [20]. Studies have shown that a cell
undergoing apoptosis can be described by a series of characteristic morphological changes,
including cell shrinkage, membrane blebbing, chromatin condensation, and nuclear fragmen‐
tation [21]. In addition to the morphological changes, biochemical changes happening during
apoptosis have also been revealed, and the three main ones are (1) the activation of caspases,
(2) the breakdown of DNA and protein, and (3) the modifications of cell surface markers
tagging the apoptotic cells for recognition by phagocytic cells [22].
Tissue homeostasis is maintained by an elaborate balance between cell growth by proliferation
and/or survival on one side and cell death via apoptosis and other pathways on the other side.
Any changes in the contribution of cell growth versus cell death can seriously affect the tissue
homeostasis leading to human diseases. Accumulated evidence indicates that defect in
apoptosis can contribute to cancer or onset of autoimmune responses, while excessive cell
death can cause acute or chronic degenerative diseases, immunodeficiency, and infertility [23].
Under normal conditions, apoptosis represents a safeguard mechanism to prevent tumori‐
genesis, which indicates that evasion or resistance to apoptosis is a pivotal feature of cancer
[24]. Alterations in cancer cells, which lead to impaired apoptotic signaling, not only promote
tumor formation, progression, and metastasis but also contribute to treatment resistance [6-8,
24]. Thus, a better understanding of the molecular events that are involved in the regulation
of apoptosis and their dysregulation in human cancers is expected to provide novel strategies
for cancer therapy.
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2.1. Two main signaling pathways involved in drug-induced apoptosis
Apoptosis can be triggered by various stimuli from outside or inside of the cells, for example,
by ligation of cell surface receptors, by DNA damage as a results of treatment with cytotoxic
drugs or irradiation, by a lack of survival signals or by developmental death signals. These
death signals of diverse origins eventually converge to activate a series of cysteine aspartyl-
specific proteases (caspases) through two main pathways, namely, extrinsic (death receptor)
and intrinsic (mitochondrial) pathways [25]. Caspases are central to the mechanisms of
apoptosis, which cleave key cellular proteins and dismantle the cells (Figure 1). Given the
death-causing effects of caspase activation, these two pathways are strictly and closely
regulated at each step. Apart from the two pathways mentioned, endoplasmic reticulum (ER)-
mediated apoptosis is a lesser known third pathway [26].
Figure 1. The extrinsic and intrinsic apoptosis signaling pathways. The extrinsic pathway primarily involves the acti‐
vation of procaspase 8 by death receptors (e.g., TNFR1 and Fas/Apo 1), whereas the intrinsic pathway involves the
release of factors from mitochondria, such as cytochrome c, that forms a complex with APAF1 and procaspase 9, re‐
sulting in the cleavage and activation of procaspase 9. In mammals, either active caspase 8 or caspase 9 is capable of
activating effector caspases such as caspase 3 or caspase 7, which then cleave apoptotic substrates leading to apoptosis.
A link between the extrinsic and intrinsic pathways is observed in certain cells. This involves the cleavage of the Bcl-2
family member Bid by caspase 8, leading to the release of cytochrome c from the mitochondria and activation of cas‐
pase 9. For detailed signaling pathways, please see Sections 2.1.1-2.1.3.
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Apoptosis in response to cancer therapy proceeds through the activation of the core apoptotic
machinery, including the receptor and the mitochondrial signaling pathway [10]. In many
tumor cell types, the main signaling pathway leading from drug-induced damage to cell death
involves the mitochondrial release of proapoptotic molecules under the control of the B-cell
lymphoma 2 (Bcl-2) family of proteins. However, death receptors of the tumor necrosis factor
receptor (TNFR) superfamily, mainly CD95 (APO-1/Fas), have also been shown to play a role
in linking drug-induced damage to the apoptotic machinery and modulating drug response.
2.1.1. Extrinsic (death receptor) pathway
The extrinsic apoptotic pathway is activated by the binding of death ligands to cell surface
death receptors, which transmit extracellular death signals to the intracellular apoptotic
machinery to elicit cell death [27]. Although several death receptors have been identified, the
best known death receptors belong to the TNFR superfamily, including TNFRs, CD95
(Fas/Apo 1), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors
[28]. These receptors become activated once bound by their cognate ligands such as TNF, CD95
(Fas), and TRAIL, which in turn results in death receptor aggregation, and recruitment of
various adaptor proteins to the intracellular death domains (DD) of the death receptors and
formation of death-inducing signaling complex (DISC). In this complex, Fas-associated death
domain (FADD) recruits other DD- and/or death effector domain (DED)-containing proteins,
such as procaspase 8 and procaspase 10, via homotypic death domain interactions (Figure 1)
[29]. In contrast, TNF receptor-associated death domain (TRADD) recruits proteins leading to
the formation of two complexes [30]. For example, TNFR1 binds to and forms complex I with
TRADD, TNF receptor-associated factors 2 and 5 (TRAF2/5), receptor interacting protein 1
(RIP1), and the cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2) (Figure 1). This
complex is important for the TNF-induced activation of NF-κB and MAPKs and the subsequent
transcription of antiapoptotic genes. In certain circumstance, RIP1 is deubiquitinated by
cylindromatosis and leads to the dissociation of RIP1 and TRADD from complex I. RIP1 and
TRADD then form complex II with FADD, caspase 8, and/or caspase 10, which is analogous
to the DISC induced by FasL and TRAIL (Figure 1) [4, 31, 32]. The activation of caspases 8 and
10 leads to the activation of the downstream caspase cascade to mediate apoptosis. In some
cells, named type I cells, the activation of effector caspases, such as caspases 3, 6, and 7, by
caspase 8/10 alone can induce apoptosis [33]. However, in type II cells, activated caspase 8/10
triggers the activation of intrinsic apoptotic pathway by the cleavage of the Bcl-2-homology 3
(BH3)-only protein Bid. Cleaved Bid is myristoylated to form tBid and translocates to the
mitochondria membrane, which promotes the oligomerization of Bax and Bak and causes the
release of apoptotic mediators from the mitochondria (Figure 1) [34, 35].
2.1.2. Regulation of the extrinsic pathway
Caspase 8 is the predominant initiator caspase in the extrinsic pathway, which plays a pivotal
role in determining the cell fate following the death receptor activation. Therefore, the major
signals that affect the recruitment of caspase 8 and its activation can modulate this signaling
pathway. For example, cellular FADD-like interleukin-1β-converting enzyme inhibitory
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protein (cFLIP) shares significant structural similarities with caspases 8 and 10, which allows
it to compete for binding sites and thus displace caspase 8/10 in the DISC complex. cFLIP lacks
a functional caspase domain, suggesting it to be a dominant-negative inhibitor [36]. Besides
caspase 8/10, cFLIP can also bind to FADD and TRAIL receptor 5 (DR5), and this interaction
in turn prevents the formation of the DISC complex and the subsequent activation of caspase
cascade [37]. Similarly, A20-binding inhibitor of NF-κB 1 (ABIN1) exerts its antiapoptotic effect
by interfering with the interaction of RIP1 and FADD with caspase 8 [38].
cIAP1/2 contain a signature baculovirus IAP repeat (BIR), a caspase-recruitment domain
(CARD), and a really interesting new gene (RING) domain at their C-terminal that exhibits E3
ubiquitin ligase activity, which help to recruit TRAF1/2 and inhibit TNFα-apoptotic signaling.
Although cIAP1/2 are not efficient caspase 8 inhibitors, they can play a regulatory role in
extrinsic pathway through the activation of prosurvival signals, such as NF-κB pathway. This
effect was shown to result from the cIAP1/2 induction of RIP1 ubiquitination and the recruit‐
ment of TAK1, TAB2/3, and the IKK complex [39]. The NF-κB signaling pathway has been
linked to death receptor signaling because RIP, which serves as an adaptor molecule for TNFR1
in the NF-κB pathway, can be cleaved by caspases. Upon TNF receptor signaling, this modu‐
lates the balance between proapoptotic and antiapoptotic signals and may even stimulate an
autocrine “death loop” [10, 40]
Ubiquitination has been shown to regulate the activity of caspase 8. A clear example is that the
polyubiquitination of the p10 subunit of caspase 8 by a cullin3-based E3 ligase can enhance its
enzymatic activity [41]. This modification occurs after the recruitment of caspase 8 to DISC
complex and allows for the binding of active caspase 8 to the polyubiquitination-binding
protein, p62, which is thought to increase the stability of cleaved caspase 8 [41]. The deubi‐
quitinating (DUB) enzyme A20 was reportedly involved in reversing this modification [41].
2.1.3. Intrinsic (mitochondrial) pathway
The intrinsic pathway, as implied by its name, is activated by internal stimuli such as DNA
damaging agents, growth factor deprivation, oxidants, hypoxia, overload of calcium, and
microtubule targeting drugs [42]. Upon the detection of the internal stimuli, two proapoptotic
Bcl-2 family members, Bax and Bak, undergo structural changes and subsequent oligomeri‐
zation at the outer membrane of the mitochondria, leading to the induction of mitochondrial
outer membrane permeabilization (MOMP) and the release of mitochondrial cytochrome c
(Cyt-c) into the cytosol [43-46]. The released Cyt-c assembles a multiprotein caspase-activating
complex, known as the “apoptosome” [47]. The central component of the apoptosome is Apaf1
that is transiently bound by released Cyt-c in the presence of ATP or dATP, which leads to the
oligomerization of Apaf1 and then the exposure of its CARD [48]. Subsequently, Apaf1 binds
to procaspase 9 via interaction between their CARDs. In this complex, procaspase 9 dimerizes
and autoactivates. Activated caspase 9 then cleaves and activates the downstream executioner
caspases 3 and 7 to perpetrate cell death rapidly (Figure 1) [49]. Besides Cyt-c, other apoptotic
factors are also released from the mitochondrial intermembrane space into the cytoplasm such
as apoptosis-inducing factor (AIF), second mitochondria-derived activator of caspase/direct
inhibitor of apoptosis (IAP)-binding protein with low pI (Smac/DIABLO), and Omi/high
temperature requirement protein A2 (Omi/HtrA2) [50]. Smac/DIABLO and Omi/HtrA2
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promote caspase activation by neutralizing the inhibitory effects on IAPs, while AIF causes
DNA condensation [51-53]
2.1.4. Regulation of the intrinsic pathway
The intrinsic pathway is tightly regulated by the intricate interactions between pro- and
antiapoptotic members of the Bcl-2 family, which are categorized according to the organization
of their Bcl-2 homology (BH) domains: (1) antiapoptotic members such as Bcl-2, Bcl-xL, Bcl-w,
A1, and Mcl-1, which all possess the four BH1-BH4 domains and inhibit proapoptotic coun‐
terparts; (2) effector proapoptotic members such as Bax, Bak, and Bok, which all possess the
three domains BH1-BH3; and (3) BH3-only proteins, including Bid, Bad, Bim, Bik, Bmf, Hrk,
Noxa, Puma, Blk, BNIP3, and Spike, which only have the short BH3 motif and promote MOMP,
either by inhibiting antiapoptotic proteins or by activating Bax and Bak [54-56]. Antiapoptotic
Bcl-2 members block the oligomerization of Bax and Bak or their association with BH3-only
proteins, thus preventing MOMP and Cyt-c release. However, upon a cytotoxic stimulus, the
effects of antiapoptotic members are counteracted by BH3-only proteins, such as Bim and
Noxa. BH3-only proteins release Bax-Bak from inhibition and allow them to promote MOMP
and apoptosis.
The inhibitor of apoptosis protein (IAP) family represents another negative regulator of the
intrinsic apoptotic pathway. So far, eight members have been identified, including cIAP1,
cIAP2, X-linked IAP (XIAP), neuronal apoptosis inhibitory protein (NAIP), melanoma IAP
(ML-IAP), survivin, Apollon, and IAP like protein 2 (ILP2) [57]. All IAPs contain BIR domains
and 70 amino acid motifs, which are essential for antiapoptotic properties of IAPs because BIR
domains bind the active sites of caspases and inhibit proteolytic function. Indeed, XIAP,
survivin, and cIAP1/2 have been found to directly inhibit caspases 3, 7, and 9 [58]. In case of
XIAP, its BIR3 domain directly binds to the small subunit of caspase 9, while its BIR2 domain
interacts with the active-site substrate-binding pocket of caspases 3 and 7 [59, 60]. Some IAPs
such as cIAP1/2 and XIAP contain a highly conserved RING domain that possesses E3
ubiquitin ligase activity and may target effector caspases for ubiquitination and subsequent
proteasomal degradation [61, 62].
Other apoptotic factors, for example, Smac/DIABLO, when released from the mitochondrial
intermembrane space during mitochondrial apoptotic events, are able to bind to various IAPs,
mainly XIAP in a manner that displaces caspases from XIAP and enables their activation. In
addition, the binding of Smac/DIABLO to IAPs facilitates the latter to be degraded by protea‐
some [63]. However, unlike Cyt-c, the ablation of Smac/DIABLO, Omi/HtrA2, or both proteins
does not lead to the inability to activate caspases or undergo apoptosis [64-66]. This suggests
that there may be considerable redundancy in XIAP inhibition, and in fact other proteins have
also been demonstrated to inhibit XIAP [67].
3. Autophagy
The term autophagy (from the Greek auto, meaning “oneself, ” and phagy, meaning “eating”)
was first introduced by Christian de Duve based on the observation that cells were able to
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digest their own components [68]. Nowadays, autophagy is defined as a self-digestive cellular
process by which eukaryotes degrade and recycle long-lived proteins, cellular aggregates, and
damaged cellular organelles to maintain cellular homeostasis. Three types of autophagy,
macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), have been
identified to date, which could be distinguished from one another via different modes of
delivery of the cargo to the lysosome and their function. Microautophagy is a direct engulfment
of cytoplasmic components into the lysosomal lumen for degradation [69], while in CMA, a
subset of soluble cytosolic proteins containing a KFERQ motif are recognized by molecular
chaperons, including the HSPA8/HSC70 (heat shock 70 kDa protein 8), and directly translo‐
cated into lysosomes through a receptor (LAMP-2A) on the lysosomal membrane [70].
Macroautophagy is a process that is responsible for the delivery and degradation of macro‐
molecules and organelles by generating specialized cytosolic vesicles (hereafter referred to as
autophagy) [71].
Autophagy is activated under physiological and pathological conditions, such as nutrient
starvation, hypoxia, hyperthermia, and oxidative stress, and in response to drugs and
radiation. This dynamic process generates cellular energy resources that allow a cell to adapt
its metabolism to energy demand. Defects in the autophagy process lead to the accumulation
of damaged proteins and/or genomic damage and can cause diseases such as neurodegener‐
ation, infectious diseases, heart diseases, and cancers [72, 73]. Although autophagy can
suppress tumor growth, it clearly plays a role in promoting tumor cells to survive under stress
[74]. The suppression of autophagy can sensitize cancer cells to anticancer therapy [75, 76], but
under apoptosis deficiency condition, autophagy can also cause cell death through a process
termed “autophagic cell death” [72, 77].
3.1. Pathway of autophagy
After induction by a stress signal such as starvation, the process of autophagy begins with the
formation of autophagosomes, which assemble around and encapsulate the targeted proteins
or organelles, and then fuse with lysosomes to form autolysosomes for degradation. This
complex process can be divided into five major steps, namely, nucleation, elongation, matu‐
ration, fusion, and degradation, which are tightly controlled by a subset of molecules encoded
by autophagy-related genes (ATGs) (Figure 2A). The first step of autophagy is the nucleation
of the phagophore, an isolation membrane that most likely derives from the ER [78, 79]. Besides
the ER, studies have also shown that the plasma membrane and membranes of mitochondria
and Golgi are also involved in the formation of the phagophore [80, 81]. The phagophore then
extends and sequesters the substrates destined for degradation and finally forms the charac‐
teristic double membrane vesicle, known as autophagosome. The outer membrane of the
mature autophagosome then fuses with the lysosome or inner body to generate a structure
named autolysosome, where the inner membrane of autophagosome and its contents are
degraded by the activity of acidic hydrolases provided by the lysosome [82, 83]. The catabolic
products are then either recycled into different metabolic pathways or undergo further
degradation to yield energy (Figure 2A).
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Figure 2. Schematic representations of the autophagy pathway and its regulation. (A) The five major steps of autopha‐
gy, namely, nucleation, elongation, maturation, fusion, and degradation, are illustrated. Phagophore membrane elon‐
gation and subsequent sealing of the autophagosome require two ubiquitin-like conjugation systems that mediate the
formation of ATG5-ATG12 complex and LC3-II. (B) The signaling molecules and pathways involved in autophagy reg‐
ulation (see Sections 3.1-3.3 for details).
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Autophagy is a highly regulated process by ∼30 ATGs discovered hitherto in mammals.
Several signaling pathways that initiate autophagy converge at a serine/threonine protein
kinase mammalian target of rapamycin (mTOR), a key regulator of the autophagic pathway,
which inhibits  autophagy in the presence of nutrients and growth factors [84].  In mam‐
mals, the initiation of phagophore formation is regulated by a great deal of macromolecu‐
lar  complexes  or  groups  of  proteins,  including the  ULK1 kinase  and its  regulators,  the
autophagy-specific phosphatidylinositol 3-kinase (PI3K) complex, and the multi-spanning
transmembrane  protein  ATG9  [85-88].  The  PI3K  complex,  which  consists  of  the  active
enzyme VPS34, a class III PI3K, together with p150 and Beclin 1, the counterparts of yeast
Vps15  and  Vps30/Atg6,  and  ATG14,  catalyze  the  production  of  phosphatidylinositol-3-
phosphate, thereby triggering the recruitment of effectors proteins, such as double FYVE-
containing protein 1 (DFCP1) and WD-repeat domain phosphoinositide-interacting (WIPI)
family  proteins  [89-93].  The  elongation  of  the  isolation  membrane  and  the  subsequent
closure of the autophagosome require two ubiquitin-like conjugation systems. First is the
ATG12-ATG5-ATG16L system: ATG12 is conjugated to ATG5 by the ATG7 (E1-like enzyme)
and ATG10 (E2-like enzyme). The resulting ATG5-ATG12 complex interacts with ATG16L
and then oligomerizes to form a large ATG16L complex, which localizes on the outer surface
of the extending autophagosomal membrane, but it dissociates from the membrane before
autophagosome formation is completed (Figure 2A) [94]. A recent study demonstrated that
under  certain  stress  conditions,  autophagy  can  occur  independently  of  ATG5/ATG7,
suggesting  the  existence  of  an  alternative  pathway  for  autophagosome  formation  [95].
Second is the phosphatidylethanolamine (PE)-light chain 3 (LC3) system: LC3 (the mamma‐
lian homologue of yeast Atg8) is cleaved by the cysteine protease ATG4 and then conjugat‐
ed to the lipid PE by the activity of ATG7 and ATG3 (E2-like enzyme) [94, 96]. The lipidated
form of LC3 (LC3II) specifically accumulates on nascent autophagosomes and recruits cargo
adaptor proteins (also known as autophagy receptors), such as p62, Nbr1, or NIX. These
proteins,  in  turn,  recruit  cargo  from  the  cytoplasm,  for  example,  ubiquitinated  protein
aggregates and damaged organelles, to promote the closure of the autophagosome [97-99].
Once  autophagosome  formation  is  complete,  it  fuses  with  lysosomes  through  mecha‐
nisms that remain largely unknown in mammalian cells. Some regulators have been found
to be involved in the autophagosome-lysosome fusion process, including LC3, the lysoso‐
mal proteins LAMP-1 and LAMP-2, the small GTP-binding protein RAB7, and the AAA-
type ATPase SKD1 [100-102]. Autophagosome-lysosome fusion then leads to the activation
of the hydrolases and the degradation of the sequestered cargo (Figure 2A).
3.2. Signaling pathways involved in the regulation of autophagy
3.2.1. Mammalian target of rapamycin
The mTOR, a PI3K-related serine/threonine protein kinase, plays a key role in maintaining the
balance between cell growth and proliferation. It has also been found to regulate the autophagy
in response to nutrient status, growth factor signals, and cell stress [103]. In higher eukaryotes,
mTOR exists in at least two distinct protein complexes, known as mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2) [104, 105]. The mTORC1 consists of mTOR, mLST8 (mam‐
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malian lethal with SEC13 protein 8), RAPTOR (regulatory-associated protein of mTOR),
PRAS40 (proline-rich Akt substrate of 40 kDa), and DEPTOR (DEP domain containing mTOR-
interacting protein) and is considered to be the principal regulator of autophagy [106].
mTORC1 is downstream of PI3K and is activated in response to mitogenic stimuli or nutrient
availability. When nutrients and growth factors are available, mTORC1 inhibits autophagy by
phosphorylating ULK1-ATG13-FIP200 complex, which is required for the phagophore
formation [107, 108]. In addition, activated mTORC1 promotes mRNA translation via activat‐
ing S6K and inhibiting 4EBP1. The inhibition of mTORC1 strongly induces autophagy, for
example, rapamycin (an mTORC1 inhibitor), and potently induces autophagy even in the
presence of rich nutrients. As indicated (see Figure 2B), mTOR activity is activated by different
signaling pathways, which converge on the tuberous sclerosis complex (TSC) and the ras
homolog enriched in brain (Rheb), a small GTPase that activates mTORC1 when in its GTP-
bound state [109]. TSC, which is comprised of TSC1 (harmartin) and TSC2 (tuberin), acts as a
GTPase-activating protein (GAP) for Rheb, promoting hydrolysis of its bound GTP and thus
inhibiting Rheb and mTORC1 activity [110]. The inhibition of TSC1/2 by Akt phosphorylation
allows Rheb-GTP to accumulate and activates mTOR [111]. Phosphatase and tensin homology
(PTEN), a phosphoinositide-3 phosphatase, is a negative regulator of the PI3K/Akt pathway
and thus an inducer of autophagy [112].
3.2.2. AMP-activated protein kinase
AMP-activated protein kinase (AMPK), a serine/threonine protein kinase, is another sensor of
cellular energy status and regulates the metabolism of glucose and lipids in response to
changes in nutrient and intracellular ATP concentration. In conditions of nutrient deprivation,
reduced ATP production causes an elevated AMP/ATP ratios that activates the energy-sensing
serine/threonine kinase 1(LKB1)-AMPK signaling axis [113]. Elevated AMP/ATP ratio
activates the LKB1 and subsequently phosphorylates and activates AMPK. The activation of
AMPK mediates the phosphorylation of TSC, which results in the inactivation of mTORC1
and induction of autophagy [114, 115]. Moreover, AMPK has also been found to directly
phosphorylate RAPTOR, an activating component of mTORC1, thereby inhibits mTORC1 in
a TSC-independent manner (Figure 2B) [116].
AMPK also directly regulates autophagy through the phosphorylation and activation of ULK1.
Studies have shown that AMPK interacts with the N-terminal proline/serine (PS)-rich domain
of ULK1, and this interaction is required for the ULK1-mediated autophagy (Figure 2B) [117].
Furthermore, AMPK has been shown to associate with and directly phosphorylate ULK1 on
several amino acid sites, and this modification is required for ULK1 activation in response to
nutrient deprivation [118]. It was reported that AMPK can interact with and phosphorylate
ULK1 at Ser555, Ser637, and Thr659 and that AMPK-dependent phosphorylation of ULK1 is
involved in the localization of ATG9 and increases autophagy efficiency [119]. Similarly, Kim
et al. found that under the conditions of glucose starvation, AMPK activates ULK1 through
direct phosphorylation of ULK1 on Ser317 and Ser777, thereby activating ULK1 and promoting
autophagy [120]. By contrast, Shang et al. found that ULK1 undergoes dramatic dephosphor‐
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ylation on Ser638 and Ser758 upon starvation, and the dephosphorylation of ULK1 leads to its
dissociation from AMPK and becoming more active in autophagy induction [113, 121].
3.3. Regulation of autophagy by oncogenes and tumor suppressor
3.3.1. Bcl-2 family members
Bcl-2 family members were initially identified and characterized as regulators of apoptosis;
however, more and more evidence has revealed that the members of this family also regulate
the autophagy process. The antiapoptotic Bcl-2 family members, including Bcl-2, Bcl-xL, Bcl-
w, and Mcl-1, have been found to interact with Beclin 1 and inhibit autophagy [122-124] (see
Figure 2B). Because the overexpression of these antiapoptotic genes is commonly seen in cancer
cells, the inhibition of autophagy may promote the oncogenic properties of these Bcl-2 family
proteins. Indeed, the small interfering RNA (siRNA)-mediated knockdown of Bcl-2 can trigger
autophagy and apoptosis in tumor cells [125, 126]. The antiapoptotic proteins were found to
interact with Beclin 1 through their BH3 receptor domain and the BH3 domain of Belcin 1,
thereby inhibiting Beclin-1-dependent autophagy [122]. The disruption of such interaction by
ABT737, a BH3-mimetic agent, or the expression of other proteins with Bcl-2 homology 3 (BH3)
domain that competitively disrupt the interaction can induce autophagy [123]. Additionally,
the death-associated protein kinase, DAPK, a protein that phosphorylates Beclin 1 thereby
disrupting Beclin-1-Bcl-2 interaction and inducing autophagy, is another inducer of autophagy
that is commonly silenced by methylation in different types of human cancers.
In contrast to antiapoptotic proteins, the proapoptotic BH3-only proteins, such as BNIP3L, Bad,
Noxa, Puma, BimEL22, and Bik, can promote autophagy [127]. For example, autophagy
induced by hypoxia occurs through a hypoxia inducible factor-1 (HIF-1)-dependent transcrip‐
tional activation of BNIP3L that disrupts the interaction between Bcl-2 and Beclin 1 [128].
Furthermore, Puma, another “BH3-only” protein, induces mitochondrial autophagy in
response to mitochondrial perturbations in a Bax/Bak-dependent manner [129].
3.3.2. p53 and p53-related regulators
The p53 tumor suppressor protein is well known for its role as a transcription factor that
regulates the expression of a series of genes, contributing to cell cycle arrest, DNA damage and
repair, apoptosis, and senescence [130, 131]. Underscoring its importance in the regulation of
proliferative homeostasis, it is the most commonly mutated tumor suppressor in human cancer
[132]. In mammalian cells, p53 shuttles between the nucleus and the cytoplasm; activated p53
translocates to the nucleus and induces the expression of target genes. Although p53 is best
known as a nuclear transcription factor, studies also demonstrate that cytoplasmic p53
mediates mitochondrial outer membrane permeabilization and transcription-independent
apoptosis [133, 134].
Similarly, p53 has been shown to modulate autophagy depending on its subcellular localiza‐
tion. Nuclear p53 stimulates autophagy in a transcription-dependent fashion by modulating
the expression of a number of regulators that inhibit the mTOR pathway. For example, p53
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activates the genes encoding AMPKβ1 (a component of AMPK), TSC1/2 and PTEN, which are
all known negative regulators of mTORC1, leading to the activation of autophagy [135]. In
addition, sestrin 1 and sestrin 2, two p53 target genes, have been identified as a critical link
between p53 activation and mTORC1 activity [136]. Sestrin is induced in response to DNA
damage and oxidative stress in a p53-dependent manner and inhibits mTORC1 activity via
AMPK-mediated TSC activation (Figure 2B) [136]. Furthermore, sestrin 2 was shown to be
required for autophagy induction in response to various cellular stress conditions, including
nutrient starvation and rapamycin exposure [137]. In addition, p53 can promote autophagy in
an mTOR-independent manner via the upregulation of damage regulated autophagy modu‐
lator (DRAM), a lysosomal protein mediating autophagic cell death [138]. However, p53 can
also suppress autophagy [139], an effect attributable to cytoplasmic rather than nuclear p53
(Figure 2B). A recent study indicates that cytoplasmic p53 can regulate autophagy through
direct interaction with FIP200 [140]. In addition, several autophagy inducers, such as nutrient
starvation, rapamycin, and ER stress, stimulate proteasome-mediated degradation of p53;
hence, the inhibition of p53 degradation can suppress autophagy induced by these cellular
stress signals.
4. Necroptosis/programmed necrosis
For a long time, necrosis has been considered as a form of cell death that is uncontrolled and
lacks underlying signaling events resulting in dramatic irreversible alterations in essential cell
parameters of metabolism and cell structure [141]. This might be true for cell death in response
to severe physical or chemical damage or adverse conditions; however, accumulating evidence
supports the notion that necrosis is a regulated process involving multiple developmental,
physiological, and pathological scenarios [142, 143]. For such a reason, it is called necroptosis
or programmed necrosis. Necroptosis is characterized by cytoplasmic and organelle swelling,
followed by the disruption of the cell membrane integrity, leading to the release of the cellular
contents into the extracellular milieu, which may result in an inflammatory response. Unlike
apoptosis, the nuclei of necrotic cells remain largely intact [144]. Necroptosis can be induced
by inhibition of cellular energy production, generation of ROS, imbalance of intracellular
calcium flux, or extracellular cell death signals, which are also able to induce apoptosis,
suggesting that different types of cell death may share, at least in part, common mechanisms.
In this sense, time and intensity of stimulus may determine the type of cell death. Indeed, one
study showed that depending on glutathione depletion and oxidative stress level, apoptosis
can switch to necroptosis [145].
4.1. Molecular mechanisms of necroptosis
Necroptosis can be triggered by ligands through numerous death receptors, including TNFR1
and TNFR2, TRAILR1 and TRAILR2, CD95 (Fas), and toll-like receptors (TLRs) [146-148], as
well as by different kinds of physical-chemical stress stimuli, such as anticancer drugs, ionizing
radiation, and calcium overload [149].
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The death receptors are activated by their ligands followed by the recruitment and activation
of caspase 8 that trigger the apoptosis in the absence of NF-κB survival pathway. However,
under conditions that fail to trigger apoptosis, necroptosis may be an alternative cell death
pathway. As shown in Figure 3, in the context of TNFR1 signaling, TNFα activates TNFR1,
which in turn induces the recruitment of RIP1 kinase and other proteins, including TRADD,
TRAF2, and cIAP1/2, to form a transient molecular complex referred to as complex I [144]. In
complex I, RIP1 is rapidly modified by k63-linked polyubiquitination mediated by E3 ligases,
cIAP1, and cIAP2. The ubiquitination of RIP1 serves as a platform to dock additional signaling
molecules, IKK complex, key mediators that lead to the activation of the canonical NF-κB
signaling, or inflammatory pathways [150-152]. RIP1 can be subsequently deubiquitinated by
the enzyme cylindromatosis (CYLD) [153] and, together with proteins involved in cell death
signaling, form complex II, which comprises as key components RIP1, TRADD, FADD, and
caspase 8 [154]. The formation of complex II initiates the cell death signals, and the cell death
via apoptosis or necroptosis is determined at this step. In the absence of cIAP1 or FLIP, RIP1,
FADD, and caspase 8 form complex IIa to activate the caspase cascade and to induce apoptosis
[31]. However, when caspase 8 activation is inhibited due to genetic or pharmacological
inhibition, RIP1 together with RIP3 forms a complex that leads to the necroptotic signal
transduction pathway [155]. This RIP1/RIP3-containing cytoplasmic necroptotic protein
complex is called complex IIb (also known as necrosome), which constitutes a key molecular
platform of necroptosis. RIP1 and RIP3 can phosphorylate reciprocally in an autocrine/
paracrine manner, leading to the activation of their kinase activity [32, 156].
The mixed lineage kinase domain-like protein (MLKL), also detected in complex IIb, is the
most downstream effector of necroptosis so far identified [157, 158]. The N-terminal domain
of MLKL is required for assembly of higher order structure and recruitment of MLKL to the
plasma membrane, followed by permeabilization of the plasma membrane [159-161]. The C-
terminal pseudokinase domain of MLKL interacts with RIP3 and is phosphorylated by the
latter at the threonine 357 and serine 358 residues, and these phosphorylation events are critical
for necroptosis [161]. In fact, blocking MLKL activity leads to necroptosis inhibition. Besides
the plasma membrane, activated MLKL may translocate to intracellular membranes, possibly
leading to the permeabilization of the ER, mitochondria and lysosome [160]. In addition, RIP3
phosphorylates MLKL, which in turn activates the mitochondrial phosphatase phosphogly‐
cerate mutase 5 (PGAM5), a central downstream effector of the necrosomal complex. PGAM5
in turn initiates the dephosphorylation of GTPase dynamin-related protein 1 (DRP1), a
mitochondrial fission regulator, which leads to the mitochondrial fission and mitochondrial
fragmentation. This process is essential for the necroptotic pathways, as necrosis cannot occur
without mitochondrial fission [162].
In addition to necrosome, another necroptosis-inducing complex referred to as ”ripoptosome”
has also been identified [163, 164]. Under normal conditions, the core components of this
complex, namely, RIP1, FADD, and caspase 8, are ubiquitinated by IAPs, which leads to the
degradation of these core components and thereby suppresses ripoptosome formation (Figure
3). However, when exposed to Smac mimetics or genotoxic stress, IAPs are downregulated,
resulting in the spontaneous formation of the ripoptosome and triggering of caspase-8-
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mediated apoptosis or caspase-independent necroptosis. There are three signaling pathways
initiated following ripoptosome formation. (1) The formation of caspase 8 homodimers within
the complex results in full catalytic activity and thus apoptosis. (2) The formation of caspase-8-
cFLIPL (long splice form of FLIP) heterodimers instead results in limited catalytic activity,
which is able to cleave RIP1 but is not sufficient to trigger apoptosis, leading to ripoptosome
disassembly and cell survival. (3) The formation of caspase-8-cFLIPS (short splice form of FLIP)
heterodimers predominates within the complex, and caspase 8 activation and RIP1 cleavage
are prevented, thereby promoting ripoptosome formation. This in turn leads to the mode of
cell death instead of being switched to necroptosis [163, 164].
A schematic overview of major signal transduction pathways induced by various stimuli and
ultimately leading to necroptosis can be found in the review article (Figure 1) by Kaczmarek
et al. [165].
Figure 3. TNFR1 engagement- or genotoxic stress-induced formations of divergent signaling complexes, leading to the
activation of NF-κB, apoptosis and necroptosis. Binding of ligands to receptors leads to the intracellular formation of
complex I. Lys63-linked polyubiquitination of RIP1 (in complex I) by cIAP ligases results in cell survival through the
activation of NF-κB and MAPKs. Deubiquitination of RIP1 by CYLD or inhibition of cIAP proteins leads to the conver‐
sion of complex I to complex IIa, activating the caspase cascade for apoptosis induction. Under conditions where cas‐
pase 8 activity is inhibited or RIP3 is highly expressed, RIP1 interacts with RIP3 to form complex IIb (necrosome),
which mediates necroptosis. The formation of complex IIb requires the kinase activity of RIP1. RIP3 and MLKL are
phosphorylated in complex IIb and translocated to the plasma membrane, where the complex mediates membrane
permeabilization. In addition, the downregulation of IAPs by Smac mimetics or genotoxic stress results in the sponta‐
neous formation of the ripoptosome, which can trigger caspase-8-mediated apoptosis or caspase-independent necrop‐
tosis.
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4.2. Regulation of necroptosis
4.2.1. FLIP and necroptosis
cFLIP molecule has been shown to be able to modulate the activation of procaspase 8 and
thereby prevents the apoptosis mediated by death receptors [166]. In the cytoplasm, RIP1 can
form complex with FADD, caspase 8, and TRADD (further referred to as ripoptosome)
following stimulation of T-cell receptor, TLR3, or TRL4. Remarkably, in response to genotoxic
stress (DNA damage), the spontaneous formation of the ripoptosome occurs independent of
death receptor activation [4, 144, 156, 163]. The ripoptosome can induce caspase-dependent or
caspase-independent cell death, depending on the cellular context or differential regulation of
caspase 8 by cFLIP. The cleavage of RIP1 in the ripoptosome complex by caspase 8 homodimers
triggers the downstream activation of effector caspases, leading to the induction of apoptosis.
Further, ripoptosome-mediated cell death or necroptosis also depends on the type of FLIP
isoform. The caspase 8/FLIPL heterodimers may induce RIP cleavage, thus leading to ripop‐
tosome disassembly and necroptosis inhibition, whereas caspase 8-/cFLIPS lacks proteolytic
activity necessary for RIP1 degradation, thus leading to necroptosis induction via RIP1 and
RIP3 [164]. Therefore, it is possible to divert cells to undergo apoptosis via the inhibition of
necroptosis through the modulation of ratio of FLIPL to FLIPS. Indeed, previous studies have
demonstrated that cFLIP protects cIAP antagonist-treated cells from Fas-induced cell death,
which involves both apoptosis and necroptosis [167]. cFLIPL inhibits the formation of the cell
death-inducing “ripoptosome, ” which functions in TLR3-induced apoptosis and necroptosis
[164]. Furthermore, siRNA-mediated silencing of cFLIPL sensitizes cells to TNF-induced RIP1/
RIP3-dependent necroptosis [168]. Therefore, FLIP plays a pivotal role not only in the regula‐
tion of apoptosis but also in necroptosis via the formation of ripoptosome and by switching
between apoptotic and necroptotic mechanism.
4.2.2. IAPs and necroptosis
The members of the IAP protein family exhibit E3 ubiquitin ligase activity and are character‐
ized by BIR domains that bind the active sites of caspases and inhibit proteolytic function [169].
During the intrinsic pathway of apoptosis, Smac/DIABLO is released from mitochondria to
cytosol thereby releases the caspases from the trap of IAP, leading to the activation of caspases
followed by apoptotic cell death. Smac protein was shown to induce the autodegradation of
cytosolic IAP1 and IAP2, allowing the formation of a caspase-8-activating complex consisting
of RIP1, FADD, and caspase 8 [170]. Several mammalian IAPs may utilize ubiquitination to
regulate their own stability. It has been recently found that Chal-24-induced autophagy
activation can result in the degradation of c-IAP1 and c-IAP2 and the formation of ripopto‐
some, thus contributing to necroptosis induction [171]. Remarkably, in the absence of IAPs
and under conditions where caspases are blocked, necroptosis can be stimulated via RIP1 and
its downstream kinase [172]. It has been demonstrated that loss of cIAPs promotes the
spontaneous formation of ripoptosome induced by genotoxic stress or TLR3 stimulation
through poly (I:C), a synthetic homologue of virus-derived double stranded DNA. Such event
occurs independently of death receptor stimulation and is suppressed by the cIAP1 or cIAP2
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that cause RIP1 ubiquitination and degradation [164]. FLIPL knockdown is able to enhance
ripoptosome aggregation, thus sensitizing cells to etoposide or TLR3-mediated cell death. The
role played by ripoptosome is complex since it can stimulate caspase-8-mediated apoptosis or
caspase-independent necroptosis depending on the cell types [163].
4.2.3. Regulation of necroptosis by caspase 8 activity
The concept of apoptosis blocking necrosis by caspase activity was firstly proved in 1998 by
the finding that the pharmacological inhibition of caspase activity sensitizes TNF-mediated
necrotic cell death in L929 cells [173]. Since then, this concept has been accepted as an estab‐
lished theory. Indeed, zVAD-fmk, a pan-caspase inhibitor, has been widely used to induce
necroptosis in a variety of cell lines as well as in mice models [173, 174]. Among the caspases,
caspase 8 is responsible for the switching between apoptosis and necroptosis [174]. Necroptosis
but not apoptosis was observed in caspase-8-deficient Jurkat cell lines in response to Fas and
TNFR stimulation. In vivo studies have also shown that caspase-8-deficient mice have signifi‐
cant necroptotic death, leading to embryonic lethality, which support the roles of caspase 8 in
blocking necroptosis. T-cell- or intestinal epithelial cell-specific deletion of caspase 8 in mice
also exhibited severe necroptotic features, inducing immunodeficiency or terminal ileitis,
respectively [175, 176].
The critical roles of caspase 8 on necroptosis are known to induce the cleavage of RIP1 and
RIP3 [31, 177]. Therefore, cells treated with caspase inhibitor or deficient in caspase 8 increase
the RIP1-RIP3 complex formation as well as necroptosis [156, 172, 178]. In addition, CYLD was
recently identified as a target of caspase 8 and a critical mediator. Caspase 8-mediated CYLD
cleavage at Asp215 prevents necroptosis, whereas the expression of mutant CYLD (D215A),
which is resistant to caspase 8-mediated cleavage, enhances necrosome formation and
necroptosis [178].
4.2.4. RIP1/RIP3 and necroptosis
RIP1  and  RIP3  are  key  signaling  molecules  in  inducing  necrosis  and  are  regulated  by
caspases and ubiquitination. The activity of RIP1 is specifically associated with necrosis and
not with apoptosis, which is demonstrated by use of Necrostatin-1 (Nec-1) that specifical‐
ly blocks the kinase activity of RIP1 [179]. Nec-1 inhibits TNF-induced necrosis in L929 cells
and  FasL-induced  necrosis  in  Jurkat  cells  that  were  pretreated  with  caspase  inhibitor
zVADfmk or  deficient  in  FADD [180].  In  addition  to  RIP1,  RIP3  kinase  activity  is  also
involved  in  caspase-independent  cell  death  [177],  and  it  has  become  clear  that  RIP3
determines cells to undergo necrosis in response to TNF treatment [32, 156, 172]. In contrast
to RIP1, RIP3 is not required for TNF-induced NF-κB activation [156, 181]. RIP1 activity is
essential  for  necrosome  formation  and  its  C-terminal  RHIM  domain  (RIP  homotypic
interaction  motif),  allowing  homotypic  interaction  with  RIP3  to  from  a  TNF-induced
complex, which is important for stabilizing the necrosome [182]. Under necrotic cell death
conditions,  RIP3  also  binds  to  other  metabolic  enzymes,  such  as  the  cytosolic  glycogen
phosphorylase (PYGL), the cytosolic glutamate-ammonia ligase (GLUL), and the glutaminol‐
ysis-initiating  enzyme GLUD1,  which  positively  modulates  RIP3  enzymatic  activity  [32,
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182].  These interactions result  in glutamine production and regulate glycogenolysis.  The
knockdown of PYGL, GLUL, or GLUD1 partially reduced the degree of TNF- and zVAD-
fmk-mediated ROS production and necrosis. It seems that both RIP1 and RIP3 are respon‐
sible for an increased cellular metabolism of carbohydrate and glutamine, leading to higher
ROS formation  and  subsequent  necrotic  cell  death  [182,  183].  The  activity  of  caspase  8
inhibits the necrotic cell death, likely by the cleavage of RIP1 and RIP3 [184], and down‐
stream,  through caspases  3  and 7  activation and poly-ADP-ribose  polymerase  (PARP)-1
[185].  Again,  this  demonstrates the importance of  RIP1/3 and the enhanced ROS forma‐
tion during the inhibition of caspases for the subsequent induction of necrosis [185-187].
5. Targeting cell death pathways in cancer treatment
5.1. Activating apoptosis in cancer treatment
5.1.1. TNF-Related Apoptosis-Inducing Ligand (TRAIL)
The TRAIL has been considered as a promising anticancer drug since it was found that TRAIL
preferentially triggers cell death in cancer cells compared to normal cells. Furthermore, unlike
TNF and FasL, TRAIL and antibodies against the TRAIL receptors were confirmed to be well
tolerated and safe in nonhuman primates even at relatively high concentrations [28, 188].
Recombinant human TRAIL has been shown to have the capacity to induce apoptosis in a
variety of cancer cells in vitro and in tumor xenografts [11]. TRAIL receptor agonists, including
recombinant TRAIL, as well as humanized antibodies against TRAIL receptors have been
evaluated in clinical trials [189-191]. However, several clinical trials using such drugs as single
agents to induce cancer cell death did not recapitulate the promising results obtained in animal
studies, which might be due to insufficient cross-linking of TRAIL receptors by the available
TRAIL agonists. This has led to the investigation of TRAIL-based combination therapies to
maximize antitumor activity. It has been shown that both conventional chemotherapy with
DNA damaging agents and radiotherapy induce the expression of TRAIL receptors in response
to DNA damage, thus suggesting a potential synergistic effect when combining these therapies
with TRAIL-targeted treatment [188, 192]. For example, histone deacetylase (HDAC) inhibitors
can induce the expression of TRAIL, thereby leading to the apoptosis in acute myelogenous
leukemia (AML) [193]. HDAC inhibitors enhance the synthesis of several proteins involved in
TRAIL signaling, such as DR5, and are able to sensitize the TRAIL-resistant cancer cells when
combined with TRAIL treatment [194, 195]. In addition, enhanced assembly of the TRAIL DISC
has been proposed to confer increased sensitivity in TRAIL-based combination therapies [196].
Many cytotoxic chemotherapeutic agents have been shown to induce the stabilization of p53
tumor suppressor protein in response to DNA damage and other cellular stresses, which
transcriptionally activates DR5 and other proapoptotic proteins that synergizes with TRAIL.
Therefore, TRAIL combination with such agents could be a useful therapeutic strategy for
cancer.
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However, the efficiency of TRAIL-based therapy in human cancers is not satisfactory due to
the existence of both agonistic receptors (TRAIL-R1 and TRAIL-R2) and antagonistic decoy
receptors (TRAIL-R3 and TRAIL-R4) in human cells. This implies that recombinant TRAIL
ligand is capable of eliciting proapoptotic or antiapoptotic signals depending on the availa‐
bility of these different receptors on the cell surface. Moreover, in some cancer cells, TRAIL
can induce the activation of NF-κB, thus promoting cancer cell survival rather than apoptosis
[188, 197]. Thus, the context-based effect of TRAIL signaling may explain the lack of efficacy
seen in recent studies of TRAIL-targeted anticancer therapy. It was reported that TRADD is a
key component that activates NF-κB in TRAIL signaling, and siRNA-mediated knockdown of
TRADD in cancer cells sensitizes them to TRAIL-induced apoptosis. Therefore, TRADD may
serve as a target for sensitizing cancer cells to TRAIL cytotoxicity [198].
5.1.2. Bcl-2 family
Antiapoptotic proteins of the Bcl-2 family, such as Bcl-2, Bcl-xL, and Mcl-1, are promising
targets for anticancer drug development because they play a crucial role in regulating
apoptosis, and the overexpression of these proteins is frequently observed in a variety of tumor
types. Currently, three main strategies targeting this pathway are under investigation: (1) small
molecules that affect gene or protein expression, (2) silencing of the upregulated antiapoptotic
proteins with antisense oligonucleotides, and (3) BH3-only peptides or synthetic small
molecule inhibitors interfering with Bcl-2 like protein function. With regard to transcription
silencing, studies have shown that, depending on the tissue origin of the malignancy, the
expression of Bcl-2 or Bcl-xL can be downregulated in specific types of cancer and leukemia
cells by small molecule drugs that modulate the activity of retinoic acid receptors (RAR),
retinoid X receptors (RXR), peroxisome proliferator-activated receptors (PPAR), vitamin D
receptors (VDR), and certain other members of the steroid/retinoid superfamily of ligand-
activated transcription factors (SRTFs). Consequently, RAR and RXR ligands as well as PPAR
modulators have been developed and evaluated for the treatment of some types of leukemia,
lymphoma, and solid tumors, such as breast and prostate cancers [23, 199]. HDAC inhibitors,
which function as transcriptional repressors via interaction with retinoid receptors and other
transcription factors, can also favorably modulate the expression of Bcl-2 or Bcl-xL in some
tumor lines [23]. These findings provide the basis for developing novel strategies for cancer
treatment by suppressing the expression of antiapoptotic Bcl-2-family genes in cancer.
Besides  the  chemical  compounds,  antisense  oligonucleotides  have  also  been  studied  to
knockdown the Bcl-2  family  of  antiapoptotic  proteins.  One agent  that  is  currently  most
advanced in clinical trials is Genasense (also known as oblimersen or G3139), which is a
synthetic, 18-base, single-stranded phosphorothioate oligonucleotide targeting Bcl-2 mRNA
that was developed by Genta Inc. (Berkeley Heights, NJ). More precisely, Genasense is in
phase II and phase III clinical trials treating a wide variety of adult and childhood tumors
[200]. In addition, treatment with Genasense markedly improved the antitumor activity of
many chemotherapeutic agents, such as taxanes, anthracyclines, alkylators, doxorubicin, or
dacarbazine [201-203]. In a phase III clinical trial, Genasense in combination with dacarba‐
zine was reported to significantly improve multiple clinical outcomes and increase overall
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survival  in  patients  with  advanced melanoma [203].  Furthermore,  a  bispecific  antisense
oligonucleotide selectively targeting Bcl-2 and Bcl-xL has been reported to simultaneously
downregulate  the  expression  of  both  Bcl-2  and Bcl-xL  and enhance  chemosensitivity  in
various cancer cells [204-206].
Intracellular stress signals can activate BH-3 only proteins to antagonize antiapoptotic Bcl-2
family members. An attempt to mimic the BH3-only action was the development of BH3
mimetic compounds containing exposed BH3 domain that occupy the BH3-binding site on
Bcl-2 or Bcl-xL, abrogating their antiapoptotic functions. ABT-737 and its oral derivative,
ABT-263 (also called navitoclax), are among the first promising BH3 mimetics in cancer therapy
[207, 208]. Both drugs avidly bind and inhibit Bcl-2, Bcl-xL, and Bcl-w, but not Mcl-1 or A1.
ATB737 has been shown to be effective as a single agent against certain lymphomas and small
cell lung cancer in vitro and in vivo [207] and against non-small cell cancer [209]. ATB737 has
also been reported to have synergistic cytotoxicity with conventional chemotherapeutic
agents, and other targeted agents, including tyrosine kinase inhibitor, EGFR inhibitor, MEK
inhibitor, and BRAF inhibitor, to reverse drug resistance and kill tumor cells [210, 211]. Initial
clinical trials have demonstrated a significant antitumor activity of ATB263 as a single agent
in the treatment of B-cell malignancies, especially CLL [212]. Several preclinical studies have
shown promising effects of combinatorial use of ATB263 with conventional cytotoxic agents
or targeted therapy in both solid tumor and hematologic malignancy models [210, 213].
However, the practical use of ATB263 is limited due to its propensity to induce acute throm‐
bocytopenia. ABT-199, a newer BH3 mimetic that specifically targets Bcl-2, has been shown to
suppress the growth of Bcl-2-dependent tumors in vitro and in vivo without causing thrombo‐
cytopenia since it does not antagonize Bcl-xL, which is critical for platelet survival [214-216].
Also, ATB263 has been demonstrated to enhance the antitumor activity when administrated
in combination with other chemotherapeutic agents [217, 218]. Other BH3 mimetics, such as
WEHI-539, BXI-61, BXI-69, Obatoclax, S1, JY-1-106, Gossypol, and its derivatives (apogossypol,
apogossypolone, and TW-37) as well as selective Mcl-1 inhibitors, have been developed, and
their antitumor effects have also been investigated or are under investigation (reviewed by
Vogler [211]).
5.1.3. IAP inhibitors
IAPs play a critical role in the control of cell survival and death by regulating key signaling
events such as caspase activation and NF-κB signaling that makes them become attractive
molecular targets. XIAP has been reported to be the most potent inhibitor of apoptosis among
all IAPs, consequently targeting XIAP using antisense oligonucleotides, or siRNA molecules
have been developed in the treatment of cancer. Indeed, targeting XIAP by antisense oligo‐
nucleotides or siRNA has been demonstrated to be able to induce apoptosis and sensitize
cancer cells to death receptor- and chemotherapeutic agents-induced cell death in a variety of
cancer in vitro and in vivo [219-223]. Similarly, the siRNA-mediated downregulation of other
IAPs, such as cFLIP and survivin, has also been shown to enhance chemotherapy activity in a
range of cancers [224-226]. In addition, some chemical compounds, for example, mTOR
inhibitors and HDAC inhibitors, can suppress the cFLIP expression via blocking its translation
and transcription, respectively [226, 227].
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Another approach for targeting IAPs is to disrupt IAP binding to caspases by small molecule
IAP antagonists. IAP antagonists bind to the BIR2 or BIR3 domain of XIAP, cIAP1, and cIAP2,
leading to the activation of caspase and induction of apoptosis [228]. Most of IAP antagonists
are Smac mimics, and in addition to monovalent compounds that contain one Smac-mimicking
unit, bivalent or dimeric IAPs have also been developed, which consists of two Smac-mim‐
icking units that are connected via a chemical linker [229]. When used as a single agent, IAP
antagonists can only effectively trigger cell death in a small subset of human malignancies,
suggesting that IAP antagonist-based combination therapies might be required for the effective
treatment of a majority of tumors. A variety of chemotherapeutic agents (including doxoru‐
bicin, etoposide, gemcitabine, paclitaxel, cisplatin, vinorelbine, SN38, 5-fluorouracil (5-FU),
cytarabine, and HADC inhibitor vorinostat), death receptor agonists, and signal transduction
modulators (including proteasome inhibitors, various kind of kinase inhibitors and monoclo‐
nal antibodies targeting growth factor receptor) have been shown to act cooperatively with
IAP antagonists to enhance antitumor activity in vitro and in preclinical models of cancers
[230-236]. For instance, beneficial synergistic effects were observed when IAP antagonists were
used in combination with other compounds, such as bortezomib, TRAIL, or DNA damaging
agents, such as melphalan, to reduce tumor burden in multiple myeloma models [237]. Along
these lines, LBW242 was also highly beneficial in an FLT3-mutated AML xenograft mouse
model when administered along with the protein kinase inhibitor PKC412 [238]. A recent study
depicted the combinatorial effect of Pak1, a downstream Rac effector, inhibition on IAP
antagonist treatment in NSCLC cell lines, rendering these cells hypersensitive to apoptotic cell
death [239]. The development of combination therapy is warranted as it promotes better
patient survival, as shown in a metastatic breast cancer Phase III clinical trial [240]. Combina‐
tion therapy might promote synergistic effects leading to low drug dosage, as well as sup‐
pressing resistance to therapy if multiple cell survival pathways are targeted at once, although
the probability of toxicity is also increased [241]. Fortunately, clinical trials with IAP antago‐
nists have not showed any dose-limiting toxicity [242].
5.2. Targeting autophagy in cancer treatment
Therapeutic targeting of the autophagy pathway as a new anticancer strategy has been under
extensive investigation. Since autophagy can play roles in tumor growth depending on the
context, such as tumor type or stage, both of the autophagy-enhancing and autophagy-
inhibiting agents may elicit beneficial effects in the treatment of cancer.
5.2.1. Inhibition of autophagy
High levels of autophagy are commonly observed in tumor cells following anticancer therapy.
For example, chemotherapeutic agents (e.g., doxorubicin, temozolomide, camptothecin, and
tamoxifen), HDAC inhibitors (e.g., SAHA), tyrosine kinase inhibitor (e.g., imatinib, sorafenib),
and monoclonal antibody (e.g., trastuzumab) have all been demonstrated to induce autophagy
in a variety of tumor cells [243-248]. Furthermore, a number of studies have shown that genetic
knockdown of ATGs or pharmacological inhibition of autophagy can effectively promote cell
death induced by various anticancer agents in many cancer lines and in multiple tumor models
[249-252]. These findings suggest that the activation of autophagy is a protective strategy for
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tumor cells to avoid being entirely killed by anticancer agents. The prosurvival ability of
autophagy renders tumor cells resistant to anticancer agents, which greatly compromises
curative efficacy of chemotherapy. In these contexts, the inhibition of autophagy can be a
promising strategy to reestablish or increase the sensitivity of tumor cells to therapeutic agents.
The common inhibitors of autophagy can be categorized into three types according to their
action mechanisms: (1) inhibit the formation of autophagosome via restraining the recruitment
of Class III PI3K to the membrane, such as 3-methyladenine (3-MA) and Wortmannin; (2)
prevent the degradation of proteins within autophagosome by disrupting lysosomal function,
such as chloroquine (CQ) and its analog hydroxychloroquine (HCQ); and (3) intervene in the
fusion of autophagosome with lysosome, such as bafilomycin A1 (BafA), a direct inhibitor of
vacuolar ATPase [253].
CQ and its derivative HCQ are the most common autophagy inhibitors used in clinical trials.
Preclinical studies have shown that CQ and HCQ are equipotent at autophagy inhibition and
potentiate the anticancer effects of different drugs both in vitro and in vivo. For example,
Amaravadi et al. reported that in a Myc-induced lymphoma mouse model, QC and HCQ
significantly enhance the cytotoxic effects of p53 expression and alkylating agents and
substantially impair the recurrence of tumor after chemotherapy [254, 255]. In chronic
myelocytic leukemia (CML) cell lines, the inhibition of autophagy by CQ markedly augments
the cell death induced by imatinib, a tyrosine kinase inhibitor that is a first-line therapeutic
agent for BCR/ABL-positive CML [256]. CQ has also been shown to promote the cytotoxic
effects of SAHA, an HDAC inhibitor, to overcome imatinib-resistant CML cells [246]. In a colon
cancer xenograft model, CQ in combination with vorinostat was shown to significantly reduce
tumor burden and increase apoptosis [257]. Similarly, CQ enhances the anticancer effect of the
saracatinib, an src inhibitor, in a xenograft mouse model of prostate cancer [258]. Currently,
phase I/II clinical trials are ongoing to evaluate the potential benefits of CQ and HCQ in
combination with standard cancer therapies for a variety of cancers [259], and these clinical
trials are listed at http://www.clinicaltrial.gov/.
In addition to CQ and its derivatives, other potential autophagy inhibitors have also been
studied for their anticancer efficacy in vivo and in vitro, including 3-MA, BafA, monensin, and
pepstatin A [260-262]. For example, the inhibition of autophagy by 3-MA increases cell death
induced by 5-fluorouracil (5-FU) in colon cancer xenograft model [263] as well as enhances
cytotoxicity induced by imatinib in glioma cell lines [264]. BafA in combination with tyrosine
kinase inhibitors, such as imatinib, nilotinib, or dasatinib, significantly increase cell death in
CML cells [256]. However, it must be remembered that the cytotoxic effects of these different
agents might not be solely due to the inhibition of autophagy; targeting key autophagy proteins
would be a more potent and specific approach. These include ULK1, Beclin 1, or ATG proteins.
5.2.2. Induction of autophagy
Although the concept of “autophagic cell death” in mammalian cells remains largely contro‐
versial, studies do show that autophagy is required for the efficient killing of tumor cells in
certain circumstances [252]. Certain tumor cells become highly resistant to apoptosis and
chemotherapy by overexpression of Bcl-2 or Bcl-xL, lack of Bax and Bak, loss of Beclin 1, or
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myelocytic leukemia (CML) cell lines, the inhibition of autophagy by CQ markedly augments
the cell death induced by imatinib, a tyrosine kinase inhibitor that is a first-line therapeutic
agent for BCR/ABL-positive CML [256]. CQ has also been shown to promote the cytotoxic
effects of SAHA, an HDAC inhibitor, to overcome imatinib-resistant CML cells [246]. In a colon
cancer xenograft model, CQ in combination with vorinostat was shown to significantly reduce
tumor burden and increase apoptosis [257]. Similarly, CQ enhances the anticancer effect of the
saracatinib, an src inhibitor, in a xenograft mouse model of prostate cancer [258]. Currently,
phase I/II clinical trials are ongoing to evaluate the potential benefits of CQ and HCQ in
combination with standard cancer therapies for a variety of cancers [259], and these clinical
trials are listed at http://www.clinicaltrial.gov/.
In addition to CQ and its derivatives, other potential autophagy inhibitors have also been
studied for their anticancer efficacy in vivo and in vitro, including 3-MA, BafA, monensin, and
pepstatin A [260-262]. For example, the inhibition of autophagy by 3-MA increases cell death
induced by 5-fluorouracil (5-FU) in colon cancer xenograft model [263] as well as enhances
cytotoxicity induced by imatinib in glioma cell lines [264]. BafA in combination with tyrosine
kinase inhibitors, such as imatinib, nilotinib, or dasatinib, significantly increase cell death in
CML cells [256]. However, it must be remembered that the cytotoxic effects of these different
agents might not be solely due to the inhibition of autophagy; targeting key autophagy proteins
would be a more potent and specific approach. These include ULK1, Beclin 1, or ATG proteins.
5.2.2. Induction of autophagy
Although the concept of “autophagic cell death” in mammalian cells remains largely contro‐
versial, studies do show that autophagy is required for the efficient killing of tumor cells in
certain circumstances [252]. Certain tumor cells become highly resistant to apoptosis and
chemotherapy by overexpression of Bcl-2 or Bcl-xL, lack of Bax and Bak, loss of Beclin 1, or
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exposure to pan-caspase inhibitors [76]. Most anticancer drugs exhibit limited effect on this
subset of tumor cells. Fortunately, studies have demonstrated that the induction of autophagy
may be an alternative way for cancer treatment when apoptosis is blocked [265, 266]; however,
the conditions under which autophagy can function as a primary cell-death mechanism remain
to be defined.
Among the potential targets in autophagy, Akt-mTOR pathway is the most investigated one.
mTOR inhibitors, including rapamycin and its analogs everolimus (RAD-001), temsirolimus
(CCI-779), and deforolimus (AP-23573), have been developed and studied for their ability to
induce autophagy and cell death. Everolimus and temsirolimus have been approved for the
treatment of renal cell carcinoma and mantle cell lymphoma [267]. Rapamycin has been shown
to inhibit cell growth and initiate cell death in mantle cell lymphoma cell lines and various
primary tumor cells, such as malignant gliomas, breast cancers, renal cell carcinomas, non-
small cell lung cancers, and cervical and uterine cancers [13, 253]. Everolimus induces massive
autophagy in leukemia [268], in advanced pancreatic cancer [269], and in many other cancers
[270], accompanied by reduced tumor burden. In addition, everolimus in combination with
etoposide, cisplatin, or doxorubicin display synergistic effects without significant increase in
toxicity [271]. However, rapamycin and its analogs would inevitably activate Akt kinases,
which associate with the induction of insulin receptor substrate-1, jeopardizing the antitumor
effects of these mTOR inhibitors [272]. Other inhibitors, including ATP-competitive inhibitors
of both mTORC1 and mTORC2 as well as the dual PI3K-mTOR inhibitor NVP-BEZ235 [273,
274], have exhibited more potent capacity to induce autophagy in cancer cells [275, 276].
Antiapoptotic Bcl-2 family members are frequently overexpressed in many human tumor
types, rendering tumor cells resistant to apoptosis. Bcl-2 family members are important
regulators involved in both apoptosis and autophagy. As a result, the modulation of Bcl-2
family proteins leads to not only apoptotic but also autophagic cell death. The underlying
mechanism of this effect reflects the fact that Bcl-2/ Bcl-xL proteins can bind and disrupt the
autophagic function of Beclin 1, which contains a BH3 domain [277]. This is notably the case
for BH3 mimetics (ABT737, ABT236, gossypol, obatoclax) that targets Bcl-2/Bcl-xL, thus
allowing Beclin 1 to be released to trigger autophagy [277, 278]. Obatoclax has been shown not
only to induce cell death on its own but also to potentiate the effects of other anticancer agents
such as the dual EGFR/HER2 inhibitor lapatinib, or HDAC inhibitors [279]. Although the
inhibitory effect affects both apoptosis and autophagy, the tumor cells preferentially undergo
autophagic cell death in apoptosis-defective cells. For example, doxorubicin primarily induces
autophagy at low doses while apoptosis at high doses, and the combination of Bcl-2 siRNA
treatment with a low dose of doxorubicin enhances the autophagic response, tumor growth
inhibition, and cell death [126].
In pursuit of new drugs to selectively kill renal cell carcinoma (RCC), Giaccia and colleagues
identified a compound, STF-62247, that strongly induced autophagy and massive vacuoliza‐
tion in VHL (a tumor suppressor gene lost in 75% of RCCs)-deficient RCC cells with no
apparent apoptosis induction. Blocking autophagy using ATG5 or ATG7 siRNA or 3-MA
prevents STF-62247-induced cell death, indicating that this compound induces cell death by
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autophagy in VHL-deficient RCC cells [280]. In addition, other autophagic cell death-inducing
anticancer agents have been developed and studied [279].
5.3. Modulation of necrosis for cancer treatment
The accumulating data have indicated that necrotic cell death can be activated to induce the
damage of tumor tissue. DNA-damaging agents are the most widely used and effective
chemotherapeutic approach for cancer treatment, which has been shown to be able to stimulate
a regulated form of necrosis [281]. The PARP is activated in response to DNA damage, which
facilitates the access of DNA repair enzymes to damaged DNA. The hyperactivation of PARP
depletes cytosolic nicotinamide adenine dinucleotide (NAD) and induce necrosis [282], which
may lead to selectively killing tumor cells because highly proliferating tumor cells depend on
cellular NAD to generate energy through aerobic glycolysis. PARP-mediated necrosis may
explain the phenomenon that neither Bax/Bak nor p53 deficiency impedes cell death in
response to DNA-damaging agents. Jouan-Lanhouet et al. found that the death receptor ligand
TRAIL induces necroptosis in human HT29 colon and HepG2 liver cancer cells via RIP1/RIP3-
dependent PARP1 activation and depletion of cellular ATP levels, suggesting PARP1 activa‐
tion as an effector mechanism downstream of RIP1/RIP3 [283].
There are more and more compounds and anticancer drugs that have been demonstrated to
induce cancer cell death through necrosis, such as shikonin, FTY720, staurosporine, derivatives
of amiloride (5-benzylglycinyl-amiloride and glycinyl-amiloride), and BI2536 (a small
molecule inhibitor of the mitotic kinase Plk1). Most of them were not necessarily designed in
a mechanism-based fashion but were only later found to induce necrotic features in the dying
cells [284-289]. Shikonin, a naturally occurring naphthoquinone, was reported to induce
necroptotic cell death in cancer cells that can be prevented by RIP1 inhibitor necrostatin-1, a
specific inhibitor of necroptosis. Moreover, shikonin-induced necroptosis can overcome drug-
and apoptosis-resistant cancer cell lines overexpressing P-glycoprotein, MRP1, BCRP, Bcl-2,
or Bcl-xL [284, 285]. FTY720, a sphingolipid analogue drug that mimics ceramide, was shown
to target the I2PP2A/SET oncoprotein, which results in the activation of tumor suppressor
PP2A and subsequently induces RIP1-mediated necroptotic cell death and tumor growth
inhibition [286]. Staurosporine, an inhibitor of a broad spectrum of protein kinases, has been
shown to induce necroptosis in leukemia cells when caspase activation is inhibited. The
induction of necroptosis was blocked by several pharmacological inhibitors, including
necrostatin-1, HSP90 inhibitor geldanamycin, MLKL inhibitor necrosulfonamide, and a
cathepsin inhibitor CA-074-OMe, which has been demonstrated to rescue the caspase-
independent necrotic cell death of leukemia cells treated by staurosporine [289]. Other
anticancer agents have also been shown to induce necroptosis via different mechanisms.
Bonapace et al. reported that obatoclax (GX15-070), a putative antagonist of Bcl-2 family
members, could overcome glucocorticoid resistance in childhood acute lymphoblastic
leukemia (ALL) through the induction of autophagy-dependent necroptosis, which bypassed
the block in mitochondrial apoptosis [290]. Obatoclax was also shown to promote the assembly
of the necrosome on autophagosomal membranes, thereby connecting obatoclax-induced
autophagy to necroptosis signaling pathways [291]. Coimmunoprecipitation assays demon‐
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strated that obatoclax promoted the physical interaction of ATG5, a constituent of autopha‐
gosomal membranes, with FADD, RIP1, and RIP3 as key components of the necrosome [291].
Small molecule inhibitors targeting IAPs such as Smac mimetics, which have been developed
to induce apoptotic cancer cell death, have been found to also engage necroptotic cell death.
He et al. first reported that, upon the inhibition of caspase activity, Smac mimetics in combi‐
nation with TNFα provoke a strong necroptotic response in Smac mimetic-resistant cancer
cells [172]. Similarly, Smac mimetic BV6 promotes TNFα-induced necroptosis not only in
leukemia cell lines deficient in caspase 8 or FADD but also in primary, patient-derived ALL
cells [292]. This Smac mimetic/TNFα-triggered necroptosis occurred in an RIP1-dependent but
caspase-independent manner in these leukemia cells lacking caspase 8 or FADD; however, in
FADD- or caspase-8-proficient leukemia cells, the same cotreatment of Smac mimetic and
TNFα induced apoptotic cell death [292]. This illustrates that Smac mimetic can prime
leukemia cells to TNFα-mediated cell death via either necroptosis or apoptosis depending on
the cellular context. Mechanistically, by promoting the degradation of cIAP proteins, Smac
mimetics stimulate the necrosome formation and promote necroptosis [293]. Furthermore, a
recent study demonstrated that Smac mimetic cooperates with demethylating agents to
synergistically induce cell death and can circumvent apoptosis resistance of AML cells by
switching to necroptosis [294].
Targeted toxins are fusion proteins that combine a targeting protein, such as a ligand for a
specific receptor, and a toxic peptide derived from a bacterial pathogen [295]. Diphtheria toxin
GM-CSF (DT-GMCSF) was shown to kill AML cells by simultaneously activating both caspase-
dependent apoptosis and caspase-independent necroptosis [296]. Interestingly, DT-GMCSF-
induced necroptotic cell death even occurred in apoptosis-resistant AML cells, indicating that
necroptosis may open new perspectives for cancer drug development in AML [296].
6. Conclusions and future perspectives
The dysregulation of the cell death process is closely related to cancer progression and
resistance to chemotherapy. The concept to therapeutically target apoptotic signal transduc‐
tion pathways has significant implications for cancer therapy since intact apoptosis programs
are critically required for the antitumor activity of most current cancer therapies that are used
in clinical oncology. The reactivation of apoptosis not only directly induces cell death in tumor
cells but also sensitizes tumor cells to other chemotherapeutic or targeted therapy agents.
However, given the wide variety of genetic and epigenetic defects that lead to apoptosis
resistance in most cancers, understanding the mechanism and regulation of other cell death
pathways in response to antitumor agents is important. Autophagy and necrosis are two
nonapoptotic cell death models that can be triggered as a consequence of cancer therapy and
may have overlapping but separable regulatory networks. Unlike apoptosis or necrosis,
autophagy has been shown to exert dual functions in cancers. On one hand, autophagy can
function as a survival pathway in response to anticancer agents; hence, autophagy inhibitors
may be used as adjuvants to standard cancer therapies. On the other hand, autophagy can lead
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to cell death in certain circumstances; thus, autophagy inducers may help to eradicate cancer
cells. As the effect of autophagy on cancer therapy varies depending on cell context such as
cell type, phases, and microenvironment, personalized pharmacotherapeutic strategies should
be adopted alone or most likely in combination with standard chemotherapeutic agents.
The success of compounds like the BH3 mimetics, Smac mimetics, TRAIL, and mTOR inhibi‐
tors in preclinical studies is proof that the reactivation of defective cell death pathways in
cancer cells is possible and can effectively eradicate tumor cells. Therefore, efforts should be
put to further delineate and identify regulatory components of the different cell death
pathways that can be targeted and manipulated to execute death. Understanding the crosstalk
between the different cell death pathways as well as between cell death and non-cell death
pathways in cancer is crucial to spot prospective convergence points between pathways.
Targeting the convergence points will allow the switching between pathways and improvi‐
sation of alternate means of inducing cancer cell death. For example, TNF signaling to the NF-
κB prosurvival and inflammatory pathway can be rerouted to the necroptotic pathway to
promote cell death just by modulating cIAP levels [163].
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Abstract
The cell biology of viral infections is the focus of this research, in which the role of the
cytoskeleton in dengue virus (DENV) replication in cell cultures was evaluated by
means of Nocodazole and Cytochalasin D treatments before and after of DENV
infection. The potential contribution of cytoskeleton elements with/without the
treatment of depolymerizing agents was evidenced and quantified by the subcellular
distribution of viral proteins, virions produced, and viral protein quantification. The
cytoskeleton is involved in DENV replication because treatments with actin microfi‐
laments and microtubule depolymerizing agents in non-cytotoxic concentrations,
affected DENV2 replication in Vero cells and decreased both the viral protein
expression and infectious virion production, when compared with non-treated cells.
The actin and microtubules are partly involved in DENV2 replication, since the
treatment does not completely blocked viral replication, suggesting that these
components are necessary but not sufficient alone for DENV2 replication in Vero cells.
The structural and functional role of actin and the microtubules in replication are
postulated here, opening new perspectives for understanding the architecture of the
replicative complex and viral morphogenesis processes, due to the role of the
cytoskeleton in the organization, recruitment, and function of the cellular elements
necessary for the assembly of viral factories.
Keywords: Cell biology, infection, dengue virus, cytoskeleton, viral replication
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1. Introduction
The cell biology of viral infection, as a new scientific approach, considers the cell as the
structural and functional unit of viral infection. Within this new research program there are
four topics:
1. Virus and the cytoskeleton.
2. Virus and endomembrane systems.
3. Virus and signal cascades.
4. Virus and the nucleus–nuclear envelope [1].
There are a lot of publications already covering these four points of the cell biology of virus
infection; however, here we will focus only on the role of the cytoskeleton on DENV infection.
Although many years ago these studies could be classified as “virus–host cell interactions” as
it was usually considered in many virology journals, since the onset of the new millennium
and the advent of converged methodologies/fields of research it is possible to take another
view of viral infections. Recent developments in confocal microscopy hardware, image capture
and collection with augmented resolution using charge-coupled device (CCD) cameras, digital
image processing, improvements in the genetic engineering of green fluorescent protein (GFP)
and the chemistry of fluorophores, together with the increased capacity of computational tools
for taking thousands of images, have created innovative conditions permitting the under‐
standing of viral infections as a whole [2, 3]. Several researchers consider viruses as tools, or
molecular scalpels, which are very useful for dissecting complex molecular and cellular
mechanisms [4]. This chapter will consider the cycle of Virus Dengue Serotype 2 (DENV2) as
a series of steps in which the virus takes control of the cytoskeleton from host cells [5].
The possibility of real-time visualization of viral infections was reached by means of genetic
manipulation of the cells and viruses – cells with fluorescent subcellular compartments and
viruses with fluorescent tags [6, 7]; this will be not considered here since the main goal of our
approach is to study complete virions within host cells. In this context, molecular studies of
isolated viral proteins in a cellular environment are not considered under the cell biology of
viral infections discipline, however, those approaches are important if they are following
previous research in cell biology of viral infections, because these reductionist studies can offer
details regarding the identification of molecular actors in the complex cellular environment of
viral infection.
On the other hand, the study of intracellular invaders [5], considering not only viruses but also
bacteria, fungi, and protozoan parasites, which aims to find a cellular platform for microbiol‐
ogy research with the eukaryotic host cell as the main actor, is defined as cellular microbiology
[8]. Since viruses are obligated parasites, they entirely depend on the cellular machinery to
carry out its replication cycle; in this sense for enveloped viruses the intracellular–vesicle
trafficking and the cytoskeleton play a decisive role, mainly because both of them offer
structural and functional platforms where many RNA viruses are assembled and whose
morphogenesis occurs in the cytoplasm of known viral factories [9, 10]. From this viewpoint,
DENV will be considered as one experimental system for studying the cell biology of viral
infections – its complex interactions could throw light on the search for disease therapies.
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Dengue is emerging globally as the most important arboviral disease threatening human
populations. It is caused by the Flavivirus DENV [11, 12], which is a small and enveloped
virus  with a  single-stranded,  positive-sense  RNA, which can be  translated into  a  single
polyprotein by a host cell and viral proteins [1, 13], and is transmitted to humans by Aedes
genus mosquitoes [14-17]. There are nearly 2.5 billion people at risk of infection with DENV
in tropical and subtropical countries. It is endemic in more than 100 countries and about
100 million cases of dengue fever are estimated annually, with over 500,000 cases being the
potentially fatal dengue hemorrhagic fever [12]. Dengue virus is therefore associated with
high socio-economic impacts [18, 19].
The availability of vaccines and drugs for RNA viruses has become a much greater challenge
than expected, because RNA viruses evolution/mutation rates continue to elude both, vaccine
design and drug effectiveness, generating extensive drug-resistant mutants, and therefore over
time creating far more virulent strains [20-23]. Therefore, searching for answers inside the cell
may offer an alternative method to combat the virus. Recently Villar and collaborators [24], in
a big clinical trial implicating several Latin American countries, have shown important
protection percentages (greater than 60%), representing an important advance in the fight
against the first viral infection in Colombia. In spite of these encouraging clinical responses in
patients given the tetravalent vaccine for dengue, it is necessary to wait for several years in
order to evaluate the impact of this vaccine has in changing the epidemiological data of the
disease. Since such vaccines take time to develop or be assessed, hope could come in the form
of the development of antiviral drugs directed to cellular/molecular targets in host cells.
In this way, the cell biology of viral infections [1] has matured considerably in recent years,
with cytoskeleton–virus interactions being of particular interest, because it plays both a
structural and functional roles in several steps of the viral replication cycle [25, 26], connecting
the cell with its environment and participating decisively in the spreading of the virus to
neighboring uninfected cells [27]. The virus cannot be transported into the cell by diffusion
like small molecules can, therefore, the cytoskeleton and other intracellular structures become
a barrier to these [28]. This is why many viruses have shown that viral infection can cause
extensive and sophisticated cytoskeletal rearrangements [10, 29-31] and alterations in the
endomembrane system, something required for the replication and assembly of new virions
[10, 32]. All of this leads to a cytopathic effect, which is widely known and distinctive for viral
infection in cellular cultures [32]. This structural and functional intimate interaction between
intracellular pathogens and the cell, involves the three elements of the cytoskeleton (actin,
microtubules, and intermediate filaments) [30, 33, 34].The involvement of the cytoskeleton in
viral infection has been studied for over 30 years [35], and has been found to be involved
throughout the life cycle of different viruses. There are many descriptions of its involvement
for adenovirus [36], human and equine herpes virus [37], HIV [38], HTLV-1 [27], Rous Sarcoma
Virus [39], poliovirus [40], Epstein–Barr Virus [41], human respiratory syncytial virus [42],
SV40 [43], Vaccinia virus [44, 45], poliedrosis [46], papiloma [47], and pseudorabies [48]. The
replication cycle of DENV has been extensively studied with particular regard to early events
such as binding, fusion, uncoating, and intracellular transport of viral proteins [28, 49, 50]. On
the other hand, the relationships between the replication of DENV and the cytoskeleton host
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cell are not fully characterized, although data in some literature, concerning influenza and
other viruses, support their existence [13, 51-56].
A structural and functional integration of vesicle trafficking and cytoskeletal/endomembrane
systems in viral replication and morphogenesis represents the viral factories redefinition [10,
57, 58]. It has been postulated that trafficking occurs in microtubule motor proteins (entry via
dynein and exit through kinesin [59]), something which explains the translocation of proteins
between the two routes in the microtubule organizing center (MTOC) [59]. Specifically, with
respect to DENV, cytoskeleton and endo/exocytosis have not been studied comprehensively
[60], especially where there is dependence between vimentin intermediate filaments and the
DENV infection, in which microtubules now were apparently necessary. Intercalating
fluorophores were used to label the envelopes of virions associated with cholesterol isolated
DENV [50, 61]; tracking was achieved in the early events of cell entry, but this did not shed
new light on the endomembrane system and cytoskeleton. It has also been reported that DENV
entry by endocytosis, which is pH dependent and mediated by clathrin [62], and the involve‐
ment of actin microfilaments and microtubules in mosquito cells DENV had infected was
important because the inhibition of these cytoskeleton components decreased infection by 80%.
The small Rho GTPases are a protein family which among other cellular functions, govern
cytoskeleton reorganization [63]. When isoprenylation of Rho GTPases was blocked, using
statins, the incidence of HIV[64] and DENV [65, 66] infection was reduced via alteration of the
virus assembly pathway in the rough endoplasmic reticulum.
The interactions between specific viral components and different molecular complexes of the
host cell are fundamental in determining the infection rate. By such reasoning, cell biological
characterization of the host–pathogen interactions, and knowledge of the possible role of the
basic components of the cytoskeleton, microtubules, and actin microfilaments, allow the
elucidation of some mechanisms involved in the pathogenesis of DENV. This allows the
identification of new potential host targets that could be used to design efficient and rational
antiviral therapies.
The applied focus of the cell biology of viral infections is to searching for antiviral therapies
based in cellular targets, which have special importance, because the mutation rates of cellular
genes are several thousands of times smaller than the antivirals directed to the specific viral
proteins. To illustrate this there are several reports of antiviral candidates blocking cellular
targets in the host (Src kinase), like the works of Yang and collaborators [67, 68], and some
reports from our working group where the HMG-CoA was blocked by lovastatin on assays
in vitro and in vivo [65, 69]. Additionally, we have found out that ubiquitin–proteasome and
cytoskeletal elements seem altered after dengue infected cells were treated with curcumin [70].
However, the most relevant finding in this approach is that one protein (IFITM, interferon-
induced transmembrane protein) could be altered for blocking different viruses belonging to
several families [71].
In order to determine the contribution of the two cytoskeleton elements (actin and microtu‐
bules) in DENV replication, a series of experimental assays was completed using Cytochalasin
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D and Nocodazole concomitantly using a high preservation/fixation method on the cytoske‐
leton in order to analyze cellular images taken using fluorescent microscopy in combination
with viral titration and quantification of viral proteins. This gave a better understanding of the
participation of the cytoskeleton on the functional and structural issues of DENV replication.
The data shown here are in agreement with previous reports from several authors confirming
distinct roles in the viral infections of DENV [72-76]. The high quality of the subcellular
resolution of cytoskeleton elements in this research actually reinforces their role in these
structures in DENV replication.
2. Results and discussion
2.1. Preservation/ fixation of the cytoskeleton in infected cells
To understand the cytoskeletons involvement in the DENV replication cycle and virus–host
cell interaction, it is necessary to make appropriate preservations with minimal levels of
perturbations to the cell morphology. To test which components of the cytoskeleton (micro‐
tubules and actin microfilaments) play a role in DENV infection, a method for preserving and
fixing the cytoskeleton should be implemented [39, 40], because the conventional preparations
for fluorescence microscopy with methanol/acetone, have a very dramatic effect on the cell by
flushing (emptying) most of its cellular contents; thus, the information obtained from ultra‐
structural studies depends on the type of fixation, among other things, and therefore the level
of structure conservation [77-79]. In several cell lines it was demonstrated (Fig. 1) that meth‐
anol/acetone treatment preserves microtubules but depolymerizes microfilaments and
disrupts both mitochondrial and nuclear morphology. PFA-PBS preserves the general
cytoarchitecture, but compromises the quality of microstructural detail. PFA-CBS was found
to be the best method to fix and preserve cellular microarchitecture (actin, tubulin), without
inducing any cellular change.
     
         
Figure 1. Fluorescence microscopy optimization for visualizing cellular elements. The methanol-acetone (MA)
standard protocol does not preserve actin filaments. A comparison between PFA-PBS and PFA-CBS did not demon‐
strate wide differences in the most notable structures, however, only PFA-CBS method revealed some cellular compo‐
nents which were stabilized satisfactorily. It was found that the optimal concentration for cytoskeletal element
visualization was with 3.8% PFA-CBS to fix the cells and antibodies or fluorophores dilutions in CBS of +5% FBS.
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2.2. Non-cytotoxic concentrations of cytoskeleton depolymerizing agents
The integrity and functionality of cytoskeleton elements are necessary for their hypothesized
role in DENV infections, for which there functionality was evaluated by means of depolyme‐
rizing agents. These agents are not entirely harmless to the cells, something which was
determined by means dosage ranges having low cytotoxicity (10–20% cytotoxicity) Fig. 2 (a,
b). In Fig. 2 (c), the pattern and distribution of cytoskeleton and nucleus components are
normal, with no condensation or fragmentation observed. Cellular alterations due to a toxic
injury were not evident in these concentrations.
     
Figure 2. Cytotoxicity assays for cytoskeleton depolymerizing agents. Cytotoxicity assays were performed by cell vi‐
ability measuring by the method of MTT [3-[4,5 dimetiltiazole-2yl)-2,5 diphenyl tetrazolium bromide), to determine
NZ and CytD concentrations that were below the toxic level to cells. We were able to observe the NZ (a, c, e) and CytD
(b, d, f) effect in Vero cells. It was found that NZ 10 µM and 4 µM CytD had a cytotoxicity of about 20% and 15%,
respectively.
2.3. Relationship between DENV2 and the cytoskeleton
In order to determine some relationship between viral particles and cytoskeletal elements in
several steps of the replicative cycle of DENV, Vero cells were infected with DENV2, and
processed 18 hours post infection (hpi) by fluorescence microscopy. The fluorescence signal
coincident between actin, Fig. 3 (a, b), or the microtubules (c–f), and the viral protein, matching
the envelope protein with stress fibers (b) for actin, and microtubules (d), suggests some
potential structural relationship, which has an involvement of these cytoskeleton elements
within some steps of the DENV infectious cycle.
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Figure 3. DENV2–cytoskeleton interaction. Vero cell DENV2 infected, viral particles interact with actin (a–b); viral
particles interact with microtubules (c–f), were used Phalloidin-Alexa 594 for detect actin or Mab antiβ III Tubulin-Cy3
for microtubules, polyclonal antibody anti-Envelope + antiR IgG Alexa Fluor® 488 for viral envelope protein and
Hoechst 33258 for nuclei.
2.4. Subcellular distribution pattern of viral protein altered by depolymerization of
microtubules (treatment with nocodazole, NZ)
To investigate the effect of the interrupted cytoskeleton on the viruses replication cycle, Vero
cells were treated with NZ before, or after, DENV2 infections. As shown in Fig. 4 (a) and Fig.
5 (a), mock-infected cells without treatment using microtubule depolymerizing agent, NZ, had
structures and patterns of observed microtubules traditionally described, i.e., long filaments
which are flexible and winding that occupy almost the entire space of the cytosol which emerge
from the perinuclear region and are consistent with the MTOC. In contrast, cells that were
treated with NZ, Fig. 4 (a), had microtubules which were completely depolymerized, as
evidenced by a very fine spotted pattern when observed – something which was not observed
the perinuclear region of the MTOC.
Infected cells without treatment with NZ showed a subcellular pattern distribution of diffuse
staining of the viral envelope protein, with some small dotted clumps. In order to understand
whether microtubules are required for viral entry, treatment was performed 6 hours before
infection with NZ (5µM and 10µM), and then with DENV2 at a multiplicity of infection (MOI)
of 5 for 1 hour. The inoculum was retired, washings were performed with PBS, and cells were
fixed at 24 hpi. The results obtained by fluorescence microscopy indicated that there was a
great decrease in the number of infected cells, Fig. 4 (a). In contrast to this, when the cells were
infected and post-treated with NZ, significant alterations were produced in this distribution
pattern, showed the envelope protein in vesicles as being distributed throughout the cyto‐
Cell Biology of Virus Infection. The Role of Cytoskeletal Dynamics Integrity in the Effectiveness of Dengue...
http://dx.doi.org/10.5772/61704
147
plasm, with an apparent subcellular distribution compatible with a Golgi complex Fig. 5 (a).
This is because microtubule depolymerization–induced NZ treatment leads to Golgi apparatus
disintegration, since the DENV maturation processes used the secretory route in this organelle.
In all treatments with NZ, the nucleus was observed with a normal structure.
2.5. Subcellular distribution patterns of viral protein altered by actin depolymerization
(treatment with CytD)
To investigate the effect of the interrupted cytoskeleton on the virus replication cycle, Vero
cells were treated with cytochalasin D (CytD) before or after infection with DENV2. The mock-
infected cells without the depolymerizing agent, CytD, showed a normal pattern with long
and parallel fibrils distributed throughout the cytosol, mainly stress fibers, Fig. 4(a) and Fig.
5 (a). This is dramatically reduced after treatment with CytD, resulting in actin depolymeri‐
zation, and leaving it in a spotted pattern of coarse grains, producing some larger groupings.
In the case of actin microfilaments, in DENV2 infected cells, somewhat different findings arose
compared with those observed with microtubules. In cells without CytD treatment, remodel‐
ing of actin microfilaments was clear, where cells were characterized by filopodia formation
and many cells were observed with actin tails. These two actin conformations may be related
to actin remodeling by Rho GTPases signaling pathway effectors. The envelope viral protein
showed two subcellular distribution patterns, one being a diffuse pattern which was very fine
          
Figure 4. Effects of treatment with NZ and CytD prior to DENV2 infection Vero cells were treated with NZ 5 at 10
µM and CytD 2 at 4 mM, 6 hours before infection to determine if these elements were necessary for virus entry. In both
treatments a decrease in infected cells was observed using fluorescence microscopy (a). For NZ and CytD there was an
inhibition of about 50% in PFU compared to the control (b), and also a significant decrease of viral protein (c). Were
used monoclonal anti-β III Tubulin-Cy3 to detect microtubules, Phalloidin-Alexa 594 for detect actin, polyclonal anti-
Envelope + antiR IgG Alexa 488 for viral envelope protein and Hoechst 33258 for nuclei.
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and distributed in the perinuclear region throughout the cytosol, while the other pattern
showed a few small clumps of viral protein. According to previous findings in vaccinia virus
[45] and DENV [45, 65] the first patters is called "non-assembled viral protein" and the second
"assembled viral protein."
In order to understand actin’s role in whether microtubules are required for viral entry, the
treatment was performed 6 hours before infection with CytD (2µM and 4µM) then with
DENV-2 at a MOI of 5 for 1 hour. The inoculum was retired, washings were performed with
PBS, and cells were fixed at 24 hpi. To depolymerize actin filaments with CytD in DENV2
infected cells, the subcellular distribution pattern of these cells was altered similarly to
uninfected cells. The results obtained by fluorescence microscopy indicated that there was a
decrease in the number of infected cells, Fig. 4 (a), with observations using fluorescence
microscopy showing a clear accumulation in the perinuclear region that matched the viral
factory. In contrast, when cells were infected and post-treated with CytD, significant altera‐
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both cells infected with DENV2 and treated with CytD, and in those infected without CytD,
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Figure 5. Effects of treatment with NZ and CytD after DENV infection. Vero cells were infected with DENV for 1
hour, the inoculum was removed and washed with PBS, after this the cells were treated with NZ 5–10 µM and CytD 2–
4 mM, for 24 hours, in order to determine if these elements were necessary during the replicative cycle of DENV. In
both treatments there was a decrease in infected cells when viewed using fluorescence microscopy (a), which was con‐
firmed by the reduction of PFU in the supernatant of the treated cells (b) and viral protein concentration (c). Were used
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2.6. The dynamic integrity of microtubules necessary to maintain efficiency of viral
replication
To assess if microtubule dynamic integrity has any functional impact on the viral replication
process, DENV2-infected cells were pre- or post-treated with 5µM and cell ELISA, after which
supernatants were collected in order to quantify viral infectious particle production and
intracellular viral protein. NZ pre-treatment, in addition to causing a decrease in the number
of infected cells, also produced a decrease in the number of plaque forming units (PFU)
quantified in the supernatant with respect to a control group, where the percentage of
inhibition od PFUs was 37% for NZ 5 µM and 46% for 10 µM, Fig. 4 (b), and the amount of
viral protein in infected cells was reduced to 43% and 37%, respectively, Fig. 4 (c). NZ post-
treatment produced a decrease in the number of infectious particles with respect to the control
group (infected cells, DMSO), measured by plaque assay (PFU), between 25% and 28% for 5µM
and 10uM of this depolymerizing agent, Fig. 5 (b), consistent with a decreased viral protein of
42% approximately for both NZ concentrations, Fig. 5 (c). Together, these results suggest a role
is played by microtubules in the assembly, and export, of infectious viral particles. It is probable
that, if cellular structures are not properly preserved, not possible observe changes associated
with the infection. In this work, we note that altering microtubule dynamics has a direct effect
on infection with DENV2, contrary to what was reported by [60].
2.7. Integrity of actin filaments has a greater role in viral protein production than
microtubule integrity
To assess if actin dynamic integrity has any functional impact on the viral replication process,
DENV2-infected cells were pre- or post-treated with 2µM and 4mM of CytD, after which
supernatants were collected for quantifying the viral infectious particle production, and cell
ELISA measured intracellular viral protein expressed. In CytD 2–4 µM pre-treated cells, a clear
diminution of viral infectious particles was observed, 35–43%, Fig. 4 (b), and viral protein 47–
56%, Fig. 4 (c). Interestingly, CytD post-treatment produced a significant decrease in the
number of infectious particles production with respect to a control group (infected cells,
DMSO), which were measured by plaque assay (PFU), detecting a reduction in viral titer of
approximately 37% for CytD 2 µM and 50% for 4 µM, Fig. 5 (b). Actin filament depolymeri‐
zation produced an insignificant decrease in the amount of viral protein, with non-statistical
differences with respect to the control cells, Fig. 5 (c). This suggests that actin may be involved
not only in virus entry, but also in any step of virus maturation and, since depolymerized can
alter the assembly of viral infectious particles and/or delay the output of these, reflected in a
decrease of PFUs and in an intracellular accumulation of viral protein. Thus, although the
depolymerization of microtubules and actin filaments reduces the production of infectious
viral particles, actin filaments appear to have the most relevant role in this process.
Most recently authors found out that the cytoskeleton is not really necessary for diverse virus
replication, specifically for these viruses: Sindbis virus (SINV; family Togaviridae), vesicular
stomatitis virus (VSV; family Rhabdoviridae), and Herpes simplex virus (family Herpesviri‐
dae) [80]. Although these interesting data suggest a non-conventional role of the cytoskeleton,
it must be taken into account that the images are only partially showing the phenomena,
Cell Biology - New Insights150
2.6. The dynamic integrity of microtubules necessary to maintain efficiency of viral
replication
To assess if microtubule dynamic integrity has any functional impact on the viral replication
process, DENV2-infected cells were pre- or post-treated with 5µM and cell ELISA, after which
supernatants were collected in order to quantify viral infectious particle production and
intracellular viral protein. NZ pre-treatment, in addition to causing a decrease in the number
of infected cells, also produced a decrease in the number of plaque forming units (PFU)
quantified in the supernatant with respect to a control group, where the percentage of
inhibition od PFUs was 37% for NZ 5 µM and 46% for 10 µM, Fig. 4 (b), and the amount of
viral protein in infected cells was reduced to 43% and 37%, respectively, Fig. 4 (c). NZ post-
treatment produced a decrease in the number of infectious particles with respect to the control
group (infected cells, DMSO), measured by plaque assay (PFU), between 25% and 28% for 5µM
and 10uM of this depolymerizing agent, Fig. 5 (b), consistent with a decreased viral protein of
42% approximately for both NZ concentrations, Fig. 5 (c). Together, these results suggest a role
is played by microtubules in the assembly, and export, of infectious viral particles. It is probable
that, if cellular structures are not properly preserved, not possible observe changes associated
with the infection. In this work, we note that altering microtubule dynamics has a direct effect
on infection with DENV2, contrary to what was reported by [60].
2.7. Integrity of actin filaments has a greater role in viral protein production than
microtubule integrity
To assess if actin dynamic integrity has any functional impact on the viral replication process,
DENV2-infected cells were pre- or post-treated with 2µM and 4mM of CytD, after which
supernatants were collected for quantifying the viral infectious particle production, and cell
ELISA measured intracellular viral protein expressed. In CytD 2–4 µM pre-treated cells, a clear
diminution of viral infectious particles was observed, 35–43%, Fig. 4 (b), and viral protein 47–
56%, Fig. 4 (c). Interestingly, CytD post-treatment produced a significant decrease in the
number of infectious particles production with respect to a control group (infected cells,
DMSO), which were measured by plaque assay (PFU), detecting a reduction in viral titer of
approximately 37% for CytD 2 µM and 50% for 4 µM, Fig. 5 (b). Actin filament depolymeri‐
zation produced an insignificant decrease in the amount of viral protein, with non-statistical
differences with respect to the control cells, Fig. 5 (c). This suggests that actin may be involved
not only in virus entry, but also in any step of virus maturation and, since depolymerized can
alter the assembly of viral infectious particles and/or delay the output of these, reflected in a
decrease of PFUs and in an intracellular accumulation of viral protein. Thus, although the
depolymerization of microtubules and actin filaments reduces the production of infectious
viral particles, actin filaments appear to have the most relevant role in this process.
Most recently authors found out that the cytoskeleton is not really necessary for diverse virus
replication, specifically for these viruses: Sindbis virus (SINV; family Togaviridae), vesicular
stomatitis virus (VSV; family Rhabdoviridae), and Herpes simplex virus (family Herpesviri‐
dae) [80]. Although these interesting data suggest a non-conventional role of the cytoskeleton,
it must be taken into account that the images are only partially showing the phenomena,
Cell Biology - New Insights150
because the fine elements of the cytoskeleton (i.e., actin and microtubules), apparently
demonstrated some artificial effects due to their preservation/fixation conditions.
There is an important role played by cytoskeleton elements in the assembly and morphogen‐
esis of several viruses, reported in classical works [81] and more recent papers [30, 82, 83],
which partially explains the data shown here. The replication complex and the viral factories
are cellular structures from viral origins, but these complex structures need macromolecular
and cellular constituents. In viral factories membranes and cytoskeleton elements are recruited
as part of their constituents, because it is necessary to limit viral activities in this limited space
[32]. In this sense, it is logical to attribute the important role of actin and microtubules in the
viral assembly process, which in the case of some kind of blocking might produce a reduction
in viral particle production.
Although there are some works about the role of the cytoskeleton on DENV infection, in which
the participation of filopodia in DENV entry, as well as the function of Rho GTPases in
regulation, is confirmed – a process by means of a cross-talk between Rac1 and Cdc42 [74, 76]
– the preservation/fixation techniques in those specimens were not the best. Therefore, there
are some doubts about the real participation of these elements in the dengue viral infections,
because once the cells are significantly damaged the possibility for making the ulterior steps
of the infectious cycle are difficult. However, the early stages of viral infections, like those
shown by means of filopodia, are undoubtedly because the fine elements are well preserved.
In this vein, there is a collection of data, via images, proteins, and production of virions,
demonstrating that the cytoskeleton plays an essential function in the viral replication
processes. The viruses can be considered as probes for dissecting cellular signaling, cytoske‐
leton reorganization, and endocytosis [83, in this sense the research with dengue viruses could
be considered similarly – with the actin microfilaments used for the viral assembly process
since the disruption of these elements causes envelope viral protein aggregation. Images of
“non-assembled” viral proteins have not been shown in others works. This pattern described
here is compatible with other viruses [45, 84]. One such piece of work shows that altering actin
remodeling by inhibition of a HMG-CoA reductase produces a scattered punctuated fluores‐
cence pattern in viral protein after the treatment of lovastatin, which is compatible with an
impaired assembly process. In agreement with these findings, we have shown the DENV2
infected cells treated with lovastatin, produce a clustering of envelope viral protein which also
is attributed to some difficulties in the viral assembling process [65].
Consistent with this interpretation, the amounts of viral protein which had accumulated after
the inhibition of actin filaments with cytochalasin D treatment was higher in comparison with
the microtubules inhibited in the same conditions. If the “non-assembled” protein is reflecting
some difficulty in this case [45, 65, 84], the potential role of actin microfilaments is implied in
the viral assembly and/or maturation process of DENV. The indirect connection of actin
microfilaments, Rho GTPases, with DENV assembly [65] had been used for clinical trials [85],
based on the pleiotropic effects of inhibition of HMG-CoA by means of lovastatin [66]. The
findings shown here offer new perspectives in the viral replication and morphogenesis of
DENV, since at present there is lack of knowledge about the role played by actin in the viral
factories and/or in the replication complex. On the other hand, the advantages of the technical
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approach shown here have been evidenced with other work, in which curcumin is able to alter
the DENV2 replication process by blocking several cellular processes such as ubiquitin-
proteasome and those of the cytoskeleton [72].
In spite of the diverse roles microtubules and actin microfilaments have in the different viral
steps of replication for diverse viruses, more recently it was found that the replicative complex
has intermediate filaments of vimentin which have a close, and structural, relationship with
the non-structural protein 4A of DENV, forming part of their replication complex [86].
3. Conclusions
There has been an increased interest in recent years in understanding the cellular mechanisms
that viruses exploit in the host cell, “Cell Biology of Viral Infection” is a new discipline that
seeks to understand these intricate mechanisms [1]. Hence, in order to describe the participa‐
tion of the cellular elements in DENV2 infection it is necessary to preserve the fine structure
of cell morphology as closely as possible by avoiding any generation of artifacts.
In this work we have demonstrated the involvement of the cytoskeleton during DENV
replication. It was determined that depolymerized microtubules and actin microfilaments
generate disturbances in the DENV2 lifecycle, which causes a reduction in the production of
infectious viral particles and in the intracellular expression of the viral envelope protein, as
well as an altered subcellular distribution pattern of the viral protein envelope. This effect was
more significant in the depolymerization of microtubules that in actin microfilaments. It has
been reported that viral infections alter the global host proteomic in response to these,
including cytoskeletal proteins [87-89]. However, although a role for the involvement of these
proteins in viral infection is hypothesized, a route through which this occurs has yet to be
identified.
4. Methods
4.1. Cell lines and virus
Aedes albopictus mosquito C6/36HT cells and epithelial Vero cell line (American Type Culture
Collection CCL-81™) were grown in Dulbecco’s Eagle’s minimum essential medium (DMEM,
GIBCO) supplemented with 2% or 10% fetal bovine serum (FBS, GIBCO), with 100 U/ml
penicillin/100 µg/ml streptomycin and 0.25 µg/mL Amphotericin B. The cells were grown at
34°C with 5% CO2 (C6/36HT) and 37°C with 5% CO2 (Vero). DENV2 (New Guinea strain) was
generously donated by María Elena Peñaranda and Eva Harris from the Sustainable Sciences
Institute (SSI), San Francisco, California. The viruses were propagated in C6/36HT cells at low
multiplicity of infection (MOI: 0,01 PFU/cell) and stored at -80ºC until used. Viral titers were
detected by plaque assay, using a Vero cell monolayer culture under 1% methylcellulose
overlay medium.
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4.2. Antibodies and chemicals
The serum from rabbits against the envelope protein of DENV (polyclonal anti-DENV) was
donated by Dr. Eva Harris and Robert Beatty (University of California, Berkeley, CA, USA).
The secondary antibody coupled to peroxidase and anti-β-tubulin monoclonal coupled to Cy3
were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Mycotoxin phalloidin
conjugated with Alexa Fluor-488 or Alexa Fluor 594 and acetylated tubulin were purchased
from Molecular Probes Invitrogen Life Technologies (Carlsbad, CA, USA). CytD, NZ, and 3-
(4,5-dimethyl thiazol-2yl)-2,55-diphenyltetrazolium bromide (MTT) were purchased from the
Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). FluorSave was purchased from Calbio‐
chem.
4.3. MTT assay
Cell viability was measured by MTT assay [90] to determined NZ and CytD concentrations
that were below cytotoxic levels. Cells were seeded, 25,000 cells/well, in 96-well plates and
allowed to adhere for 24 hours at 37ºC in 5% CO2; cells were exposed to MTT (0.5mg/ml) for
4 hours, acid isopropanol (100µl) was then added to solubilize the formazan crystals produced.
The culture dishes were incubated for 30 minutes and the absorbance was measured at 570nm
in a Benchmark reader (Bio-Rad Laboratories, Hercules, CA). Vero cells were treated with 6
concentrations of these cytoskeleton-depolymerizing agents (NZ: 1.25, 2.5, 5, 10, 20 and 40µM)
and (CytD: 0.25, 0.5, 1, 2, 4 and 8µM) for several periods (3, 6, 12, and 24 hours). The NZ and
CytD were chosen at two concentrations (5µM and 10µM) and (2µM and 4mM) with a lower
cytotoxicity (10% and 15%), but a preserved ability to depolymerize microtubules and inhibit
actin polymerization, respectively. These agents were added to cultures 1 hour post-infection
(hpi) with DENV.
4.4. Viral infection and treatments
In order to determine the cytoskeletal depolymerizing agent’s effects on DENV2 replication,
experiments were undertaken as follows. Confluent Vero cell monolayers were grown on 24
(1 x 10 5) and 96 (2.5 x 104) multi-wells, in DMEM with 2% FBS, at 37°C and 5% CO2. Cells were
infected in the absence of FBS at an MOI of 5 PFU/cell, after a 1-hour adsorption period at 4ºC,
the viral inoculum was replaced with maintenance DMEM and incubated at 37ºC. Infected
cells were incubated in the presence of NZ, CytD, or DMSO for the indicated times. These cells
were maintained for 24 hours after infection and treatment. As a cytoskeleton infection control,
we performed the same procedure without DENV under the same conditions. Coverslips for
immunofluorescence (IF) were placed in 24 multi-wells. The cell monolayers were fixed and
processed to visualize the viruses and cytoskeleton components by confocal fluorescence
microscopy. Monolayers and culture supernatants were collected to determine the effect of
CytD and NZ in viral protein production by cell ELISA. Additionally, the supernatants also
were used to quantify the cytoskeleton blockage effect in infectious viral particle production
by means of titration by plaque assay.
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4.5. Titration by plaque assays
For quantification of infectious viral particles, the virus was titrated by plaque assays using
supernatants of Vero cells infected with DENV2 and treated under different conditions, as
described in [91, 92]. Briefly, cells were plated, 5x104 cells/well, on 24-well plates, in DMEM
2% FBS at 37°C in 5% CO2, and inoculated with serial dilutions of viral collected supernatants
from 10-1 to 10-5 in DMEM without FBS. At 1 hpi the inoculum was removed, washed, had
DMEM 2% FBS and finally 1.5% of carboximetilcelulose (SIGMA) added to it. After 8 days
post-infection (dpi), the cells were fixed with paraformaldehyde (PFA) at 4% in PBS and
revealed with crystal violet. The plaque number was recorded in order to calculate the
PFU/ml. Two independent experiments were performed, each in duplicate.
4.6. Cell ELISA
Viral protein was quantified by a spectrophotometric cell ELISA, which is a modification of
fluorometric ELISA previously described by [65]. To this immunodetection of viral protein in
infected cells, Vero cells (2.5x104 cells) were submitted to different experimental strategies and
were fixed for 30 minutes with 4% paraformaldehyde (PFA), washed three times with PBS,
and permeabilized for 30 minutes with 0.1% Triton X-100. Endogenous peroxidase was
quenched with 0.3% H2O2 in 10% methanol and, non-specific sites were saturated with a
blocking buffer (10% FBS in PBS). Then the anti-DENV2 diluted (1:500) blocking buffer was
incubated for 1 hour at 37°C. After washing with PBS, this was incubated for 30 minutes with
a secondary antibody, anti-mouse IgG conjugated with HRPO. Finally after washing with PBS,
chromogenic substrate SIGMA ® FAST OPD (St. Louis, MO, USA) was added to reveal the
reaction and its absorbance was read at 405nm in the Benchmark reader (Bio-Rad Laboratories,
Hercules, CA, USA). To normalize the data, the total protein concentration in each well was
determined by Bradford assay, interpolating absorbance data in a calibration curve with
known concentrations of bovine serum albumin. Two independent experiments were per‐
formed with 3 replicates for each assay.
4.7. Fluorescence microscopy
In order to use the best preservation and fixation protocol for assays linked to the research,
three fixations were assessed: paraformaldehyde 3.7% in phosphate buffered saline (PFA-PBS),
paraformaldehyde 3.7% in cytoskeletal buffered sucrose (PFA-CBS), and Methanol-Acetone
1-1 (M-A). Vero cells were cultured in 24 multi-well plates with glass cover slips, at a density
of 4.5x104 cells/well in DMEM 2% FBS. After 24 hours monolayers were fixed with different
treatments. For the PFA-CBS treatment the medium was discarded, washed with CBS at 37°C,
and fixed with PFA-CBS over 30 minutes at 37°C in 5% CO2. For the PFA-PBS treatment the
medium was discarded, washed with PBS, and fixed with PFA-PBS over a period of 30 minutes.
For the M-A treatment the medium was discarded, washed with PBS, and fixed with methanol-
acetone over a period of 30 minutes at 4°C.
To evaluate the cytoskeleton blocking effects of CytD and NZ in DENV-2 infection, 24 hours
after treatment Vero cell monolayers were rinsed once at 37ºC with CBS [10 mM PIPES (pH
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6.9) (1,4-piperazinebis-ethane sulfonic acid), 100 mM NaCl, 1.5 mM MgCl2, and 300 mM
sucrose. The cells were then permeabilized and simultaneously fixed with PFA-CBS for 30
minutes at 37ºC. To avoid auto-fluorescence the cells were placed in 50mM NH4Cl for 10
minutes, then were permeabilized with 0.3% Triton X-100 and had their non-specific sites
blocked with 5% FBS in CBS. For detection of viral protein and cytoskeleton, cells were
incubated with primary monoclonal anti-DENV antibody (1:500) and Alexa 488 conjugated
secondary antibody. After that, cells were incubated with anti-phalloidin 594 or anti-β tubulin
Cy3 and Hoechst 33258. Following washing with CBS, slides were mounted with mounting
medium and examined under a confocal fluorescent microscope (Olympus IX-81 DSU). The
micrographs were recorded using an Olympus CCD camera and processed with Image Pro
Plus software (from Media Cybernetics).
4.8. Statistical analysis
Data are presented as means ± SD. In all cases, they represent at least three independent
determinations. The significance of the results was calculated by Student’s t test. In this case,
p values < 0.05 were considered significant with respect to controls.
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Abstract
Dengue virus (DENV) is one of the most prevalent human pathogens worldwide. It caus‐
es a huge socioeconomic burden with approximately 400 million infections per year, but
yet there is no vaccine or antiviral that is currently effective against the disease. DENV is
spread by the mosquitoes Aedes aegypti and Aedes albopictus, and viral replication within
the mosquito vector is required for transmission to human host. During its replication cy‐
cle, the virus cause significant changes to the host transcriptome profile, especially in the
metabolic and trafficking pathways. Recent studies have shown a strong association be‐
tween autophagy and lipid metabolism modulation.
For many years, biochemistry studies have been forgotten and replaced by the most ad‐
vanced techniques and theories in molecular biology and their promises for solving the
"life code"; however, after many years of strong molecular biology research, it had not
found the key of many problems with which we have the elemental biosystems like vi‐
ruses. Decades of molecular virology investigations did not give more light about several
cellular processes that occurred into the host cells when the infections happen. The mo‐
lecular virologists have cloned many viral genes, manipulating full viral genomes, and
engineering chimeric constructs to study many details at the molecular level, but the host
cell and the encrypted viruses do not want to reveal their secrets.
Only with the new perspective of complex diseases, a new approach has emerged: An in‐
tegrative methodology wherein molecular cell biology is converging with the most pure
and elegant biochemistry. In this way, more extensive research is necessary for future
comparative analyses of the host and vector metabolic/signaling environments required
for viral replication.
Keywords: Autophagy, Cellular Platform, Dengue Virus, Molecular and Metabolic Path‐
ways
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1. Introduction
1.1. Dengue Virus (DENV): Some clinic and basic issues
Emergent viruses with major impact in human health include several agents of Flavivirus
gender, Flaviviridae family, the most important of these are DENV (Dengue Virus), YFV
(Yellow Fever Virus), JEV (Japanese Encephalitis Virus) and WNV (West Nile Virus) [1]. There
are nearly 3.6 billion people at risk of infection with DENV in tropical and subtropical countries
[2]. In more than 100 endemic countries with an estimated nearly 390 million of DENV
infections per year, approximately 100 million of dengue fever cases are estimated annually
with over 2 millions cases of potentially fatal dengue hemorrhagic fever [3, 4]. In most cases,
the symptoms of DF that include an acute febrile illness with retro-orbital pain, myalgia,
arthralgia are self-limited [5]. However, in a proportion of people, the disease progresses to
the severe clinical manifestations classified as dengue shock syndrome (DSS), which are
characterized by the plasma leakage leading to hypovolemic shock and/or dengue hemorrha‐
gic fever (DHF), which are characterized by massive bleeding, thrombocytopenia, evidence of
plasma leakage such as pleural effusion and a rise of hematocrit, both of which has a high
mortality rate [6-8].
DENV is a positive-single strand RNA virus surrounded by an icosahedral nucleocapsid (C)
with approximately 10,700 bases, a unique open reading frame that codify to one polyprotein,
which is post-translational cleaved by cellular and viral proteases. The 5’ end contains the
region encoding the structural proteins in the following order: core protein (protein C),
membrane precursor protein (protein M), and envelope protein (protein E). The remainder of
it genome encode for seven non-structural proteins, xlink, NS2A, NS2B, NS3, NS4A, NS4A,
and NS5 [9].
DENV exists as a four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). All of them have
a same transmission cycle, which include vertebrate hosts (primate and human) and inverte‐
brate vectors, mosquitoes of the following species: Aedes aegypti, A. albopictus y A. polynesien‐
sis mosquitoes. An infection with one serotype provides lifelong protective immunity to that
serotype. But, there is no cross-protective immunity between serotypes [10, 11]. Inside each
one of these serotypes, there are several virus groups named genotypes.
2. Autophagy
This is defined in a general form like a catabolic selective process by means of which cyto‐
plasmic material is transported to lysosomes for their degradation [12]. The autophagy is a
remarkably conserved cellular process, from yeast to human, responsible for removing
damaged organelles and misfolded proteins, and for maintaining cellular homeostasis under
both normal and stress conditions [13-15]. Compartmentalization in eukaryotic systems
brought numerous evolutionary advantages, but also great and new challenges with it, such
as the selective removal of damaged organelles, controlled organelle number and quality, or
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the utilization of their components as potential energy source during times of starvation. In
this way, autophagy represents an evolutionary answer to these challenges. It enables the
recycling of intracellular components and allows cells to survive or death [16] (Figure 1).
Figure 1. Functions of autophagy
The primary role of autophagy is to protect cells under stressful conditions. Under this
viewpoint, both autophagy and the vertebrate immune system play essential roles to maintain
cellular homeostasis in the face of external perturbations [17]. Indeed, several studies have
revealed the narrow relationship between autophagy and the vertebrate immune system [18].
Besides, the crosstalk has become evident between autophagy and apoptosis [19-22] because
the induction of autophagy has often been linked to inhibition of apoptosis [23].
More than 30 genes have been identified as crucial in the autophagy regulation process in
yeast, which are known as ATG (autophagy-related genes). Many of these genes have
homologs in mammals and are grouped according to expression and participation in the
different stages of the autophagic route [12]. The activation of this pathway depends on the
kinase mTOR (mammalian Target of Rapamycin) identified as the main negative regulator
when the cell is in the presence of growth factors and abundance of nutrients. Under starvation,
mTOR activity is inhibited. And consequently, the autophagy is activated allowing the
recruitment of complexes inducers of the route [24, 25]. There are three mechanisms identified
for autophagic degradation: macroautophagy, microautophagy, and chaperone-mediated
autophagy (CMA).
Macroautophagy imply the formation of double membrane vesicles recognized as autopha‐
gosomes. It engulfs cytoplasmic components and then are fused to lysosomes, carrying the
cytosolic material until the lysosomal lumen where a hydrolases, lipases, and cathepsins
degrade it [26, 27]. Therefore, we can divide the pathway into 4 basic steps: initiation, elonga‐
tion, termination, and fusion. During initiation, the recruitment of protein complexes, such as
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phosphatidylinositol-3-kinase Class III (PI3K), Vps15, Vps34, and beclin-1, that are critical to
the autophagosome formation is given [28]. During the elongation, the assembly occurs. In
this stage, the related protein complex ATG5-Atg12-Atg16, the lipid conjugation complex LC3-
II- phosphatidylethanolamine (PE), and the respective conjugating enzymes, which act
similarly to ubiquitin ligase system, link lipid that allows the growth of the double membrane
due to the transformation that undergone LC3-I to LC3-II, which has a PE-binding domain,
the main lipid component of autophagosomes. Later, in the termination stage, the double
membrane vesicle is closed with the intracytoplasmic content therein, which is possible
because the cut that performs Atg-4 enzyme on the binding LC3-II-PE permits the release of
the complex into the cytosol preventing the continuation of joining new lipid molecules [28].
Subsequently, the fusion process occurs between autophagosomes and lysosomes, which
generate a vesicular structure called autophagolysosome or autolysosome. This process is
mediated by the cell membrane fusion proteins, such as integral proteins SNARE (soluble N-
Ethylmaleimide-sensitive factor-attachment protein receptor) [29], the Rab family proteins,
especially Rab7 and Rab9, that are involved in the transport of the vesicles and fusion with
target membranes [30]. And besides, the lysosomal membrane receptor LAMP2 allows the
attachment between vesicular membranes and autophagosome contents discharge into the
lysosome forming the structure known as autophagolysosome, where protein degradation
occurs [31, 32] (Figure 2).
Figure 2. The Process of Macroautophagy. A portion of cytoplasm (including organelles) is enclosed by a phagophore
or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses
with the lysosome, and the internal material is degraded in the autolysosome.
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The second possible mechanism is microautophagy. It involves direct lysosomal membrane
invaginations production to generate vesicles or tubules capturing surrounding cytoplasm.
Microautophagy studies has mainly been developed in yeast, wherein several genes have been
found sharing the macroautophagy and microautophagy pathways, but the components and
regulation systems are still not well understood [33]. For the CMA mechanism, the cargo is
specifically selected by the unique pentapeptide motif present in the amino acid sequence
(KFERQ), which is recognized by the chaperone proteins specially Hsc70, in where the
membrane receptor LAMP2 (Lysosome associated membrane protein 2] carrying the load into
the lysosome lumen for degradation [34].
In the past years, autophagy has emerged as a critical player in the control of viral infection
and immunity [35-39]. On one hand, autophagy can serve as a host defense mechanism for
some pathogens by clearing them out of the cells [40-42]. On the other hand, many positive-
stranded RNA viruses have been reported to subvert this cellular machinery to favor their own
replication and release [23]. This issue will be discussed below.
3. Cellular metabolism in viral infections: Rediscovering the other side of
the coin
Metabolism is broadly defined as the sum of biochemical processes in living organisms that
either produce or consume energy [43]. In the “Golden Age of Biochemistry” (1920s to 1960s),
most of the metabolic network in humans and other organisms, which included routes like
glycolysis (Embden, Meyerhof, and Parnas), respiration (Warburg), the tricarboxylic acid
(TCA) and urea cycles (Krebs), glycogen catabolism (Cori and Cori), oxidative phosphoryla‐
tion (Mitchell), and the supremacy of ATP in energy transfer reactions (Lippmann) was
defined. This research was awarded with about 15 Nobel Prizes in Physiology, Medicine, or
Chemistry. All of them were related to energy balance or core metabolic pathways [43].
Richard W. Hanson wrote "By 1970, the writing was on the wall for metabolism; it  was
largely considered a "mature area", lacking excitement; molecular biology was the area of
the future" [44].
"A sure sign of this was that graduate students in biochemistry almost never selected their thesis research
in metabolism. The course in intermediary metabolism that I taught was dropped from the curriculum
of our graduate education program; our students were expected to learn all they needed to know about
metabolism as undergraduates before they attended graduate school. After all, as a graduate student
once said to me, "the great problems in metabolic research have been solved". As long as diseases like
diabetes, obesity, and atherosclerosis, remain to be cured, there will be no shortage of interest in
metabolism" [44].
In this way, the understanding of diseases in light of alterations in metabolic status was
dropped and shifted by the search of an explanation based on the nascent era of molecular
biology. However, the ongoing exploration of molecular biology and disease complexity has
stimulated a revival of interest in intermediary metabolism [45]. In this view, several works
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propose a new way to arrive the disease: cell metabolism, because it affects cell signaling and
modulate protein trafficking, localization, and enzyme activity [43]. For example, Acetyl-CoA
plays a central role in intermediary metabolism (carbohydrate, fatty acid, and amino acid
oxidation,) and at the same time have tremendous influence on cell signaling and gene
expression [46-48]. Recently, it has been demonstrated that some biomarkers of metabolic
syndrome are related with any infection, acute or chronic in patients [49].
To reach a deep and elegant comprehension of the role of metabolism in all levels of the human
being, it is better to take the exact quotation of DeBerardinis and Thompson: "...the metabolism
pervades every aspect of biology from the single-cell to whole organism level. No cellular
functions occur independently of metabolism, and a metabolic perturbation at one node has
ripple effects that can extend throughout the network and out into other systems. Thus,
metabolic disturbances have an extremely long reach, and this extends to disease pheno‐
types..." [43].
The Warburg effect is a concept used to link metabolism and cancer wherein a disturbance of
cellular metabolic activity is at the root of tumor formation and growth [43]. Thereby, dysre‐
gulated cellular metabolism is a key feature of cancer [50-53]. This concept could be adapted
perfectly to viral infections, because viruses are biological entities that depend on cell metab‐
olism to replicate and spread. Therefore, it would be expected that the success of viruses inside
the cell will be dependent on their ability to subrogate the metabolism and put it in his favor.
It had been shown in this sense that tumor cells display increased metabolic autonomy in
comparison to non-transformed cells [51]. In the case of viral infections, this "metabolic
autonomy" may be triggered by a viral entity in normal cells. Thinking about it, it is not absurd
if we take into account that many genes implicated in several signaling/metabolic pathways
have also been reported to be modulated and altered in viral infections [54-57]. How these
metabolic pathways are regulated in infected cells, including if they fluctuate according to
infection stage or at the cell cycle, remains to be a question. It will be important to determine
whether viral infection can regulate all aspects of the metabolic dynamics or if any special
metabolic pathway implicated in their replication or pathogenicity exists.
Many pathogens have developed sophisticated molecular machinery, which interferes with
host cell signaling. Thereby, effector molecules are introduced or released by the pathogens
during the invasion of the host [55, 58, 59]. Autophagy is a evolutionarily refined and sophis‐
ticated process wherein molecular cell signaling and cellular metabolism regulation converge
to regulate the intermediary metabolism (Figure 3) including the lipid metabolism through a
process called lipophagy, which modulate the degradation of lipid droplets in triglycerides
and free fatty acid that can be used as a fuel to elevate the rate of β-oxidation and consequently
of energy production [60-62], which recently has been demonstrated that some pathogenic
agents can subvert this cell process to ensure their own survival.
Recent investigations using genetic, cell biology, and biochemical approaches have led to a
better understanding of mechanistic interaction between pathogens and hosts. Based on this,
a resource that permit integrate terms of ViralZone, UniProtKB, and GO, has been created,
which provide a global view of viral biology and their complex host interactions, based in
evasive adaptations and inactivation of antiviral effectors [63]. Advancements in research are
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now fueled by increasing interests aimed at the discovery of novel therapeutic interventions
against major infectious diseases [64]. The cell biology of microbial pathogenesis has opened
many doors for future research into the role of lipids in host-pathogen interactions because
lipids of both host and pathogen play critical roles in the pathogen stability to replicate and
persist in host cells, and these interactions are very complex and dynamic [58].
The metabolic host cost and contribution of lipids (biosynthesis, catabolism, and trafficking)
to the formation of replication factories is in the early stages of investigation [65-69], and yet
is need to know pathogen and host lipid profiles as a starting point for tests of functional
relevance and comparative profiling in several physiological conditions (status before/after
infection) to better understand the details of the metabolic role in the different conditions of
the disease and dissect the complicated signaling during host-pathogen interactions for
developing drugs and disease biomarkers pathways identification [64].
4. Role of autophagy in infectious disease
The intracellular invaders, after million years of evolution, have developed several sophisti‐
cated strategies for evading the host defenses like the immune system. In this regard, autoph‐
Figure 3. Autophagy and intermediary metabolism relationship
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agy is a complex cellular process that can have a dual role in viral infections depending on the
pathogenic agent and host [70, 71]. Although it has been extensively cited and reviewed, the
role of autophagy in maintaining the cellular homeostasis [12, 13] still remains to be elucidated
in terms of what is their precise role in viral infection.
Considering several infectious agents, there are a number of important findings. For example,
macrophages can eliminate Legionella pneumophila infection through cholesterol or lipid-raft-
rich induction of autophagy [72]. Mycobacteria usurp the host lipid stores for energy produc‐
tion via β- oxidation of fatty acyls, using the glyoxylate cycle enzymes isocitrate lyases for
survival and persistence in its human host [73, 74]. Helicobacter pylori have been related with
elevated cholesterol levels and metabolic syndrome alterations. However, it remains contro‐
versial [75, 76]. In HSV-1 (Herpes Simplex Virus), the virulence factor ICP34.5 inhibits
autophagy via inhibition of Beclin 1 and PKR [77], and Us3 acts as a viral Akt surrogate to
activate mTORC1 inhibiting host autophagy [78]. Curiously, additional members of the herpes
virus family employ similar strategies to inhibit autophagy. Gamma herpes virus 68 (gHV68)
encodes a virulence factor vbcl2 (M11), which inhibits host autophagy via interaction with
Beclin 1 [79]. Kaposi’s Sarcoma Herpes Viruses (KSHV) interact with ATG3 and inhibit
autophagy [80]. Human Cytomegalovirus (HCMV) inhibits autophagy via upstream activa‐
tion of mTOR signaling [81]. Autophagy functions as an antiviral host defense of central
nervous system against Sindbis Virus (SIN) infection [40, 41].
Hepatitis C virus (HCV) infection has a controversial role in lipid metabolism and autophagy.
It has shown that this infection is associated with enhanced lipogenesis, reduced β-oxidation,
decreased lipoprotein secretion, and increased autophagy counteracting the alterations in lipid
metabolism induced by HCV. In this way, a disruption of autophagic process might contribute
to develop steatosis (occurs in about 50% or more of patients) in patients with HCV [82, 83].
It has also been described that the infection of human cells with Poliovirus and Rhinovirus
induces autophagosome formation, which are used as sites of viral RNA replication [84].
Autophagosome is required for the formation of Coronavirus replication complexes with the
formation of the double membrane vesicles significantly enhancing viral replication efficiency
[85]. The use of small interfering RNAs against LC3 or Atg12 has shown to reduce both the
intracellular and extracellular yields of poliovirus (+ss) [84]. Reduction in the intracellular
concentration of Atg7 reduces the amount of viral capsid protein synthesized in Coxsackievi‐
rus B3 [86]. Hepatitis C Virus (HCV) infection was found to activate autophagy, and it extends
cell survival for the establishment of a successful viral infection [87].
It should be noted that not only RNA virus (poliovirus, etc.) but also DNA virus (Epstein-Barr
virus) infection can induce autophagic machinery, and whether the activation of autophagic
machinery can enhance viral replication (poliovirus and mouse hepatitis virus) or not (Vaccinia
virus and Herpes Simplex Virus type 1 etc.) depends on the type of viruses [84, 85, 88-90] and
on cell type infected [91]. Thus, for some areas for research, the development of the specific
inducers of autophagy will offer a promise as a novel class of antiviral therapeutics [16], while
for others, the design of specific inhibitors of autophagy could provide new therapeutic
strategies [92]. Either will serve as a powerful tool to dissect the autophagic process.
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In summary, many different viruses and other pathogens can induce the cellular process, such
as apoptosis and autophagy, and on the other hand, host cells can also activate the same
pathways when they participate in clearance of infectious agent (Figure 4). Thus, although
some viruses may encode one or more inhibitors of both these processes, others have been
shown to induce autophagosome-like structures and to benefit from their formation, which
may be critical for the viral spread within the infected tissues [35]. Although numerous studies
support the beneficial role of autophagy in +ssRNA virus replication [23], the induction of this
process is not always favorable for them. And drawing the path and explaining this behavior
have shown interesting findings for some researchers.
Figure 4. Viral modulation of autophagy. Several viruses have been shown to block or activate various stages of au‐
tophagy process.
5. DENV infection and autophagy: Molecular and metabolic convergences
DENV is a major but neglected global public health problem, and despite many efforts, they
are made to understand the mechanisms by which it usurps the host cells and this research
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field has grown dramatically during the last years with multiple studies in molecular and
evolutionary biology [93-96], genome sequencing [97-99], construction of infectious clones
[100], and use of these to attempt to dissect the specific role of each viral protein [101, 102], and
immunological approaches [103, 104]. All of these have failed to produce results that allow the
design of vaccines or drugs effective to cure this disease [105-107], and the secrets of DENV
and its pathogenesis remain unclear. However, a recent viewpoint of the disease highlights
the relevance of the relationship between both hosts and vector systems with the viruses and
assign a key role to energy metabolism alterations during the infection, indicating that the
virus reprogram the central carbon metabolism (lipid, glucose, TCA cycle and others)
[108-112] in order to facilitate their own replication.
Understanding how DENV can differently infect mammals and insect cells is a very interesting
issue. In the last years, there has been a notable increase in the research for mosquito DENV
infection, revealing the importance of identifying this dual behavior between the host and
vector in order to know the cell biology of viral infection. In the enveloped positive-sense RNA
viruses such as DENV, a cytoplasmic replication of its are associated with a dramatic rear‐
rangement of host cellular membranes, the merging of viral and target cell membranes, and
endosomal trafficking routes are essential to carry out a successful replication cycle [113], and
these virus-induced changes the result in induction of vesicular structures that envelope the
virus replication complex [114].
A few years ago, it was postulated that autophagosomes might play a structural role in the
replication complex formation, and numerous investigations about the role of autophagy in
DENV infection were conduced. In 2008, a researcher group from the National Cheng
University in Taiwan was the first to demonstrate that DENV can activate autophagic machi‐
nery and induce autophagosome formation to promote viral replication, and ATG5 is directly
implicated in this activation process [6]. Also, it has been demonstrated that DENV2 induce
autophagy and prevent premature cell death, thus, an inhibition of autophagy abolishes its
protective role against cell death providing an unfavorable environment for the viral propa‐
gation leading to a reduced viral replication [115]. There were experiments to compare single-
cycle infections of murine embryonic fibroblasts derived from autophagy-proficient and
autophagy-deficient mice showing clear reductions in the yield of extracellular virus in the
absence of a functional autophagy pathway [6]. But in 2009, it was demonstrated that DENV
replicates on endoplasmic reticulum (ER) cisternae invaginations and not on classical auto‐
phagosomes [116]. From this discovery, scientists kept researching the role of autophagy
induction in DENV infection.
In the same year, it was shown that the DENV Capsid structural protein contained determi‐
nants for lipid droplets targeting. This association was a determinant for reach DENV yield
[117], and this discovery was associated with previous findings that reported liver vacuoliza‐
tion and steatosis in DENV infected mice and fatal human cases of DHF [118-120], suggesting
a possible role for lipid metabolism in DENV pathogenesis. That was when researchers
reported that autophagy process induced by DENV infection plays an indirect role in DENV
replication by the modulation of cellular lipid metabolism. Furthermore, it stimulated a cellular
triglycerides depletion that are stored in the lipid droplets, leading to release free fatty acids,
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increased β-oxidation, and energy production to raise the virus yield [121-125] (Figure 5).
Subsequently, it was shown that autophagy is mediated in a cell type specific manner, given
that autophagy does not have a significant role in DENV replication in monocytic cells [91].
More recent studies in suckling mice demonstrated that DENV infection induce autophagy
mechanism in vivo, and it played an important role in viral replication, clinical symptoms
development, and survival rate [126]. Although it has been widely supported that the autoph‐
agy role in DENV infection is more related to a metabolic requirement, it also has been shown
that the autophagy pathway plays a determinant role in viral maturation [124], which conduce
to think that autophagy does not have a unique function in the viral replication cycle.
Figure 5. Roles for autophagy during DENV infection From [122].
The discovery of vector factors altered during DENV infection of mosquito may help to identify
conserved protein families and pathways that represent both anti-viral mechanisms and
requirements for viral life cycle in the vector, and understanding these effects in mosquito
vector and correlating it with conserved mammal pathways could help to comprehend the
host interactions and development of methods to treat and prevent viral infection and spread.
In this way, the mosquito vector, as well as the cell lines, derived from it, was transformed in
novel and interesting study models. It has been described in mosquito MAL04 and C6/36 cells
that DENV ensures its fusion in late endosomes exploiting cell-controlled differences between
lipid compositions of different organelles through interactions between virus and endosomes
rich in anionic lipids, protecting against premature release, viral inactivation, or endosome
fusion pore opening [127].
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The fat body plays a major role in intermediary metabolism, and it is the central storage depot
of nutrients and energy reserves essential for the holometabolous insects’ life, which must
accumulate at least a minimal amount of nutrients in larval stages to survive during starvation
and metamorphosis. Lipids, mainly triglycerides, represent the major component of fat body
and are the main source of metabolic fuel, it are stored in the core of lipid droplets, which are
mobilized for several purposes as energy provision to flight muscles, ovaries lipids provision
and overall maintenance of metabolic activity [128]. The lipolytic machinery identified in
insects includes two lipases: TGL and Brummer lipase, and two evolutionarily conserved lipid
droplet proteins, Lsd1 and Lsd2 [129]. Current information indicates that insects share with
mammals and other organisms, several aspects of the mechanisms of deposition and mobili‐
zation of triglycerides. This information validates the use of insect models to investigate basic
questions related to the processes of lipid storage and mobilization [130].
DENV drastically alters the lipid profile of mosquito-infected cells, increasing the expres‐
sion of lipids that have the capacity to change the physical properties of the bilayer such
as: bilayer curvature, permeability, and recruitment/assembly of protein complexes in the
membrane. Several of the identified molecules also function as bioactive messengers that
control  signaling  and membrane  trafficking  pathways  in  the  cells  [131].  These  observa‐
tions  shed  light  on  the  emerging  role  of  lipids  in  shaping  the  membrane  and  protein
environments during viral infections and suggest membrane organizing principles that may
influence virus-induced intracellular membrane architecture [131].  Later,  a  transcriptome
study  in  Aedes  aegypti  infected  with  several  flaviviruses  (WNV,  DENV  and  YFV)  was
described and an expression profile was observed with 20 significantly upregulated genes
and 15 downregulated genes quite similar among them. Something of  these genes were
related with the regulation of genic expression (juvenile hormone-inducible protein, core
histone H3),  genes related with antiviral  response were downregulated (Jak-STAT path‐
way downregulated, Toll pathway) and other genes related to ion binding, ion transport,
several metabolic processes and peptidase activity [132].
In [133], a mosquito protein interaction network based on large-scale protein interaction
datasets was developed, and 714 putative dengue-associated mosquito proteins (physical
interaction assays, RNAi and microarray) were identified and predicted. Subsequent analysis
of these proteins highlighted a sub-network, four regions of highly interconnected proteins
with closely related functions (replication/transcription/translation (RTT), immunity, trans‐
port, and metabolism). 15 out of 23 proteins (65.2%) were highly interconnected in metabolism
region. Consequently, the host infected by the virus can experiment dramatic metabolic
alterations. These results support the presence of some common host requirement of DENV
in humans and mosquitoes.
6. Concluding remarks and perspectives
After reviewing the historical issues about biochemistry with emphases on metabolism,
together with the remarkable findings in cell molecular biology of autophagy pathways, it is
Cell Biology - New Insights174
The fat body plays a major role in intermediary metabolism, and it is the central storage depot
of nutrients and energy reserves essential for the holometabolous insects’ life, which must
accumulate at least a minimal amount of nutrients in larval stages to survive during starvation
and metamorphosis. Lipids, mainly triglycerides, represent the major component of fat body
and are the main source of metabolic fuel, it are stored in the core of lipid droplets, which are
mobilized for several purposes as energy provision to flight muscles, ovaries lipids provision
and overall maintenance of metabolic activity [128]. The lipolytic machinery identified in
insects includes two lipases: TGL and Brummer lipase, and two evolutionarily conserved lipid
droplet proteins, Lsd1 and Lsd2 [129]. Current information indicates that insects share with
mammals and other organisms, several aspects of the mechanisms of deposition and mobili‐
zation of triglycerides. This information validates the use of insect models to investigate basic
questions related to the processes of lipid storage and mobilization [130].
DENV drastically alters the lipid profile of mosquito-infected cells, increasing the expres‐
sion of lipids that have the capacity to change the physical properties of the bilayer such
as: bilayer curvature, permeability, and recruitment/assembly of protein complexes in the
membrane. Several of the identified molecules also function as bioactive messengers that
control  signaling  and membrane  trafficking  pathways  in  the  cells  [131].  These  observa‐
tions  shed  light  on  the  emerging  role  of  lipids  in  shaping  the  membrane  and  protein
environments during viral infections and suggest membrane organizing principles that may
influence virus-induced intracellular membrane architecture [131].  Later,  a  transcriptome
study  in  Aedes  aegypti  infected  with  several  flaviviruses  (WNV,  DENV  and  YFV)  was
described and an expression profile was observed with 20 significantly upregulated genes
and 15 downregulated genes quite similar among them. Something of  these genes were
related with the regulation of genic expression (juvenile hormone-inducible protein, core
histone H3),  genes related with antiviral  response were downregulated (Jak-STAT path‐
way downregulated, Toll pathway) and other genes related to ion binding, ion transport,
several metabolic processes and peptidase activity [132].
In [133], a mosquito protein interaction network based on large-scale protein interaction
datasets was developed, and 714 putative dengue-associated mosquito proteins (physical
interaction assays, RNAi and microarray) were identified and predicted. Subsequent analysis
of these proteins highlighted a sub-network, four regions of highly interconnected proteins
with closely related functions (replication/transcription/translation (RTT), immunity, trans‐
port, and metabolism). 15 out of 23 proteins (65.2%) were highly interconnected in metabolism
region. Consequently, the host infected by the virus can experiment dramatic metabolic
alterations. These results support the presence of some common host requirement of DENV
in humans and mosquitoes.
6. Concluding remarks and perspectives
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clear that right now, we have a great open field for research. Curiously, the animal viruses,
during several decades, had been studied, but under the viewpoint of virus-host cell interac‐
tions wherein the cell and the viruses have been considered isolated entities. Only in the last
decade where the Cell Biology of Virus Infection emerged [134] was considered the cell as the
structural and functional unit of infection. Therefore, now, the animal viruses play a role in
the physiology of the cell, mimicry and using the metabolic and autophagic cell pathways for
the completion of their viral cycles.
An overview was shown here for understanding the viral disease and other human pathologies
from an integrative perspective including the theoretical framework and methodology of
biochemistry fused to the molecular biology in a cellular compartment (autophagosome),
which is triggered for several injuries and/or diseases.
It is important to establish the differences in mechanisms of infection. Therefore, in the basic
requirements for this process in both vector (mosquito) and host (mammal), it is important to
determine whether it alters in a similar way the metabolism in both models, although the
molecular signaling through which these metabolic changes are induced to be different for
everyone. It is very interesting that all of these recent researches in mosquitoes suggest
alterations in JACK / STAT signaling, toll-like receptors, and metabolism (especially lipid). But
knowing that autophagy is conserved from yeast to mammals, the role of autophagy has not
been reported in DENV infection in mosquitoes. Moreover, there is a recent research which
supports that autophagy is not decisive in the infection in monocytes. It appears that the
autophagy is dependent on the cell type.
Together the ideas exposed here with the remarkable findings of several researchers give us a
whole landscape where it is possible to find some cellular processes or events, which can be
modulated by drugs trying to discover new therapeutical tools.
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Abstract
Adipose tissue (AT) is a very important endocrine and paracrine organ that regulates oth‐
er tissues and organs. Dysfunction of AT leads to a wide range of disorders like obesity,
insulin resistance, diabetes mellitus, cardiac disorders, tumors and others. Adipose tissue
macrophages (ATMs) are the key actors in AT remodeling and dysfunction. Their role in
AT dysfunction is nowadays increasingly investigated, but still their interplay and molec‐
ular mechanisms of actions have not been fully elucidated. In this chapter, we summar‐
ized the current knowledge about the role of macrophages in AT remodeling,
dysfunction and related disorders and indicate the potential directions for future re‐
search.
Keywords: Adipose tissue, macrophages, tissue remodeling, adipose tissue dysfunctions
1. Introduction
Adipose tissue (AT) was previously considered to be only a fat depot. Today, it is well known
that AT secretes a large number of proteins collectively termed as adipokines (adiponectin,
leptin, resistin and inflammatory cytokines TNF-α, IL6, IL8, IL1, IL10, IL18 and TGF-β) that
are responsible for many different processes in the body. Therefore, AT is considered to be a
highly active metabolic, endocrine and paracrine organ that regulates other tissues and organs.
AT is very heterogeneous and consists of different cell types such as: adipocytes, pre-adipo‐
cytes, endothelial cells, fibroblasts, mesenchymal stem cells and immune cells (mast cells,
lymphocytes and macrophages). Adipose tissue macrophages (ATMs) are cells that are
responsible for AT remodeling. There are two types of ATMs, M1 (classically activated) or
inflammatory macrophages and M2 (alternatively activated), anti-inflammatory or reparatory
macrophages. The role of ATMs in disorders such as obesity, insulin resistance, diabetes
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mellitus, cardiac disorders, tumors and others is nowadays increasingly investigated, but still
their interplay and molecular mechanisms of actions have not been fully elucidated. This
chapter provides an overview of current knowledge about the role of macrophages in AT
remodeling, dysfunction and related disorders and indicates the potential directions for future
research.
2. Adipose Tissue Macrophages (ATMs)
Although adipocytes play a central role in adipose tissue (AT) remodeling, an increasing
attention is directed toward adipose tissue macrophages (ATMs). Since adipose tissue
remodeling is nowadays considered as chronic inflammation, ATMs and their interaction with
adipocytes are key events that orchestrate the adipose tissue remodeling process.
Resident ATMs are very heterogenic population of cells that is reflected on their function in
AT [1, 2]. During AT remodeling, factors that are released from AT induce the recruitment of
monocytes into AT. It has been shown that most of the macrophages in AT are derived from
bone marrow [3, 4].
There are two types of ATMs: M1 (classically activated) and M2 (alternatively activated)
macrophages. They are characterized based on their polarization state, the expression of
particular antigens [2, 5, 6] and secretion products. M1 (classically activated) macrophages,
also called pro-inflammatory macrophages, are dominant type of macrophages during AT
expansion and inflammation. They are characteristic of obese AT. Classically activated
macrophages can be induced by LPS and the Th1 cytokine IFN-γ and express high levels of
pro-inflammatory mediators including F4/80, CD11c, TNF-α, IL-6, iNOS, CCR2, IL-12 and
IL-23 [6–9]. M2 (alternatively activated) macrophages, also called reparatory or anti-inflam‐
matory macrophages, are dominant in lean AT. M2 macrophages are responsible for AT
homeostasis, tissue repair and immunosuppression. Exposure of macrophages to the TH2
cytokine IL-4 produces M2 phenotype. They express F4/80, CD301, arginase 1 [6, 7] and CD163
and high levels of scavenger, mannose, and galactose-type receptors. They secrete anti-
inflammatory cytokines such as IL-10 and IL-1 receptor antagonist [8, 9] and are shown to
inhibit NOS (iNOS) activity. M2 macrophages preserve normal adipocyte function by pro‐
moting tissue repair and angiogenesis in an increasing AT mass [2, 10].
3. The role of ATMs in adipose tissue dysfunction and related disorders
The exact role of ATMs in AT dysfunction and related disorders is still not known. In recent
years, a lot of research has been done, and it has been shown that the balance between M1 and
M2 macrophages is crucial for maintaining normal adipocyte function and AT homeostasis.
Obesity is a very common chronic disease that leads to the development of insulin resistance,
diabetes mellitus, cardiac disorders and others [3, 4, 11–15]. Obesity is characterized as a low-
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grade chronic inflammation with unbalanced production of pro- and anti-inflammatory
adipokines that contributes to the development of metabolic syndrome [4, 11–14, 16] and may
be involved in a variety of physiologic and pathologic processes [17]. In obesity, the balance
between M1 and M2 macrophages is disturbed and moved toward M1 inflammatory macro‐
phages. There are two mechanisms of imbalance occurrence: infiltration of monocytes from
circulation under the influence of molecules secreted from growing AT and “phenotypic
switching” between M1 and M2 macrophages. During the AT growth, adipocytes secrete
products that promote the production of macrophage inflammatory cytokines [18, 19]. These
products influence the polarization of resident macrophages. A model of “phenotypic
switching” of macrophages has been reported by Lumeng et al. in 2007 [6]. Their model
emphasized that obesity is accompanied by a transformation in the polarized states of
macrophages, from an “alternatively activated” M2 that primarily accumulates during
negative energy balance to a more pro-inflammatory “classically activated” M1 macrophages.
This phenotypic change from M2 to M1 polarization in obese adipose tissue leads to adipose
tissue inflammation [20–23]. Macrophages that are infiltrated into AT from circulation are an
important source of inflammation in obese AT. Chemokines are small pro-inflammatory
molecules that promote macrophage mobilization from bone marrow into tissues. Increased
expression of chemokines in obese adipose tissue has been implicated in the control of
monocyte recruitment to the adipose tissue. During the expansion of AT, secretion of pro-
inflammatory cytokines is upregulated and they are released into the circulation. It is shown
that MCP-1/CCR2 pathways have pathophysiological role in macrophage infiltration into
obese adipose tissue [24, 25]. MCP-1 plays a role in the recruitment of macrophages into obese
adipose tissue. Increased levels of MCP-1, CXCL14, MIP-1α, MCP-2, MCP-3 and RANTES can
be observed in AT of mice with genetic or DIO [15, 26]. CCR2 expressed in bone marrow cells
is involved in macrophage infiltration into obese adipose tissue [27]. In addition to the MCP-1/
CCR2 pathway, there are several reports suggesting the potential involvement of other
chemotactic factors in obesity-induced macrophage infiltration such as osteopontin, angio‐
poietin-like protein 2 and CXCL14 [26, 28, 29]. Downregulation of MKP-1 is critical for
increased production of MCP-1 during adipocyte hypertrophy [30]. Increased number of pro-
inflammatory CD11c+ M1-like ATMs in established obesity is a result of increased monocyte
migration into AT, polarization of ATMs toward the M1 and a low level of proliferation of
these cells after they become ATMs [31]. Adipocyte hyperplasia and hypertrophy both
contribute to the expansion of AT that leads to hypoxia, adipocyte cell death, enhanced
chemokine secretion and dysregulation in fatty acid fluxes [32]. Necrosis of adipocytes is a
prominent phagocytic stimulus that regulates ATMs infiltration. Macrophages aggregate
around these dead adipocytes forming crown-like structures (CLSs) in advanced obesity [33–
36]. Macrophages fuse to form multinucleated giant cells and to phagocyte the residual lipid
droplet. They become increasingly activated in their attempt to clear the potentially cytotoxic
remnant lipid droplet forming large lipid-laden multinucleated syncytia in the process, a
commonly accepted hallmark of chronic inflammation [7, 33]. Macrophages aggregate to
constitute a CLS surrounding dead adipocytes in advanced obesity [6, 34, 35]. Electron
microscopic analysis also revealed lipid-laden phagolysosomes in macrophages within CLS
[33]. It is shown that massive adipocyte death can indeed drive rapid accumulation of ATMs
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as an integral element in the remodeling of fat pads [37] by using a transgenic model of
inducible lipoatrophy. The number of necrotic adipocytes positively correlates with average
adipocyte size in obese mice and other mouse models of adipocyte hypertrophy [33, 36, 38]. It
has been suggested that macrophage localization and infiltration are strongly linked to adipose
cell death [9, 33]. It is shown that adipocyte death and/or the death receptor Fas signaling
contribute to obesity-induced adipose tissue inflammation and systemic insulin resistance [39,
40]. TNF-alpha induces pro-apoptotic and/or death signals in a variety of cell types, it is
therefore interesting to speculate that hypertrophied adipocytes, which are stimulated and
thus dying by macrophage-derived TNF-alpha, can release saturated fatty acids as an endog‐
enous danger signal that reports their diseased state to macrophages in obese adipose tissue
[4]. CCL5 production by fibroblasts, platelets and monocytes/macrophages is a particular
feature of inflammatory disorders such as atherosclerosis [41, 42]. It is shown that CCL5,
through CCR1 and CCR5, contributes to transendothelial migration of monocytes and T cells
in atherogenic lesions [43]. CCL5 provides anti-apoptotic signals via the Akt and Erk1/2
pathways, which could then favor the scavenging role of tissue macrophages [44]. Obese
adipose tissue is shown to be poorly oxygenated [45, 46]. During the expansion of AT, hypoxic
areas are created due to adipocyte hypertrophy [47] that leads to the upregulated secretion of
macrophage migration inhibitory factor (MIF), the matrix metalloproteinases MMP-2 and
MMP-9, IL-6, Angplt4, PAI-1, VEGF and leptin [46, 48–50] that all together lead to inflamma‐
tion. Leptin and VEGF are hypoxia-associated genes that are directly regulated by HIF-1, a
master regulator of hypoxia and oxygen homeostasis is HIF-1 [51, 52]. Sun et al., 2011, suggest
that hypoxia-induced fibrosis that follows AT inflammation may be a key factor that ultimately
stimulates the local inflammatory responses [2]. Free fatty acids are stored in AT in the form
of triglycerides and can cause lipotoxic side effects when are present in high amounts in tissues.
During adipocytes’ hypertrophy FFAs are released through lipolysis and cause inflammatory
response. By increasing local extracellular lipid concentrations, FFAs lead to the accumulation
of ATMs [53, 54]. FFAs may act as ligands for the TLR4 complex, like LPS [55]. Activation of
TLR4 complex by saturated fatty acids may be involved in the regulation of metabolic
homeostasis within the adipose tissue. FFAs contribute to the polarization of infiltrated
macrophages toward M1 [4]. It is shown that M1 population of macrophages is dominant in
the states of overnutrition and that inflammatory response is mediated by FFAs [7, 56].
4. The role of macrophages in tumors
The exact role of macrophages in tumor development and progression is still not fully
examined, but it is shown that macrophages are associated with solid tumors. Studies
performed with various tumors showed that tumor-associated macrophages (TAMs) have a
lot of similarities with M2 type of macrophages with high expression of IL-10 and low
expression of IL-12. The expression of CD163 is high in TAMs and is used as a reliable marker
for TAMs [57, 58]. These are potential indicators that TAMs are M2 polarized macrophages
[59] with potent immunosuppressive functions. It is shown that TAMs possess anti-inflam‐
matory, pro-angiogenic and tumor-promoting properties [60] and are characteristic of the late
stage of tumor progression. Adipose tissue may support breast and prostate cancer develop‐
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ment and progression via secretion of pro-inflammatory cytokines. Studies performed with
mammary gland-associated AT and periprostatic AT showed that secretion of pro-inflamma‐
tory cytokines is increased in surrounded AT [61].
5. Conclusions and future perspectives
Further investigations are needed to understand the molecular mechanisms by which ATMs
participate in the development of various disorders, which would open the door to the findings
and development of new molecular target therapies. Dalmas et al., 2015 [62], suggested that
inhibition of interferon regulatory factor 5 (IRF5), transcription factor implicated in polariza‐
tion of macrophages towards M1, could be a potential strategy to control pathological AT
expansion in obesity and insulin resistance. Repolarization of ATMs could also be one of the
possible ways of treatment, but further investigation in this direction is needed.
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